Unnamed: 0,title,date,stock,sentiment
765964.0,Lilly's Chief Scientist Says Co's COVID-19 Treatment Could be Authorized for Use by September,2020-06-11 05:40:00-04:00,LLY,neutral
765965.0,"Eli Lilly Shares Spike To Session High, Up 1.7%, Following Report Co. Chief Scientist Has Said One Of Co.'s Antibodies Could Be Authorized As Coronavirus Treatment As Early As Sept.",2020-06-10 15:40:00-04:00,LLY,positive
765966.0,Travel Stocks Lose Momentum In Pre-Market After Leading Yesterday's Sharp Rally,2020-06-09 09:49:00-04:00,LLY,negative
765967.0,First Patient Dose Delivered For Lilly's Tirzepatide Cardiovascular Outcomes Trial,2020-06-09 06:47:00-04:00,LLY,neutral
765968.0,"Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment, Doses First Patient",2020-06-08 07:18:00-04:00,LLY,neutral
765969.0,"Fauci: Need To 'Definitively Show' Treatments Are Effective, On Eli Lilly's Recent Human Trials",2020-06-05 12:36:00-04:00,LLY,positive
765970.0,"The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study",2020-06-03 07:39:00-04:00,LLY,negative
765971.0,Eli Lilly CEO Talks Coronavirus Treatment Progress: 'This Is An Important Bridge Therapy',2020-06-01 15:40:00-04:00,LLY,positive
765972.0,Eli Lilly's Supplemental Biologics License Application for Taltz for the Treatment of Active Non-Radiographic Axial Spondyloarthritis Approved by the FDA,2020-06-01 06:49:00-04:00,LLY,positive
765973.0,Eli Lilly Doses Patients in its Phase 1 Coronavirus Antibody Treatment,2020-06-01 06:31:00-04:00,LLY,neutral
765974.0,Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma at ASCO,2020-05-31 19:33:00-04:00,LLY,neutral
765975.0,Lilly Yesterday Received U.S. FDA Approval of TAUVID for Use in Patients Being Evaluated for Alzheimer's Disease,2020-05-29 10:01:00-04:00,LLY,positive
765976.0,"Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector.",2020-05-28 12:33:00-04:00,LLY,positive
765977.0,'List of external participants expected at Rose Garden event starting momentarily where @POTUS will announce @MedicareGov patients will be provided with new choices of Part D plans for insulin at no more than $35 for a month's supply.' -Steve Herman Tweet,2020-05-26 16:13:00-04:00,LLY,negative
765978.0,"Eli Lilly Intend To File An IND, Initiate Clinical Trials In U.S. & China In Q2 2020 For Company's COVID-19 Neutralizing Antibodies",2020-05-26 09:24:00-04:00,LLY,neutral
765979.0,Boehringer Ingelheim And Lilly To Collaborate With Duke Clinical Research Institute On A Pragmatic Trial Examining Jardiance's Effects Following An Acute Myocardial Infarction,2020-05-26 08:02:00-04:00,LLY,neutral
765980.0,Eli Lilly Announces Emgality 'significantly improved work productivity and reduced interictal burden' In Migraine Patients,2020-05-26 06:49:00-04:00,LLY,positive
765981.0,"Eli Lilly Reports Results Of GERAS-US Study Showed Societal Cost Burden For Patients, Caregivers During Early Stages Of Alzheimer's Disease",2020-05-19 09:05:00-04:00,LLY,negative
765982.0,"The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger",2020-05-14 08:32:00-04:00,LLY,positive
765983.0,"AbbVie's Potential Is 'Underappreciated,' Says Morgan Stanley Analyst",2020-05-13 12:03:00-04:00,LLY,neutral
765984.0,Why Eli Lilly's Stock Is Trading Higher Today,2020-05-11 14:26:00-04:00,LLY,neutral
765985.0,Eli Lilly shares are trading higher amid strength in the healthcare sector. The company late Friday announced FDA approval for Retevmo in patients with advanced RET-driven lung and thyroid cancers.,2020-05-11 13:57:00-04:00,LLY,positive
765986.0,"Lilly Late Friday Announced Co. Received U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers",2020-05-11 10:54:00-04:00,LLY,positive
765987.0,Eli Lilly Press Release Highlights 'Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A1C and body weight in people with type 2 diabetes',2020-05-08 14:23:00-04:00,LLY,neutral
765988.0,5 Biopharmas Where BofA Would Put Its Money To Work,2020-05-08 11:23:00-04:00,LLY,neutral
765989.0,Shares of several healthcare companies are trading higher amid positive investor sentiment as some US states begin to reopen their economies and as oil prices gain for the session.,2020-05-05 12:44:00-04:00,LLY,positive
765990.0,Lilly And Junshi Biosciences To Co-Develop Antibody Therapies For The Prevention And Treatment Of COVID-19,2020-05-04 08:07:00-04:00,LLY,neutral
765991.0,Shanghai Junshi Biosciences Says Entered Research Collaboration and License Agreement With Eli Lilly; Says Parties Will Collaborate in Research Relating to Sars-cov-2 Neutralizing Antibodies,2020-05-03 20:00:00-04:00,LLY,positive
765992.0,"Apple And Amazon Earnings, Fed Meeting Among Highlights In Busy Week Ahead",2020-04-27 09:44:00-04:00,LLY,positive
765993.0,"CFRA Maintains Hold on Eli Lilly, Raises Price Target to $167",2020-04-24 11:40:00-04:00,LLY,neutral
765994.0,Eli Lilly shares are trading higher after the company announced the NMPA has of China has accepted the supplemental NDA for Sintilimab in combination with ALIMTA and Platinum as first-line therapy in non-squamous non-small cell lung cancer.,2020-04-24 10:36:00-04:00,LLY,negative
765995.0,Stocks That Hit 52-Week Highs On Friday,2020-04-24 10:33:00-04:00,LLY,neutral
765996.0,"The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures $54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO",2020-04-24 08:38:00-04:00,LLY,positive
765997.0,Mid-Afternoon Market Update: Sleep Number Surges On Strong Q1 Results; NETGEAR Shares Drop,2020-04-23 14:43:00-04:00,LLY,positive
765998.0,Afternoon Market Stats in 5 Minutes,2020-04-23 12:26:00-04:00,LLY,neutral
765999.0,Mid-Day Market Update: Crude Oil Jumps 31%; Invesco Shares Slide On Downbeat Earnings,2020-04-23 12:20:00-04:00,LLY,negative
766000.0,Stocks That Hit 52-Week Highs On Thursday,2020-04-23 10:41:00-04:00,LLY,neutral
766001.0,Mid-Morning Market Update: Markets Open Higher; Eli Lilly Beats Q1 Views,2020-04-23 10:15:00-04:00,LLY,neutral
766002.0,Eli Lilly Kicks Off Earnings Day With A Beat And Investors Prepare For Intel After Close,2020-04-23 09:45:00-04:00,LLY,neutral
766003.0,"From Eli Lilly Earnings Conference Call: CFO Says Expecting Muted Impact From Unemployment In 2020, Sees A Bigger Impact In 2021",2020-04-23 09:38:00-04:00,LLY,negative
766004.0,Eli Lilly And Co shares are trading higher after the company reported better-than-expected Q1 EPS and sales results. The company also issued FY20 EPS and sales guidance above analyst estimates.,2020-04-23 08:50:00-04:00,LLY,positive
766005.0,"The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt",2020-04-23 07:53:00-04:00,LLY,negative
766006.0,"UPDATE: Eli Lilly FY20 Adj. EPS Guidance Raised, Widened From $6.70-$6.80 To $6.70-$6.90",2020-04-23 06:29:00-04:00,LLY,neutral
766007.0,"Eli Lilly Sees FY20 Adj. EPS $6.70-$6.90 vs $6.73 Estimate, Sales $23.7B-$24.2B vs $23.84B Est.",2020-04-23 06:28:00-04:00,LLY,neutral
766008.0,"Eli Lilly Q1 Adj. EPS $1.750 Beats $1.480 Estimate, Sales $5.860B Beat $5.510B Estimate",2020-04-23 06:27:00-04:00,LLY,neutral
766009.0,"A Peek Into The Markets: US Stock Futures Flat Ahead Of Earnings, Economic Reports",2020-04-23 06:10:00-04:00,LLY,neutral
766010.0,"8 Stocks To Watch For April 23, 2020",2020-04-23 04:55:00-04:00,LLY,neutral
766011.0,"Earnings Scheduled For April 23, 2020",2020-04-23 04:23:00-04:00,LLY,neutral
766012.0,"Shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows, partially stemming from weak demand caused by the coronavirus pandemic.",2020-04-21 11:35:00-04:00,LLY,negative
766013.0,"The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives",2020-04-21 08:19:00-04:00,LLY,positive
766014.0,"A Peek Into The Markets: US Stock Futures Fall Ahead Of Coca-Cola, Lockheed Martin Earnings",2020-04-21 05:50:00-04:00,LLY,neutral
766015.0,"UBS Downgrades Eli Lilly to Neutral, Raises Price Target to $158",2020-04-21 04:55:00-04:00,LLY,neutral
766016.0,"The Week Ahead In Biotech (April 19-25): Eli Lilly, Biogen Earnings On Tap, Sanofi Awaits FDA Decision",2020-04-19 17:22:00-04:00,LLY,positive
766017.0,Stocks That Hit 52-Week Highs On Friday,2020-04-17 10:19:00-04:00,LLY,neutral
766018.0,"Big Earnings Day As Honeywell, Procter & Gamble, Schlumberger Among Those Reporting",2020-04-17 09:46:00-04:00,LLY,neutral
766019.0,"The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement",2020-04-17 07:35:00-04:00,LLY,positive
766020.0,10 Stocks Hitting All-Time Highs Amid The COVID-19 Pandemic,2020-04-16 17:21:00-04:00,LLY,neutral
766021.0,Stocks That Hit 52-Week Highs On Thursday,2020-04-16 10:19:00-04:00,LLY,neutral
766022.0,"The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant",2020-04-16 08:09:00-04:00,LLY,neutral
766023.0,"Eli Lilly Reports Non-Branded Versions Of Humalog KwikPen, Humalog Junior KwikPen Now Available For Order By US Pharmacies",2020-04-16 06:53:00-04:00,LLY,neutral
766024.0,Every Member Of Trump's 'Great American Economic Revival' Industry Groups,2020-04-15 13:09:00-04:00,LLY,positive
766025.0,"Cowen & Co. Maintains Outperform on Eli Lilly, Raises Price Target to $160",2020-04-15 08:55:00-04:00,LLY,neutral
766026.0,"The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US",2020-04-15 08:03:00-04:00,LLY,neutral
766027.0,Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic.,2020-04-14 10:59:00-04:00,LLY,positive
766028.0,Stocks That Hit 52-Week Highs On Tuesday,2020-04-14 10:31:00-04:00,LLY,neutral
766029.0,Lilly On Friday Anounced It Has Begun Clinical Testing of Therapies for Coronavirus,2020-04-13 10:03:00-04:00,LLY,neutral
766030.0,"Benzinga's Bulls And Bears Of The Week: Apple, Disney, Intel And More",2020-04-11 14:10:00-04:00,LLY,neutral
766031.0,"Morgan Stanley Downgrades Lilly On Valuation, Says Growth, Pipeline Potential Balanced By Stock Premium",2020-04-09 11:02:00-04:00,LLY,positive
766032.0,"Benzinga's Top Upgrades, Downgrades For April 9, 2020",2020-04-09 10:02:00-04:00,LLY,positive
766033.0,Eli Lilly And Co shares are trading lower after Morgan Stanley downgraded the stock from Overweight to Equal-Weight.,2020-04-09 08:30:00-04:00,LLY,negative
766034.0,Morgan Stanley Downgrades Eli Lilly to Equal-Weight,2020-04-09 06:21:00-04:00,LLY,neutral
766035.0,"Eli Lilly shares are trading higher, not seeing company-specific news from the session. NOTE: The healthcare sector has been strong this week amid positive market sentiment as well as increased demand for therapies and medical supplies due to coronavirus.",2020-04-08 08:57:00-04:00,LLY,positive
766036.0,Eli Lilly And Co Says New $35 Co-Pay Now Available Through Lilly Insulin Value Program In Response To Coronavirus Crisus,2020-04-07 06:34:00-04:00,LLY,positive
766037.0,"'There are four main antibody programs underway in U.S. by Lilly, Regeneron, Vir, and Amgen. Regeneron may be furthest along and have the best chance of doing this at the scale required...' -Weekend Tweet From Former FDA Commish Gottlieb",2020-04-06 12:24:00-04:00,LLY,positive
766038.0,"Morgan Stanley Maintains Overweight on Eli Lilly, Lowers Price Target to $148",2020-04-02 09:11:00-04:00,LLY,negative
766039.0,Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.,2020-04-01 09:20:00-04:00,LLY,negative
766040.0,Patent Court Rejects Eli Lilly Challenge To Teva Patents On Migraine Drug Ajovy,2020-03-31 13:11:00-04:00,LLY,negative
766041.0,"The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions",2020-03-31 08:26:00-04:00,LLY,negative
766042.0,Lilly And Sitryx Announce Licensing And Research Collaboration To Discover And Develop New Immunometabolic Medicines,2020-03-31 06:33:00-04:00,LLY,neutral
766043.0,Why Eli Lilly's Stock Is Trading Higher Today,2020-03-30 11:19:00-04:00,LLY,neutral
766044.0,Eli Lilly shares are trading higher after the company received FDA approval for Taltz  for treatment of pediatric patients with moderate to severe plaque psoriasis.,2020-03-30 09:46:00-04:00,LLY,positive
766045.0,Eli Lilly's Taltz Receives FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis,2020-03-30 06:48:00-04:00,LLY,positive
766046.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus legislation has boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 09:22:00-04:00,LLY,positive
766047.0,Veeva Systems' CRM Product Is Seeing Ten Times More Usage During Coronavirus Pandemic,2020-03-27 02:59:00-04:00,LLY,neutral
766048.0,"Shares of several healthcare companies are trading higher following Senate passage of a $2 trillion economic stimulus package, which has lifted stocks across sectors.",2020-03-26 11:49:00-04:00,LLY,positive
766049.0,"Shares of several healthcare companies are trading higher as equities gain amid hopes of a US stimulus agreement. Additionally, the coronavirus outbreak has increased demand for certain medical supplies.",2020-03-24 12:20:00-04:00,LLY,positive
766050.0,"Eli Lilly Offers Update On Insulin Supply, Affordability, Says Does Not Source Active Pharma Ingredients From China, Says US Pharmacies Temporarily Unavailable For Co. Medicines Can Order From Wholesalers",2020-03-24 08:12:00-04:00,LLY,negative
766051.0,Eli Lilly Delays New Study Starts,2020-03-23 11:17:00-04:00,LLY,neutral
766052.0,Eli Lilly and Co. shares are trading lower after the company announced it will delay most of the new study starts and pause enrollment in most of the ongoing studies amid Coronavirus.,2020-03-23 07:51:00-04:00,LLY,negative
766053.0,AC Immune Receives a Second Milestone Payment of CHF 10M From Eli Lilly,2020-03-23 07:03:00-04:00,LLY,positive
766054.0,Eli Lilly Says it Will Delay Most New Trial Starts and Pause Enrollment in Ongoing Studies Amid Coronavirus,2020-03-23 06:31:00-04:00,LLY,negative
766055.0,"FDA Issues Complete Response Letter For Empagliflozin 2.5 Mg As Adjunct To Insulin For Adults With Type 1 Diabetes, Indicates FDA Is Unable To Approve Application In Current Form; Empagliflozin 2.5 Mg Is Being Developed By Boehringer Ingelheim & Lilly",2020-03-20 16:33:00-04:00,LLY,neutral
766056.0,Eli Lilly Reports Partnership With Indiana State Dept. Of Health With Support From FDA To Accelerate Testing For Coronavirus In Indiana,2020-03-18 14:45:00-04:00,LLY,positive
766057.0,"Shares of several healthcare companies are trading higher, rebounding from Monday's crash. Stocks may also potentially be getting a boost from expectations of further stimulus proposals.",2020-03-17 09:10:00-04:00,LLY,positive
766058.0,"Shares of several healthcare companies are trading lower as the coronavirus outbreak continues to cause economic disruption around the globe, leading to a steep selloff in equities across sectors.",2020-03-16 10:50:00-04:00,LLY,negative
766059.0,Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata,2020-03-16 06:46:00-04:00,LLY,neutral
766060.0,"The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals",2020-03-13 10:53:00-04:00,LLY,neutral
766061.0,Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.,2020-03-13 09:29:00-04:00,LLY,positive
766062.0,"Eli Lilly Shares Make Parabolic Move, Spike Higher Then Sell Off; Hearing Co. Said To Join Race To Develop Coronavirus Treatment",2020-03-12 12:20:00-04:00,LLY,positive
766063.0,Eli Lilly & Co shares are trading lower despite receiving fast track designation to Jardiance by the FDA for the treatment of chronic kidney diseases. NOTE: Markets continue to drop amid the global coronavirus outbreak.,2020-03-12 09:35:00-04:00,LLY,negative
766064.0,US FDA Grants Fast Track Designation to Jardiance® for The Treatment of Chronic Kidney Disease,2020-03-12 08:04:00-04:00,LLY,positive
766065.0,Lilly To Participate In New Model Designed To Make Insulins More Affordable For Seniors In Medicare Part D,2020-03-11 12:39:00-04:00,LLY,neutral
766066.0,"Goldman Sachs Maintains Buy on Eli Lilly, Announces $168 Price Target; Adds To Conviction Buy List",2020-03-11 07:53:00-04:00,LLY,neutral
766067.0,Shares of several drugmakers and healthcare companies are trading higher following US Super Tuesday results in which Joe Biden won the highest number of delegates. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.,2020-03-04 07:48:00-05:00,LLY,positive
766068.0,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More",2020-03-03 07:51:00-05:00,LLY,positive
766069.0,"Lilly Issued A Statement On Coronavirus And The Reliable Syooly Of The Company's Medicines; The Company Does Not Anticioae Shortage For Any Of Its Products, Including All Forms Of Insulin",2020-03-03 07:08:00-05:00,LLY,positive
766070.0,Pfizer's Biologics License Application for Tanezumab Accepted for Review by the FDA,2020-03-02 06:49:00-05:00,LLY,positive
766071.0,Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.,2020-02-28 09:06:00-05:00,LLY,negative
766072.0,EMA Says Adopted Negative Opinion For Eli Lilly's Indication Extension For Emgality To Add Prevention Of Attacks In Adults With Episodic Cluster Headache,2020-02-28 06:38:00-05:00,LLY,negative
766073.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,LLY,positive
766074.0,FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer,2020-02-27 05:26:00-05:00,LLY,negative
766075.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,LLY,negative
766076.0,"Eli Lilly Earlier Announced It Has Received FDA Approval For Trulicity, The First And Only Type 2 Diabetes Medicine Approved To Reduce Cardiovascular Events In Adults With And Without Established Cardiovascular Disease",2020-02-24 09:27:00-05:00,LLY,positive
766077.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,LLY,neutral
766078.0,"Watching Sanofi Shares As Hearing Co., Eli Lilly Will Face Claims Of Violation Of RICO Act Related To Pricing Of Insulin",2020-02-20 12:30:00-05:00,LLY,negative
766079.0,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",2020-02-12 09:18:00-05:00,LLY,positive
766080.0,Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatitis,2020-02-12 05:10:00-05:00,LLY,positive
766081.0,Eli Lilly Suffers Setback As Alzheimer's Study Fails To Meet Primary Endpoint,2020-02-10 12:22:00-05:00,LLY,negative
766082.0,12 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-02-10 07:51:00-05:00,LLY,neutral
766083.0,30 Stocks Moving in Monday's Pre-Market Session,2020-02-10 07:30:00-05:00,LLY,neutral
766084.0,Eli Lilly And Co shares are trading lower after the company reported the results for Solanezumba from the Alzheimer's study did not meet its primary endpoint.,2020-02-10 07:20:00-05:00,LLY,neutral
766085.0,Lilly Announces Alzheimer's Study Did Not Meet Primary Endpoint,2020-02-10 04:20:00-05:00,LLY,neutral
766086.0,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns",2020-02-07 07:32:00-05:00,LLY,negative
766087.0,"UPDATE: Mizuho Initiates Coverage On Eli Lilly with Neutral Rating, Announces $148 Price Target Notes 'we expect Verzenio's impact to increase following recent positive data releases and see the Loxo acquisition providing additional mid-term growth drivers.'",2020-02-06 11:27:00-05:00,LLY,positive
766088.0,Stocks That Hit 52-Week Highs On Thursday,2020-02-06 10:39:00-05:00,LLY,neutral
766089.0,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",2020-02-06 07:47:00-05:00,LLY,negative
766090.0,"Mizuho Initiates Coverage On Eli Lilly with Neutral Rating, Announces $148 Price Target",2020-02-06 05:17:00-05:00,LLY,neutral
766091.0,"Mizuho Initiates AbbVie, Biohaven With Buy Ratings, Eli Lilly, Alkermes With Neutral Ratings",2020-02-05 16:42:00-05:00,LLY,neutral
766092.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-05 10:16:00-05:00,LLY,neutral
766093.0,Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.,2020-02-05 09:47:00-05:00,LLY,positive
766094.0,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data",2020-02-05 07:43:00-05:00,LLY,neutral
766095.0,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus",2020-02-02 13:04:00-05:00,LLY,neutral
766096.0,Lilly's Announces That Its REYVOW C-V Is The First And Only Medicine In a New Class Of Acute Treatment For Migraine,2020-01-31 10:45:00-05:00,LLY,neutral
766097.0,"The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO",2020-01-31 09:09:00-05:00,LLY,negative
766098.0,Eli Lilly Reports Its Liumjev Receives Positive CHMP Opinion,2020-01-31 06:16:00-05:00,LLY,positive
766099.0,Eli Lilly shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.,2020-01-30 14:31:00-05:00,LLY,positive
766100.0,"The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance",2020-01-30 09:26:00-05:00,LLY,positive
766101.0,"A Peek Into The Markets: US Stock Futures Tumble Ahead Of Earnings, GDP Data",2020-01-30 06:46:00-05:00,LLY,neutral
766102.0,Eli Lilly Reaffirms FY20 Adj. EPS Guidance $6.70-$6.80,2020-01-30 06:26:00-05:00,LLY,neutral
766103.0,"Eli Lilly Q4 Adj. EPS $1.73 Beats $1.51 Estimate, Sales $6.114B Beat $5.9B Estimate",2020-01-30 06:26:00-05:00,LLY,neutral
766104.0,Eli Lilly Reports Top-Line Results From BREEZE-AD5 Phase 3 Study Of Oral Selective JAK Inhibitor In Patients With Moderate To Severe Atopic Dermatitis,2020-01-30 06:15:00-05:00,LLY,negative
766105.0,"Earnings Scheduled For January 30, 2020",2020-01-30 04:59:00-05:00,LLY,neutral
766106.0,"14 Stocks To Watch For January 30, 2020",2020-01-30 04:05:00-05:00,LLY,neutral
766107.0,Lilly Receives FDA Priority Review For Selpercatinib New Drug Application,2020-01-29 07:48:00-05:00,LLY,neutral
766108.0,"The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics",2020-01-28 07:12:00-05:00,LLY,positive
766109.0,FDA Approves Lilly's Trijardy,2020-01-27 17:45:00-05:00,LLY,positive
766110.0,Eli Lilly and Incyte's Phase 3 BREEZE-AD4 Study Met its Primary Endpoint,2020-01-27 06:47:00-05:00,LLY,neutral
766111.0,"The Week Ahead In Biotech: Amgen, Eli Lilly, Pfizer In Earnings Mix, IPO Flow Resumes",2020-01-26 10:23:00-05:00,LLY,neutral
766112.0,"The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment",2020-01-23 07:24:00-05:00,LLY,positive
766113.0,9 Takeaways From The JPMorgan Healthcare Conference,2020-01-17 14:47:00-05:00,LLY,neutral
766114.0,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares",2020-01-17 08:07:00-05:00,LLY,negative
766115.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-16 10:22:00-05:00,LLY,neutral
766116.0,"The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics",2020-01-16 07:22:00-05:00,LLY,neutral
766117.0,"The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance",2020-01-15 08:22:00-05:00,LLY,negative
766118.0,"The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug",2020-01-14 07:55:00-05:00,LLY,positive
766119.0,"Lilly Announces Insulin Cost-Saving Options; Lower-Priced Versions Of Humalog Junior KwikPen And Humalog Mix75/25 KwikPen To Have 50% Lower List Price Than Branded Versions, Will Be Available By Mid April",2020-01-14 06:53:00-05:00,LLY,negative
766120.0,Eli Lilly's Phase 3 ORIENT-11 Study of Tyvyt Combined with ALIMTA Met its Primary Endpoint,2020-01-13 06:32:00-05:00,LLY,neutral
766121.0,Mid-Afternoon Market Update: Dow Falls 90 Points; RumbleON Shares Plummet,2020-01-10 14:41:00-05:00,LLY,positive
766122.0,"'California Gov. Gavin Newsom wants the state to become the first to create its own generic drug label, an attempt to create more competition and bring down prices.' -Axios, From Earlier",2020-01-10 12:55:00-05:00,LLY,positive
766123.0,40 Stocks Moving In Friday's Mid-Day Session,2020-01-10 12:29:00-05:00,LLY,neutral
766124.0,Stocks That Hit 52-Week Highs On Friday,2020-01-10 12:18:00-05:00,LLY,neutral
766125.0,Mid-Day Market Update: Crude Oil Down Over 1%; Ultragenyx Pharmaceutical Shares Jump,2020-01-10 12:13:00-05:00,LLY,negative
766126.0,Mid-Morning Market Update: Markets Open Higher; Eli Lilly To Buy Dermira For $18.75/Share,2020-01-10 10:14:00-05:00,LLY,neutral
766127.0,"Benzinga Pro's Top 5 Stocks To Watch For Fri., Jan. 10, 2020: LLY, JPM, SRNE, ELAN, TWTR",2020-01-10 09:03:00-05:00,LLY,positive
766128.0,Eli Lilly Reports Deal To Buy Dermira For $1.1B,2020-01-10 07:28:00-05:00,LLY,neutral
766129.0,33 Stocks Moving in Friday's Pre-Market Session,2020-01-10 07:26:00-05:00,LLY,neutral
766130.0,Eli Lilly Reports Deal To Buy Dermira For $18.75/Share In Cash,2020-01-10 06:30:00-05:00,LLY,neutral
766131.0,"Eli Lilly, In Collaboration With Strateos, Inc. Launches Remote-Controlled Robotic Cloud Lab",2020-01-09 08:09:00-05:00,LLY,neutral
766132.0,U.S. District Court Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit,2019-12-30 13:10:00-05:00,LLY,positive
766133.0,"UPDATE: Argus Maintains Buy On Eli Lilly, Raises Target To $165 Notes 'We see increased volume and expanded indications for existing drugs, along with potential regulatory approvals, as cat-alysts for growth in 2020'",2019-12-30 10:41:00-05:00,LLY,positive
766134.0,10 Biggest Price Target Changes For Monday,2019-12-30 08:58:00-05:00,LLY,neutral
766135.0,"Argus Research Maintains Buy on Eli Lilly, Raises Price Target to $165",2019-12-30 07:27:00-05:00,LLY,neutral
766136.0,Lilly Opens Phase 3 Clinical Trial In RET-Mutant Medullary Thyroid Cancer,2019-12-30 06:45:00-05:00,LLY,negative
766137.0,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",2019-12-29 18:38:00-05:00,LLY,neutral
766138.0,A Perspective On Biopharma's Record M&A Run In 2019,2019-12-23 14:57:00-05:00,LLY,neutral
766139.0,"PreMarket Prep Recap: $TSLAQ Crowd Continues To Be Punished, Eli Lilly's Incredible Friday Open",2019-12-23 13:27:00-05:00,LLY,negative
766140.0,PreMarket Prep Recap: Buyers And More Buyers On Quadruple Witch Expiration,2019-12-20 14:39:00-05:00,LLY,negative
766141.0,Stocks That Hit 52-Week Highs On Friday,2019-12-20 11:59:00-05:00,LLY,neutral
766142.0,"UPDATE: Morgan Stanley On Eli Lilly Notes 'While Novo appears set to win market share in diabetes, we still expect strong and durable Lilly franchise growth, including benefits from initial high-dose Trulicity sales in 2021 and tirzepatide in 2022'",2019-12-18 12:42:00-05:00,LLY,positive
766143.0,"UPDATE: Morgan Stanley Upgrades Eli Lilly To Overweight, Raises Target To $150 Notes 'We expect LLY shares to outperform, driven by strong growth and pipeline optionality'",2019-12-18 12:42:00-05:00,LLY,positive
766144.0,"Eli Lilly CEO Hits Back At Elizabeth Warren, Blames PBMs, Insurance For Blocking Affordable Insulin",2019-12-18 11:07:00-05:00,LLY,negative
766145.0,"Benzinga's Top Upgrades, Downgrades For December 18, 2019",2019-12-18 10:40:00-05:00,LLY,positive
766146.0,Eli Lilly And Co shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised the price target from $116 to $150 per share.,2019-12-18 09:36:00-05:00,LLY,positive
766147.0,"JP Morgan Maintains Overweight on Eli Lilly, Raises Price Target to $150",2019-12-18 08:54:00-05:00,LLY,neutral
766148.0,30 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-12-18 08:11:00-05:00,LLY,neutral
766149.0,"Morgan Stanley Upgrades Eli Lilly to Overweight, Raises Price Target to $150",2019-12-18 07:41:00-05:00,LLY,negative
766150.0,Lilly Announces Launch Of TRIUMPH Real-World Evidence Study Of Emgality For Migraine Prevention,2019-12-18 06:46:00-05:00,LLY,positive
766151.0,Eli Lilly shares are trading higher after the company issued upbeat FY20 guidance.,2019-12-17 11:27:00-05:00,LLY,positive
766152.0,Eli Lilly Executive Says Reasonable To Expect Net Price Declines In The Low Single-Digit Level Going Forward,2019-12-17 09:53:00-05:00,LLY,negative
766153.0,"Benzinga Pro's Top 5 Stocks To Watch For Tues., Dec. 17, 2019: BA, AAPL, BLPH, JNJ, LLY",2019-12-17 08:50:00-05:00,LLY,positive
766154.0,"Lilly Reaffirms Prelim. FY19 Adj. EPS Guidance $5.75-$5.85 vs $5.81 Est., Sales Guidance $22B-$22.5B vs $22.16B Est.",2019-12-17 06:33:00-05:00,LLY,neutral
766155.0,"Lilly Sees FY20 Adj. EPS $6.70-$6.80 vs $6.61 Est., Sales $23.6B-$24.1B vs $23.52B Est.",2019-12-17 06:31:00-05:00,LLY,neutral
766156.0,Eli Lilly Raises Qtr. Dividend From $0.645 To $0.74/Share,2019-12-16 16:25:00-05:00,LLY,neutral
766157.0,DexCom Says Eli Lilly Will Integrate its Continuous Glucose Monitoring into Lilly's Personalized Diabetes Management System,2019-12-16 06:46:00-05:00,LLY,neutral
766158.0,'Fast Money' Picks For December 13,2019-12-13 14:57:00-05:00,LLY,neutral
766159.0,"Boehringer Ingelheim, Lilly Offer Update On Jardiance Phase 3 Exercise Ability Studies In Chronic Heart Failure",2019-12-13 08:02:00-05:00,LLY,negative
766160.0,Lilly Reports CHMP Issues Positive Opinion Related To Expanded Label Of CYRAMZA To Include Results From RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer,2019-12-13 06:48:00-05:00,LLY,negative
766161.0,Lilly Opens Randomized Phase 3 Clinical Trial Of LOXO-292 In Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer,2019-12-11 06:47:00-05:00,LLY,negative
766162.0,Highlights From The Deutsche Bank ADR Virtual Investor Conference,2019-12-09 06:16:00-05:00,LLY,neutral
766163.0,Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at ASH 2019,2019-12-08 18:31:00-05:00,LLY,neutral
766164.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",2019-12-07 08:35:00-05:00,LLY,positive
766165.0,U.S. Considers Scaling Back IP Protections For Big Drugmakers To Help Win Democratic Support For New Trade Pact With Mexico And Canada,2019-12-02 16:09:00-05:00,LLY,positive
766166.0,"Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade",2019-12-02 13:55:00-05:00,LLY,negative
766167.0,"Trump Says he Will Release a Plan to Let States Import Prescription Drugs Which are ""MUCH CHEAPER""",2019-11-22 14:08:00-05:00,LLY,neutral
766168.0,Lilly Announces $400M Capital Investment In Manufacturing Facilities In Indianapolis,2019-11-20 06:37:00-05:00,LLY,neutral
766169.0,Interim Analysis From Emprise Real-world Study Shows Lilly's Jardiance Decreased Risk of Hospitalization for Heart Failure vs Dpp-4 Inhibitors and Glp-1 Receptor Agonists,2019-11-17 19:57:00-05:00,LLY,negative
766170.0,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing",2019-11-14 08:07:00-05:00,LLY,positive
766171.0,"Eli Lilly, Boehringer Ingleheim Report FDA Endocrinologic and Metabolic Drugs Advisory Committee Vote 14-2 Benefits Of Empagliflozin 2.5mg Do Not Outweigh Risks",2019-11-13 17:10:00-05:00,LLY,positive
766172.0,FDA Panel Votes 14-2 Against Approval Of Eli Lilly And Boehringer Ingelheim's Empagliflozin As An Add On To Insulin Therapy For Type 1 Diabetes,2019-11-13 15:50:00-05:00,LLY,positive
766173.0,Boehringer Ingelheim And Lilly Initiate Study To Assess Jardiance In People Hospitalized For Acute Heart Failure Who Have Been Stabilized,2019-11-12 08:42:00-05:00,LLY,negative
766174.0,Eli Lilly And Co Announces 52-Week Head-To-Head Data From Taltz Versus Humira Trial In Psoriatic Arthritis Met The Primary And All Major Secondary Endpoints Of The Study,2019-11-12 07:46:00-05:00,LLY,neutral
766175.0,Lilly Announces The Pricing Terms Of Its Cash Tender Offer For Up to $2B Aggregate Principal Amount Of Its Outstanding Debt Securities,2019-11-07 12:51:00-05:00,LLY,positive
766176.0,Eli Lilly shares are trading higher. Not seeing any news to justify the price action.,2019-11-06 14:34:00-05:00,LLY,positive
766177.0,AstraZeneca Named The Most Innovative Global Pharma Company,2019-11-06 11:20:00-05:00,LLY,positive
766178.0,Eli Lilly To Present Multiple Abstracts For LOXO-305 At ASH 2019 Dec. 7-10,2019-11-06 09:07:00-05:00,LLY,neutral
766179.0,"Boehringer Ingelheim, Eli Lilly Report Modernization Of Alliance To Focus Full Expertise On Jardiance",2019-11-04 09:01:00-05:00,LLY,neutral
766180.0,Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates,2019-11-01 08:05:00-04:00,LLY,neutral
766181.0,"Eli Lilly Reports Results For Taltz In Pediatric Patients With Moderate To Severe Plaque Psoriasis, Met Co-Primary Endpoints; Co. To Submit For US Regulatory Approval",2019-10-28 10:21:00-04:00,LLY,positive
766182.0,"Notable Insider Buys In The Past Week: Eli Lilly, JPMorgan, Thor Industries",2019-10-26 15:23:00-04:00,LLY,neutral
766183.0,"The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise",2019-10-24 07:36:00-04:00,LLY,neutral
766184.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-23 11:19:00-04:00,LLY,negative
766185.0,33 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-10-23 08:48:00-04:00,LLY,neutral
766186.0,"The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data",2019-10-23 07:54:00-04:00,LLY,negative
766187.0,"Eli Lilly Reports Mixed Q3 Earnings, Raises Guidance",2019-10-23 07:36:00-04:00,LLY,neutral
766188.0,Eli Lilly And Co shares are trading lower after the company reported worse-than-expected Q3 sales results.,2019-10-23 07:27:00-04:00,LLY,neutral
766189.0,"Lilly Raises FY19 Adj. EPS Guidance From $5.67-$5.77 To $5.75-$5.85 vs $5.72 Est., Sees Sales $22B-$22.5B vs $22.23B Est.",2019-10-23 06:27:00-04:00,LLY,neutral
766190.0,"Eli Lilly Q3 Adj. EPS $1.48 Beats $1.4 Estimate, Sales $5.48B Miss $5.5B Estimate",2019-10-23 06:26:00-04:00,LLY,negative
766191.0,"12 Stocks To Watch For October 23, 2019",2019-10-23 04:36:00-04:00,LLY,neutral
766192.0,"Earnings Scheduled For October 23, 2019",2019-10-23 04:15:00-04:00,LLY,neutral
766193.0,"Mixed Bag: Better Outlooks From Lockheed, United Technologies, But McDonald's Misses",2019-10-22 10:14:00-04:00,LLY,positive
766194.0,Earnings Season Kicks Into Full Gear In Round 3 Of The WeTrader Competition,2019-10-21 11:16:00-04:00,LLY,neutral
766195.0,"The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict",2019-10-20 08:08:00-04:00,LLY,positive
766196.0,European Medicines Agency Says CHMP Recommended Granting A Marketing Authorization For Eli Lilly's BAQSIMI,2019-10-18 06:45:00-04:00,LLY,positive
766197.0,"UBS Maintains Buy on Eli Lilly, Lowers Price Target to $133",2019-10-17 08:43:00-04:00,LLY,negative
766198.0,"Bank of America Reinstates Buy on Eli Lilly, Announces $133 Price Target",2019-10-17 07:26:00-04:00,LLY,neutral
766199.0,Eli Lilly And Co shares are trading lower after the company reported that its Phase 3 study in patients with Metastatic pancreatic cancer did not meet its primary endpoint.,2019-10-16 08:16:00-04:00,LLY,negative
766200.0,17 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-10-16 07:57:00-04:00,LLY,neutral
766201.0,Eli Lilly Reports Phase 3 Study In Patients With Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint,2019-10-16 06:51:00-04:00,LLY,negative
766202.0,Lilly Presents Positive Results for Taltz in Pediatric Patients with Moderate to Severe Plaque Psoriasis at EADV 2019,2019-10-12 15:52:00-04:00,LLY,positive
766203.0,Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.,2019-10-11 11:19:00-04:00,LLY,positive
766204.0,"The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout",2019-10-11 08:14:00-04:00,LLY,positive
766205.0,"Lilly Says Taltz Met Primary, Secondary Endpoints of Ixora-R Study in People With Moderate to Severe Plaque Psoriasis",2019-10-10 18:10:00-04:00,LLY,negative
766206.0,Shares of several healthcare companies are trading lower with the broader market after the US expanded its trade blacklist to include China's top AI firms. The US also will increase its tariffs on $250 billion worth of goods from 25% to 30% on Oct 15.,2019-10-08 10:36:00-04:00,LLY,positive
766207.0,BioNTech IPO: What You Need To Know,2019-10-08 07:55:00-04:00,LLY,neutral
766208.0,Lilly To Present New Data For Treatments Of Complex Dermatological Conditions At The 28th Annual European Academy Of Dermatology and Venereology Congress Ot. 9-13,2019-10-08 06:49:00-04:00,LLY,neutral
766209.0,Eli Lilly Announces that Phase 3 CYRAMZA Results Were Published in the Journal Lancet Oncology,2019-10-07 06:47:00-04:00,LLY,neutral
766210.0,"The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck",2019-10-06 17:15:00-04:00,LLY,neutral
766211.0,Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar,2019-10-03 15:49:00-04:00,LLY,positive
766212.0,Eli Lilly Highlights Head-To-Head Data Showed Taltz Superiority Vs. TREMFYA In People with Moderate to Severe Plaque Psoriasis,2019-10-03 06:48:00-04:00,LLY,negative
766213.0,Eli Lilly Highlights Availability Of Emgality In Canada,2019-10-02 11:47:00-04:00,LLY,neutral
766214.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued fears of a recession amid a weak ADP jobs report. There is also uncertainty in the market over the upcoming U.S.-China meeting next week.,2019-10-02 10:33:00-04:00,LLY,negative
766215.0,Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates,2019-09-30 16:32:00-04:00,LLY,neutral
766216.0,"Biotech Stock On The Radar: Anavex, A Neurology-Focused Precision Medicine Company",2019-09-25 17:32:00-04:00,LLY,neutral
766217.0,Eli Lilly to Present Data at the European Society for Medical Oncology,2019-09-23 06:50:00-04:00,LLY,neutral
766218.0,Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.,2019-09-20 13:00:00-04:00,LLY,negative
766219.0,AC Immune Receives First Milestone Payment From Lilly In Small Molecule Tau Morphomer Program,2019-09-20 07:01:00-04:00,LLY,positive
766220.0,CHMP Issues Positive Opinion To Expand Lilly's Trulicity Label To Include Results From REWIND Cardiovascular Outcomes Trial,2019-09-20 06:46:00-04:00,LLY,positive
766221.0,Biotech Stock On The Radar: vTv Therapeutics' Diabetes Pipeline,2019-09-17 16:35:00-04:00,LLY,neutral
766222.0,Fitch Planning To Withdraw Ratings For Eli Lilly,2019-09-16 10:18:00-04:00,LLY,neutral
766223.0,Shares of several drugmakers are trading lower on news of a drug pricing bill being developed by House Democrats. The proposed bill would set US drug prices based on prices in other wealthy countries.,2019-09-10 10:30:00-04:00,LLY,positive
766224.0,"Bank of America Reiterates Neutral on Eli Lilly, Raises Price Target to $120",2019-09-10 09:16:00-04:00,LLY,neutral
766225.0,Eli Lilly shares are trading lower. Shares traded higher on light volume in Monday's pre-market session after the company reported results from its clinical trial of LOXO-292 and have since reversed.,2019-09-09 11:45:00-04:00,LLY,positive
766226.0,30 Stocks Moving in Monday's Pre-Market Session,2019-09-09 07:57:00-04:00,LLY,neutral
766227.0,"Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer",2019-09-09 03:35:00-04:00,LLY,negative
766228.0,"The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight",2019-09-08 11:01:00-04:00,LLY,neutral
766229.0,Eli Lilly Reports FDA Accepted Application To Enter Complex Innovative Trial Designs Pilot Meeting Program,2019-09-05 15:02:00-04:00,LLY,positive
766230.0,"Barron's Picks And Pans: Activision Blizzard, Best Buy, Coca-Cola, Microsoft And More",2019-08-31 14:37:00-04:00,LLY,positive
766231.0,Lilly Receives FDA Approval for Taltz for the Treatment of Active Ankylosing Spondylitis,2019-08-26 06:45:00-04:00,LLY,positive
766232.0,"Eli Lilly Reports Baricitinib Met Primary Endpoint In Breeze-AD7, Third Pivotal Phase 3 Trial In Breeze-AD Program To Be Completed In 2019",2019-08-23 14:58:00-04:00,LLY,neutral
766233.0,"Shares of several healthcare companies are trading lower in sympathy with the overall market after the spread between the 2-year and 10-year yield curve inverted for the first time since 2007, potentially signaling an oncoming recession.",2019-08-14 11:17:00-04:00,LLY,negative
766234.0,Lilly's Psoriasis Drug Found Superior To J&J's Tremfya In Phase 4 Study,2019-08-13 11:40:00-04:00,LLY,positive
766235.0,Lilly Announces Taltz Met Primary And All Major Secondary Endpoints In Phase 4 IXORA-R Study,2019-08-13 06:47:00-04:00,LLY,neutral
766236.0,Eli Lilly Shares Unaffected As Hearing US Appeals Court Ruled In Favor Of Co. In Alimta Alternate Salt Form Patent Suit,2019-08-09 12:19:00-04:00,LLY,positive
766237.0,Eli Lilly shares are trading higher after the company announced positive results for Emgality from the CONQUER study.,2019-08-08 11:56:00-04:00,LLY,positive
766238.0,"Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia",2019-08-08 06:49:00-04:00,LLY,positive
766239.0,"Eli Lilly shares trading higher, rebounding following a more than 3% decline on Monday. Not seeing company-specific news to justify the rebound today.",2019-08-06 13:10:00-04:00,LLY,positive
766240.0,Shares of several drug/pharma/medical equipment companies trading lower given weakness in broader stock market following concerns with China trade tensions.,2019-08-05 12:43:00-04:00,LLY,negative
766241.0,Eli Lilly Announces Positive Results For Emgality,2019-08-05 07:54:00-04:00,LLY,positive
766242.0,Lilly Announces 'Positive' Results for Emgality from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments,2019-08-05 06:48:00-04:00,LLY,negative
766243.0,"Eli Lilly 10-Q Shows Co. Received Subpoena From New York Attorney General's Office, Civil Investigative Demands From Washing, New Mexico AG's Related To Pricing, Sale Of Its Insulin Products",2019-08-02 13:25:00-04:00,LLY,neutral
766244.0,Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates,2019-07-31 17:15:00-04:00,LLY,neutral
766245.0,"Apple On Today's Menu, With Starring Roles From China Talks, Fed Meeting",2019-07-30 10:07:00-04:00,LLY,neutral
766246.0,Eli Lilly Reports Q2 Earnings Beat,2019-07-30 08:02:00-04:00,LLY,neutral
766247.0,"The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings",2019-07-30 07:00:00-04:00,LLY,positive
766248.0,Eli Lilly Sees FY19 Adj. EPS $5.67-$5.77 vs $5.66 Est.,2019-07-30 06:26:00-04:00,LLY,neutral
766249.0,"Eli Lilly Q2 Adj. EPS $1.5 Beats $1.45 Estimate, Sales $5.637B Beat $5.59B Estimate",2019-07-30 06:25:00-04:00,LLY,neutral
766250.0,Lilly Announces Verzenio Demonstrated Significant Improvement In Overall Survival In Phase 3 MONARCH 2 The  Clinical Trial,2019-07-30 06:03:00-04:00,LLY,positive
766251.0,"15 Stocks To Watch For July 30, 2019",2019-07-30 04:38:00-04:00,LLY,neutral
766252.0,"Earnings Scheduled For July 30, 2019",2019-07-30 04:05:00-04:00,LLY,neutral
766253.0,Q2 Earnings Preview For Eli Lilly,2019-07-29 14:37:00-04:00,LLY,neutral
766254.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,LLY,negative
766255.0,"The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug",2019-07-25 07:21:00-04:00,LLY,negative
766256.0,Lilly Announces FDA Approval of BAQSIMI to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older,2019-07-25 03:37:00-04:00,LLY,positive
766257.0,"AC Immune Initiates Phase 1 Study Of ACI-3024 Small Molecule Tau Morphomer, An Investigational Treatment For Alzheimer's Disease",2019-07-17 07:03:00-04:00,LLY,positive
766258.0,"Jim Cramer Weighs In On Marvell, General Motors And More",2019-07-16 07:31:00-04:00,LLY,neutral
766259.0,"Barron's Picks And Pans: Dollar Tree, Expedia, Nvidia, Prudential And More",2019-07-13 15:04:00-04:00,LLY,neutral
766260.0,Lilly Presents New Findings on Stigma Faced by People with Migraine Based on Interim Results from the OVERCOME Observational Study,2019-07-13 12:19:00-04:00,LLY,neutral
766261.0,"Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug",2019-07-12 10:19:00-04:00,LLY,neutral
766262.0,Stock Market Eyes Records On Dovish Commentary From Federal Reserve,2019-07-12 10:17:00-04:00,LLY,neutral
766263.0,"Shares of several drug manufacturing companies are trading lower, potentially on continued weakness after the Trump Administration on Thursday rolled back a proposal to eliminate rebates from government drug plans.",2019-07-12 09:53:00-04:00,LLY,negative
766264.0,Eli Lilly Highlights Upcoming Presentation Of Data From OVERCOME Study,2019-07-12 08:04:00-04:00,LLY,neutral
766265.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,LLY,negative
766266.0,Eli Lilly Names Mike Harrington New General Counsel,2019-07-11 08:15:00-04:00,LLY,neutral
766267.0,Eli Lilly Highlights Phase 3 Study Results Of Emgality For Treatment Of Episodic Cluster Headache Published In 'New England Journal Of Medicine',2019-07-11 06:48:00-04:00,LLY,neutral
766268.0,Judge Rules Against Trump Proposal Forcing Pharma Companies To Disclose Drug Prices In Commercials,2019-07-09 10:03:00-04:00,LLY,neutral
766269.0,U.S. Judge Halts Trump Administration Rule Requiring Drug Prices in TV Ads,2019-07-08 18:26:00-04:00,LLY,neutral
766270.0,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",2019-07-08 12:55:00-04:00,LLY,positive
766271.0,Entera Announces Initiation Of Phase 2 Dose Ranging Study For Oral PTH,2019-07-02 07:00:00-04:00,LLY,neutral
766272.0,Eli Lilly shares trading lower with the other major drugmakers. The downside comes despite news empagliflozin was granted Fast Track Designation by the FDA. The company also announced a Type-2 diabetes drug trial met endpoints.,2019-06-26 12:40:00-04:00,LLY,neutral
766273.0,Lilly's Heart Drug Snags Fast Track Designation; Type 2 Diabetes Drug Found Effective At Higher Doses,2019-06-26 10:22:00-04:00,LLY,positive
766274.0,"The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart",2019-06-26 07:19:00-04:00,LLY,neutral
766275.0,Lilly Announces AWARD-11 Trial Studying Higher Investigational Doses Of Trulicity Demonstrated Superiority In A1C Reduction In People With Type 2 Diabetes,2019-06-26 06:47:00-04:00,LLY,positive
766276.0,"Eli Lilly, Boehringer Ingelheim Announce FDA Grants Fast Track Designation To Empagliflozin For The Reduction Of The Risk Of Cardiovascular Death And Hospitalization For Heart Failure In People With Chronic Heart Failure",2019-06-26 06:03:00-04:00,LLY,negative
766277.0,"From Earlier: 'Drug makers Amgen, Merck, Lilly and the Association of National Advertisers file suit to prevent the disclosure of drug prices in television ads.'",2019-06-14 14:43:00-04:00,LLY,neutral
766278.0,Eli Lilly Presents Data on its Taltz Versus AbbVie's Humira in Patients With Active Psoriatic Arthiritis at the European Congress of Rheumatology,2019-06-14 06:47:00-04:00,LLY,positive
766279.0,"The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering",2019-06-11 07:34:00-04:00,LLY,positive
766280.0,Eli Lilly shares are trading lower after the company announced disappointing data for the treatment of type 2 diabetes.,2019-06-10 11:29:00-04:00,LLY,negative
766281.0,Lilly Announces Trulicity Significantly Reduced Major Cardiovascular Events for Broad Range of People With Type 2 Diabetes,2019-06-09 20:39:00-04:00,LLY,neutral
766282.0,Lilly Announces Tirzepatide Demonstrates Benefits in Data Presented at American Diabetes Association's Scientific Sessions,2019-06-09 17:43:00-04:00,LLY,positive
766283.0,"Lilly Announces Ultra Rapid Lispro Provided Similar A1C Reductions vs Humalog, With Superior Post-meal Blood Glucose Reductions at ADA Scientific Sessions",2019-06-09 17:41:00-04:00,LLY,positive
766284.0,"Eli Lilly Highlights Will Present Data For Taltz, Olumiant At EULAR 2019 Jun. 12-15, 2019",2019-06-06 06:48:00-04:00,LLY,neutral
766285.0,"The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache",2019-06-05 07:30:00-04:00,LLY,positive
766286.0,"Jim Cramer Shares His Thoughts On AMD, CME Group, Microsoft And More",2019-06-05 07:26:00-04:00,LLY,positive
766287.0,Lilly To Present Data From Dermatology Portfolio At 24th World Congress Of Dermatology,2019-06-05 06:49:00-04:00,LLY,neutral
766288.0,EliLilly Announces FDA Approval of Emgality as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks,2019-06-05 04:20:00-04:00,LLY,positive
766289.0,FDA Approves Eli Lilly's Emgality For Injection For Treatment Of Episodic Cluster Headache In Adults,2019-06-04 16:52:00-04:00,LLY,positive
766290.0,Eli Lilly Reports FDA Accepted New Drug Application For Triple Combo Tablet For Adults with Type 2 Diabetes,2019-06-04 07:33:00-04:00,LLY,positive
766291.0,"Atomwise Announces Multi-Year, Multi-Target Agreement With Lilly For AI-Driven Drug Discovery Program",2019-06-03 09:03:00-04:00,LLY,positive
766292.0,"Benzinga's Top Upgrades, Downgrades For May 28, 2019",2019-05-28 09:15:00-04:00,LLY,positive
766293.0,Lilly Announces Licensing Agreement For Non-Opioid Pain Asset From Centrexion Therapeutics; Lilly To Pay Centrexion $47.5M Up Front And Up To $575M In Potential Development Milestones,2019-05-28 07:56:00-04:00,LLY,positive
766294.0,"Goldman Sachs Initiates Coverage On Eli Lilly with Buy Rating, Announces $135 Price Target",2019-05-28 07:31:00-04:00,LLY,neutral
766295.0,"Eli Lilly Reports Insulin Lispro Injection Now Available For Order In Pharmacies For People Who Use Co.'s Rapid-Acting Insulin, Need For Lower-Cost Option",2019-05-22 06:34:00-04:00,LLY,neutral
766296.0,"Eli Lilly Reports Mirikizumab Met Primary, Key Secondary Endpoints",2019-05-21 13:00:00-04:00,LLY,neutral
766297.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs",2019-05-18 09:50:00-04:00,LLY,neutral
766298.0,"Shares of several healthcare companies are trading higher as the US market rebounds from recent weakness, driven by renewed cautious optimism surrounding US-China trade talks.",2019-05-14 13:32:00-04:00,LLY,positive
766299.0,A Peek Into The Markets: US Stock Futures Tumble; Dow Futures Down Over 300 Points,2019-05-13 06:56:00-04:00,LLY,neutral
766300.0,Eli Lilly Announces FDA Approval for its CYRAMZA for the Treatment of Patients with Hepatocellular Carcinoma,2019-05-13 06:48:00-04:00,LLY,positive
766301.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Radar Tool For Fri., May 10, 2019",2019-05-10 11:30:00-04:00,LLY,positive
766302.0,The Nextcure IPO: What You Need To Know,2019-05-08 11:22:00-04:00,LLY,neutral
766303.0,"Eli Lilly Highlights Upcoming Presentation Of Results From Pooled Subgroup Analyses Of Efficacy Data From Phase 3 EVOLVE-1, EVOLVE-2 Studies",2019-05-06 06:48:00-04:00,LLY,neutral
766304.0,Eli Lilly  Announces It Will Present 19 Scientific Abstracts For Emgality (Galcanezumab-Gnlm) And Lasmiditan At The 71St Annual Meeting Of The American Academy Of Neurology Taking Place In Philadelphia From May 4-10,2019-05-02 08:13:00-04:00,LLY,neutral
766305.0,"BMO Capital Maintains Outperform on Eli Lilly and Company Common Stock, Raises Price Target to $133",2019-05-01 09:42:00-04:00,LLY,neutral
766306.0,Eli Lilly And Co shares are trading lower after the the company reported mixed Q1 results and FY19 guidance which was slightly below the consensus estimate.,2019-04-30 09:26:00-04:00,LLY,neutral
766307.0,30 Stocks Moving In Tuesday's Pre-Market Session,2019-04-30 08:08:00-04:00,LLY,neutral
766308.0,"The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering",2019-04-30 08:06:00-04:00,LLY,positive
766309.0,"A Peek Into The Markets: US Stock Futures Mixed Ahead Of Earnings, Fed Meeting",2019-04-30 07:23:00-04:00,LLY,neutral
766310.0,"15 Stocks To Watch For April 30, 2019",2019-04-30 06:37:00-04:00,LLY,neutral
766311.0,Eli Lilly Sees FY19 EPS $5.60-$5.70 vs $5.64 Est.,2019-04-30 06:27:00-04:00,LLY,neutral
766312.0,"Eli Lilly Q1 Adj. EPS $1.33 Beats $1.26 Estimate, Sales $5.09B Miss $5.11B Estimate",2019-04-30 06:26:00-04:00,LLY,negative
766313.0,"Earnings Scheduled For April 30, 2019",2019-04-30 06:18:00-04:00,LLY,neutral
766314.0,Recommends Withdrawal Of Marketing Authorisation For Eli Lilly's Cancer Medicine Lartruvo,2019-04-26 11:42:00-04:00,LLY,negative
766315.0,US Court Of Appeals Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit,2019-04-26 11:31:00-04:00,LLY,positive
766316.0,Lilly Prepares To Withdraw Lartruvo From Global Market,2019-04-25 06:52:00-04:00,LLY,neutral
766317.0,"Benzinga's Top Upgrades, Downgrades For April 24, 2019",2019-04-24 10:23:00-04:00,LLY,positive
766318.0,Edward Jones Upgrades Eli Lilly and Company Common Stock to Buy,2019-04-24 06:30:00-04:00,LLY,neutral
766319.0,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",2019-04-23 11:52:00-04:00,LLY,positive
766320.0,"The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale",2019-04-23 08:08:00-04:00,LLY,positive
766321.0,Lilly Announces Sale of Legacy Antibiotics Brands and Manufacturing Facility in China for $375M,2019-04-23 06:14:00-04:00,LLY,neutral
766322.0,"Eli Lilly-Pfizer's Non-Opioid Painkiller Faces Safety, Efficacy Concerns",2019-04-22 10:24:00-04:00,LLY,positive
766323.0,"Pfizer, Eli Lilly Late Thurs. Announced Top-Line Results From Long-Term Phase 3 Study Of Tanezumab In Patients With Osteoarthritis",2019-04-22 08:23:00-04:00,LLY,neutral
766324.0,Eli Lilly Says its COAST-X Study of Taltz Met its Primary and Key Secondary Endpoints,2019-04-22 06:47:00-04:00,LLY,neutral
766325.0,"Eli Lilly Announces Research and Licensing Collaboration with Avidity Biosciences to Pursue Therapeutics Targets Focused on Immunology, Eli Lilly to Pay $20M Upfront and Make a $15M Investment in Avidity",2019-04-22 06:32:00-04:00,LLY,positive
766326.0,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,2019-04-18 10:51:00-04:00,LLY,negative
766327.0,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,2019-04-17 10:31:00-04:00,LLY,negative
766328.0,Shares of several drug companies are trading lower. Weakness may be tied to uncertainty over healthcare policy going into the 2020 primaries and Washington's recent efforts to curb prescription drug prices.,2019-04-16 15:34:00-04:00,LLY,negative
766329.0,"Benzinga's Top Upgrades, Downgrades For April 11, 2019",2019-04-11 09:09:00-04:00,LLY,positive
766330.0,Guggenheim Downgrades Eli Lilly to Neutral,2019-04-11 06:52:00-04:00,LLY,neutral
766331.0,Arteaus Sold its Royalty Interest on Future Global Net Sales of Eli Lilly's Emgality to Royalty Pharma for $260M,2019-04-01 05:02:00-04:00,LLY,positive
766332.0,"Jim Cramer Advised His Viewers On Canopy Growth, DowDuPont And More",2019-03-29 07:22:00-04:00,LLY,positive
766333.0,"The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO",2019-03-27 07:52:00-04:00,LLY,positive
766334.0,"Eli Lilly, EOG, McDonald's, Gold Miners ETF: 'Fast Money' Picks For March 27",2019-03-27 07:30:00-04:00,LLY,neutral
766335.0,"Eli Lilly Announces Collaboration with ImmuNext to Develop Medicines for Autoimmune Diseases, Eli Lilly to Make a $40M Upfront Payment",2019-03-26 16:31:00-04:00,LLY,neutral
766336.0,Lilly Says Net Price for Humalog Insulin Declines 8.1% from 2014-2018,2019-03-24 14:42:00-04:00,LLY,neutral
766337.0,"National Comprehensive Cancer Network Announces Its Oncology Research Program, Eli Lilly To Take On 6 Projects Aimed To Improve Delivery Of Gastric, Gastroesophageal Junction Cancer Care In US",2019-03-20 08:46:00-04:00,LLY,negative
766338.0,"The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering",2019-03-14 07:47:00-04:00,LLY,neutral
766339.0,"Eli Lilly Could Sustain Industry-Leading Growth, Says Bullish JPMorgan",2019-03-12 12:10:00-04:00,LLY,positive
766340.0,"The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug",2019-03-12 07:47:00-04:00,LLY,positive
766341.0,Lilly Announces CYRAMZA Phase 3 RELAY Trial Met Primary Endpoint In Patients With Metastatic EGFR-Mutated Non-Small Cell Lung Cancer,2019-03-12 06:49:00-04:00,LLY,negative
766342.0,Elanco Animal Health Begins Trading After Eli Lilly Split,2019-03-11 16:01:00-04:00,LLY,neutral
766343.0,Eli Lilly Reports Final Exchange Ratio OF 4.5121 Shares For Elanco,2019-03-07 06:49:00-05:00,LLY,positive
766344.0,"Cigna Says In Discussions With Lilly About Humalog Authorized Alternative, And If The Net Cost Is Lowest For Plans, Will Add It To Flex Formulary",2019-03-06 14:26:00-05:00,LLY,negative
766345.0,FDA Approves Major Novel Depression Drug For First Time In 3 Decades,2019-03-06 09:25:00-05:00,LLY,positive
766346.0,Lilly Receives FDA Priority Review Designation For Emgality Injection For The Preventive Treatment Of Episodic Cluster Headache In Adults,2019-03-05 06:46:00-05:00,LLY,neutral
766347.0,Eli Lilly Announces the Launch of Lower Priced Insulin,2019-03-04 06:33:00-05:00,LLY,negative
766348.0,"The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis",2019-03-01 08:50:00-05:00,LLY,neutral
766349.0,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",2019-02-28 08:24:00-05:00,LLY,positive
766350.0,"The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings",2019-02-27 08:13:00-05:00,LLY,neutral
766351.0,"US Senate Finance Committee Launches Bipartisan Investigation Into Rising Insulin Prices; Sends Letters To Eli Lilly, Novo Nordisk And Sanofi",2019-02-22 15:57:00-05:00,LLY,neutral
766352.0,"The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data",2019-02-22 08:50:00-05:00,LLY,neutral
766353.0,Merck To Buy Immune Design For $300M,2019-02-21 09:28:00-05:00,LLY,positive
766354.0,S&P Downgrades Eli Lilly Credit Rating From AA- To A+; Outlook Raised From Credit Watch Negative To Stable,2019-02-19 15:54:00-05:00,LLY,positive
766355.0,"Eli Lilly Files For Mixed Shelf Offering, Size Not Disclosed",2019-02-19 14:26:00-05:00,LLY,neutral
766356.0,"Eli Lilly 10-K Just Recently Out; 1 Highlight: Co. Employed ~38,680 Employees At End Of 2018",2019-02-19 11:16:00-05:00,LLY,positive
766357.0,"Supreme Court Rejects Maryland's Bid To Revive A Law Aimed At Preventing Price Gouging By Pharmaceutical Companies, Reuters Reports",2019-02-19 10:04:00-05:00,LLY,positive
766358.0,Pfizer And Lilly Announce Top-line Results From Phase 3 Study Of Tanezumab In Chronic Low Back Pain; Tanezumab Met Primary Endpoint,2019-02-19 06:48:00-05:00,LLY,negative
766359.0,"Bayer To Obtain Full Rights To Global Development And Commercialization Of Oncology Compounds VITRAKVI And AND BAY 2731954, Will Be Solely Responsible For Global Development And Commercialization Of Both",2019-02-15 09:40:00-05:00,LLY,positive
766360.0,"Stocks Trading Ex Dividend For Thurs., Feb. 14, 2019",2019-02-14 11:29:00-05:00,LLY,neutral
766361.0,"Eli Lilly, Boehringer Ingelheim Report CAROLINA Trial Of Tradjenta Met Primary Endpoint, Showed 'no increased cardiovascular risk compared with glimepiride in adults with type 2 diabetes and cardiovascular risk'",2019-02-14 06:31:00-05:00,LLY,negative
766362.0,Eli Lilly Reports Will Initiate Divestiture Of Its Remaining Interest In Elanco Animal Health,2019-02-08 06:49:00-05:00,LLY,positive
766363.0,"After State Of the Union, Focus Turns Again To Earnings News, Geopolitics, Fed",2019-02-06 10:13:00-05:00,LLY,neutral
766364.0,"The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering",2019-02-06 08:23:00-05:00,LLY,neutral
766365.0,Eli Lilly Guides FY19 EPS Of $5.55-5.65 vs $5.77 Est; Lowers FY19 Revenue Guidance From $25.3-25.8 Bln To $25.1-25.6 Bln vs $25.27 Bln Est,2019-02-06 06:34:00-05:00,LLY,negative
766366.0,"Lilly Q4 EPS $1.33 Misses $1.34 Est, Sales $6.438B Beat $6.28B Est.",2019-02-06 06:30:00-05:00,LLY,negative
766367.0,A Peek Into The Markets: US Stock Futures Down Ahead Of Earnings,2019-02-06 06:29:00-05:00,LLY,neutral
766368.0,"13 Stocks To Watch For February 6, 2019",2019-02-06 04:48:00-05:00,LLY,neutral
766369.0,"Earnings Scheduled For February 6, 2019",2019-02-06 04:10:00-05:00,LLY,neutral
766370.0,"The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results",2019-02-05 07:47:00-05:00,LLY,positive
766371.0,Eli Lilly Announces Two Phase 3 Trials of Baricitinib Met Their Primary Endpoints,2019-02-04 06:48:00-05:00,LLY,neutral
766372.0,Trump At State Of The Union Will Ask For Drug Pricing Cuts,2019-02-01 15:36:00-05:00,LLY,negative
766373.0,"Optum To Cover Amgen, Eli Lilly Migraine Drugs, Exclude Teva",2019-02-01 10:35:00-05:00,LLY,negative
766374.0,Pharma Catches Another Case Of M&A Fever,2019-02-01 10:15:00-05:00,LLY,neutral
766375.0,"The Daily Biotech Pulse: Merck Earnings, Positive Relaunch Of  Titan's Opioid Disorder Treatment Implant",2019-02-01 09:10:00-05:00,LLY,positive
766376.0,"Eli Lilly, Loxo Oncology Reports Expiration Of Hart-Scott-Rodino Antitrust Act Waiting Period For Proposed Deal",2019-02-01 06:49:00-05:00,LLY,neutral
766377.0,"Earnings, Volatility, Brexit Are Key Topics Heading Into February",2019-01-31 15:05:00-05:00,LLY,neutral
766378.0,"Eli Lilly Reports FDA Expanded ALIMTA's Label To Combine KEYTRUDA, Platinum Chemotherapy For First-Line Treatment Of Metastatic Nonsquamous Non-Small Cell Lunch Cancer",2019-01-31 06:51:00-05:00,LLY,negative
766379.0,Pfizer And Lilly Announce Second Phase 3 Study Of Tanezumab In Osteoarthritis Pain Met All Three Co-Primary Endpoints At 24 Weeks,2019-01-29 06:39:00-05:00,LLY,negative
766380.0,"A Peek Into The Markets: US Stock Futures Down, Caterpillar Earnings In Focus",2019-01-28 06:50:00-05:00,LLY,neutral
766381.0,111 and Eli Lilly to Collaborate on Pharmaceutical Distribution With a Focus on Big Data and E-Prescriptions,2019-01-28 06:23:00-05:00,LLY,neutral
766382.0,"CVS Says Puts New Migraine Drugs From Teva And Eli Lilly On List Of Covered Medicines, Excludes Amgen's AIMOVIG",2019-01-25 14:28:00-05:00,LLY,neutral
766383.0,European Medicines Agency Says No New Patients Should Start Treatment With Lilly's Lartruvo After Study Shows Cancer Medicine Does Not Prolong Life,2019-01-23 09:13:00-05:00,LLY,negative
766384.0,UBS Initiates Coverage On Eli Lilly with Buy Rating,2019-01-23 08:34:00-05:00,LLY,neutral
766385.0,Eli Lilly shares are trading lower after the company announced the Phase 3 study of LARTRUVO did not meet its primary endpoint.,2019-01-18 09:13:00-05:00,LLY,neutral
766386.0,40 Stocks Moving In Friday's Pre-Market Session,2019-01-18 08:07:00-05:00,LLY,neutral
766387.0,"The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug",2019-01-18 07:49:00-05:00,LLY,neutral
766388.0,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street,2019-01-18 07:01:00-05:00,LLY,neutral
766389.0,Eli Lilly's Phase 3 Study of LARTRUVO Did Not Meet Its Primary Endpoint,2019-01-18 06:46:00-05:00,LLY,neutral
766390.0,Zymeworks to Receive an 8M Milestone Payment from Eli Lilly,2019-01-17 17:01:00-05:00,LLY,neutral
766391.0,Eli Lilly And Ablexis Announces Expansion Of Non-Exclusive Perpetual License Agreement; Expanded Rights To Allow For Broader Use Of ALIVAMAB Mouse Platform,2019-01-17 07:13:00-05:00,LLY,positive
766392.0,Eli Lilly Form 4 From Lilly Endowment Shows Open Market Sale Of ~51.8K Shares At $117.744/Share,2019-01-16 14:42:00-05:00,LLY,positive
766393.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2019-01-13 15:50:00-05:00,LLY,neutral
766394.0,4 Biotech Pipeline Areas To Keep An Eye On In 2019,2019-01-11 14:53:00-05:00,LLY,neutral
766395.0,"The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase",2019-01-08 08:15:00-05:00,LLY,negative
766396.0,65 Biggest Movers From Yesterday,2019-01-08 05:16:00-05:00,LLY,neutral
766397.0,Mid-Afternoon Market Update: Dow Up 125 Points; Axsome Therapeutics Shares Spike Higher,2019-01-07 15:08:00-05:00,LLY,positive
766398.0,42 Stocks Moving In Monday's Mid-Day Session,2019-01-07 13:49:00-05:00,LLY,neutral
766399.0,Mid-Day Market Update: Luxoft Jumps On Acquisition News; PG&E Shares Tumble,2019-01-07 12:52:00-05:00,LLY,positive
766400.0,Mid-Morning Market Update: Markets Mixed; Commercial Metals Misses Q1 Views,2019-01-07 10:20:00-05:00,LLY,negative
766401.0,Eli Lilly Agrees To Buy Loxo For $8B In Bid To Expand Oncology Franchise,2019-01-07 09:00:00-05:00,LLY,positive
766402.0,Eli Lilly Says it Will Limit Share Buybacks to $3.5M in 1H 2019,2019-01-07 08:53:00-05:00,LLY,positive
766403.0,21 Stocks Moving In Monday's Pre-Market Session,2019-01-07 08:09:00-05:00,LLY,neutral
766404.0,Loxo Oncology to be Acquired by Eli Lilly For $235/Share Cash in Deal Worth $8B,2019-01-07 06:31:00-05:00,LLY,positive
766405.0,"Adamis Has 'Favorable' Pipeline Setup, Says Bullish Raymond James",2019-01-02 10:21:00-05:00,LLY,neutral
766406.0,Lilly Announces China's NMPA Approves Innovent's Anti-PD-1 Antibody Tyvyt for Hodgkin's Lymphoma,2018-12-27 06:04:00-05:00,LLY,positive
766407.0,Dicerna Pharma 13D Filing From Eli Lilly Shows New 8.6% Stake,2018-12-20 15:46:00-05:00,LLY,neutral
766408.0,Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company,2018-12-20 03:44:00-05:00,LLY,positive
766409.0,Eli Lilly shares are trading up after the company reaffirmed strong guidance for FY18 and FY19 and raised its quarterly dividend.,2018-12-19 10:40:00-05:00,LLY,positive
766410.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,LLY,positive
766411.0,Eli Lilly Reaffirms FY18 Sales Guidance $24.3B-$24.5B vs $24.43B Estimate,2018-12-19 06:32:00-05:00,LLY,neutral
766412.0,Eli Lilly Sees FY19 Sales $25.3B-$25.8B vs $24.77B Estimate,2018-12-19 06:32:00-05:00,LLY,neutral
766413.0,Eli Lilly Reaffirms FY18 Adj. EPS Guidance $5.55-$5.60 vs $5.58 Estimate,2018-12-19 06:31:00-05:00,LLY,neutral
766414.0,Eli Lilly Sees FY19 Adj. EPS $5.90-$6 vs $5.82 Estimate,2018-12-19 06:31:00-05:00,LLY,neutral
766415.0,Eli Lilly Raises Qtr. Dividend From $0.5625 To $0.645/Share,2018-12-19 06:26:00-05:00,LLY,neutral
766416.0,"UPDATE: Aduro Will Be Eligible For Development, Commercial Milestones Up To ~$620M/Product",2018-12-18 16:16:00-05:00,LLY,neutral
766417.0,UPDATE: Aduro To Receive Upfront Payment Of $12M,2018-12-18 16:16:00-05:00,LLY,neutral
766418.0,"Eli Lilly, Aduro Biotech Report Research Collaboration, Exclusive License Deal For Aduro's cGAS-STRING Pathway Inhibitor Program",2018-12-18 16:16:00-05:00,LLY,positive
766419.0,Lilly Highlights Publication Of Analysis Showing Benefit Of The Addition Of Verzenio In Certain Breast Cancer Patients,2018-12-18 06:46:00-05:00,LLY,negative
766420.0,Health insurers and healthcare providers are trading down today after a Texas court ruled that ObamaCare was unconstitutional.,2018-12-17 11:06:00-05:00,LLY,neutral
766421.0,"Eli Lilly Says Taltz, in a Superiority Study Vs AbbVie's Humira, in Patients with Active Psoriatic Arthritis Met All Primary and Major Secondary Endpoints",2018-12-17 06:47:00-05:00,LLY,positive
766422.0,"Eli Lilly Reports Purchase Of Pre-Clinical Pain Program From Hydra Biosciences, No Terms Disclosed",2018-12-14 15:30:00-05:00,LLY,negative
766423.0,Eli Lilly Reports Expansion Of Collaboration With Evidation Health For Andromeda Data Platform,2018-12-14 06:50:00-05:00,LLY,neutral
766424.0,"A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Jobless Claims, Import Prices Data",2018-12-13 07:07:00-05:00,LLY,neutral
766425.0,Eli Lilly Reports Fast Track Designation To Baricitinib Development Program For Treatment Of Systemic Lupus Erythematosus,2018-12-13 06:46:00-05:00,LLY,neutral
766426.0,"Eli Lilly Announces Co. Boehringer Ingelheim Partner With Duke Clinical Research Institute To Advance Multidisciplinary Care For People With Type-2 Diabetes, Cardiovascular Disease",2018-12-13 06:31:00-05:00,LLY,positive
766427.0,Lilly And AC Immune Announce License And Collaboration Agreement  To Focus On Potential Alzheimers Treatment; AC Immune To Receive CHF80M Upfront And IS Eligible For Additional Milestones While Lilly Will Purchase A $50M Note Convertible Equity Position,2018-12-12 06:07:00-05:00,LLY,positive
766428.0,"Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week",2018-12-07 16:09:00-05:00,LLY,positive
766429.0,"The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering",2018-12-06 07:56:00-05:00,LLY,negative
766430.0,"Ahead Of Mid-Week Pause, Investors Fret Over Trade Pact Details",2018-12-04 10:24:00-05:00,LLY,neutral
766431.0,"Stocks Which Set New 52-Week High Yesterday, Thurs., Nov. 29, 2018",2018-11-30 10:25:00-05:00,LLY,neutral
766432.0,"The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings",2018-11-30 08:25:00-05:00,LLY,negative
766433.0,Eli Lilly Highlights Will Present Data For Verzenio At San Antonio Breast Cancer Symposium Dec. 4-8,2018-11-29 06:50:00-05:00,LLY,negative
766434.0,Expert Consensus Decision Pathway Issued By American College Of Cardiology Recommended Lilly's Jardiance As Preferred SGLT2 Inhibitor For Adults With Type 2 Diabetes And Established Cardiovascular Disease,2018-11-26 14:37:00-05:00,LLY,positive
766435.0,"Data Dive, Trade Talks And Powell: Busy Post-Holiday Week On The Way",2018-11-26 09:41:00-05:00,LLY,neutral
766436.0,"Benzinga's Top Upgrades, Downgrades For November 26, 2018",2018-11-26 09:01:00-05:00,LLY,positive
766437.0,"A Peek Into The Markets: US Stock Futures Surge, Dow Futures Up Over 250 Points",2018-11-26 07:01:00-05:00,LLY,neutral
766438.0,Citigroup Downgrades Eli Lilly to Neutral,2018-11-26 06:50:00-05:00,LLY,neutral
766439.0,"'Eli Lilly Considers Sale of China Assets to Raise Cash' -Bloomberg, Citing Sources",2018-11-16 07:47:00-05:00,LLY,positive
766440.0,"Eli Lilly Reports Submission Of New Drug Application For Lasmiditan For Acute Treatment Of Migraine, Receives Breakthrough Designation For Emgality For Preventation Of Episodic Cluster Headache",2018-11-14 06:55:00-05:00,LLY,neutral
766441.0,Long Wait Is Over: Election Day Dawns With Markets Under Light Pressure,2018-11-06 10:06:00-05:00,LLY,negative
766442.0,A Peek Into The Markets: US Stock Futures Drop Ahead Of Earnings,2018-11-06 07:41:00-05:00,LLY,negative
766443.0,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",2018-11-06 07:04:00-05:00,LLY,positive
766444.0,UPDATE: Eli Lilly Raises FY18 Adj. EPS Guidance From $5.40-$5.50 To $5.55-$5.60 vs $5.48 Estimate,2018-11-06 06:29:00-05:00,LLY,neutral
766445.0,"Eli Lilly Q3 EPS $1.39 Beats $1.36 Estimate, Sales $6.062B Beat $6.02B Estimate; Raises Guidance",2018-11-06 06:29:00-05:00,LLY,neutral
766446.0,"10 Stocks To Watch For November 6, 2018",2018-11-06 05:43:00-05:00,LLY,neutral
766447.0,"Earnings Scheduled For November 6, 2018",2018-11-06 05:31:00-05:00,LLY,neutral
766448.0,"Eli Lilly, NextCure Report Collaboration To Discover, Develop Novel Immuno-Oncology Medicines; NextCure To Receive Upfront Payment Of $25M, Lilly Has Made $15M Equity Investment In NextCure",2018-11-05 16:35:00-05:00,LLY,positive
766449.0,Eli Lilly shares are trading up 3.8% after the company reported positive early results from a study of jardiance; The company also reported its trulicity demonstrated a 'superior' reduction of cardiovascular events in type 2 diabetes patients.,2018-11-05 15:23:00-05:00,LLY,positive
766450.0,Eli Lilly Gets Ready For First Report Post-Elanco IPO,2018-11-05 12:09:00-05:00,LLY,positive
766451.0,Eli Lilly Says Trulicity Demonstrates a Superior Reduction of Cardiovascular Events for People with Type 2 Diabetes,2018-11-05 11:25:00-05:00,LLY,positive
766452.0,Rally Fizzles As Apple's Guidance Seen Weak; Mixed Signals On China Keep Market Buzzing,2018-11-05 09:43:00-05:00,LLY,negative
766453.0,Eli Lilly Announces Positive Early Results From a Study of the First 5 Years of Jardiance Use,2018-11-05 07:15:00-05:00,LLY,positive
766454.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,LLY,neutral
766455.0,SIGA Technologies Reports Sale of Medical Countermeasures Priority Review Voucher to Eli Lilly for $80M,2018-11-01 07:57:00-04:00,LLY,neutral
766456.0,"Benzinga's Top Upgrades, Downgrades For October 31, 2018",2018-10-31 09:21:00-04:00,LLY,positive
766457.0,Credit Suisse Upgrades Eli Lilly to Neutral,2018-10-31 07:41:00-04:00,LLY,positive
766458.0,"Eli Lilly, Lowe's, Macy's, XLU: 'Fast Money' Picks For October 30",2018-10-30 06:56:00-04:00,LLY,neutral
766459.0,"Dicerna Soars After Eli Lilly Invests $100M In Licensing, Research Deal",2018-10-29 09:31:00-04:00,LLY,neutral
766460.0,"Dicerna Pharma Announces Licensing and Research Collaboration with Eli Lilly for Development and Commercialization of New Medicines in Cardio-Metabolic Disease, Neurodegeneration and Pain",2018-10-29 06:08:00-04:00,LLY,negative
766461.0,"Benzinga's Top Upgrades, Downgrades For October 24, 2018",2018-10-24 09:19:00-04:00,LLY,positive
766462.0,"Wolfe Research Initiates Coverage On Eli Lilly with Peer Perform Rating, Announces $119 Price Target",2018-10-24 06:36:00-04:00,LLY,neutral
766463.0,"Pfizer, Lilly Announce Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients",2018-10-24 03:46:00-04:00,LLY,positive
766464.0,"Earnings Scheduled For October 23, 2018",2018-10-23 04:22:00-04:00,LLY,neutral
766465.0,Eli Lilly Reports Results For 2 Phase 3 Studies Of Taltz In Ankylosing Spondylitis: 'COAST-V is the first successful AS trial to use ASAS40 as the primary endpoint',2018-10-22 15:31:00-04:00,LLY,positive
766466.0,A Preview Of Eli Lilly's Q3 Earnings,2018-10-22 14:37:00-04:00,LLY,neutral
766467.0,"Sanofi, Novo Nordisk, Lilly Shares Unaffected Amid Report State Of Minnesota Filed Suit Accusing Insulin Manufacturers Of Deceptive Drug Pricing Practices",2018-10-16 15:06:00-04:00,LLY,positive
766468.0,4 Major Market Opportunities For The Cannabis Industry,2018-10-14 13:26:00-04:00,LLY,positive
766469.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs",2018-10-14 13:21:00-04:00,LLY,neutral
766470.0,"Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $120",2018-10-12 08:20:00-04:00,LLY,negative
766471.0,"The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares",2018-10-10 07:56:00-04:00,LLY,positive
766472.0,FDA Commissioner Scott Gottlieb Issues Statement On 'new efforts to advance the development of generic copies of complex drugs to improve patient access to medicines',2018-10-09 11:19:00-04:00,LLY,positive
766473.0,"The Daily Biotech Pulse: Affimed's Cancer Drug Placed On Clinical Hold, Celgene's Positive Scalp Psoriasis Trial",2018-10-09 08:03:00-04:00,LLY,negative
766474.0,"Stocks That Made New 52-Week Highs So Far Today Include: Ameren, Pfizer, Eli Lilly, Envision Healthcare, AES, McCormick, Archer-Daniels Midland, and Ball Corp.",2018-10-08 13:32:00-04:00,LLY,neutral
766475.0,3 Screens That Hint At Which Stocks May Outperform In Q4,2018-10-05 11:57:00-04:00,LLY,neutral
766476.0,10 Biggest Price Target Changes For Friday,2018-10-05 09:52:00-04:00,LLY,neutral
766477.0,"Benzinga's Top Upgrades, Downgrades For October 5, 2018",2018-10-05 09:42:00-04:00,LLY,positive
766478.0,"Stocks Which Set New 52-Week High Yesterday, October 4th",2018-10-05 09:20:00-04:00,LLY,neutral
766479.0,"The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker",2018-10-05 08:35:00-04:00,LLY,positive
766480.0,"BMO Capital Upgrades Eli Lilly to Outperform, Raises Price Target to $130",2018-10-05 05:59:00-04:00,LLY,neutral
766481.0,"Stocks That Made New 52-Week Highs So Far Today Include: Ball Corp, CF Industries, Jacobs Engineering, Mosaic, CME Group, and Eli Lilly",2018-10-04 15:24:00-04:00,LLY,neutral
766482.0,Eli Lilly shares are up 2.8% to $111.68 after the company earlier reported its empagliflozin in a Phase III trial met its primary efficacy endpoint.,2018-10-04 12:35:00-04:00,LLY,positive
766483.0,"Stocks Which Set New 52-Week High Yesterday, October 3rd",2018-10-04 11:18:00-04:00,LLY,neutral
766484.0,"The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut",2018-10-04 07:59:00-04:00,LLY,neutral
766485.0,"Boehringer Ingelheim, Eli Lilly Report Empagliflozin In Phase III Trial Met Primary Efficacy Endpoint",2018-10-04 06:31:00-04:00,LLY,neutral
766486.0,"Eli Lilly Reports Investigational Dual GIP, GLP-1 Receptor Agonist Showed Reduction In HbA1c, Body Weight In People With Type 2 Diabetes",2018-10-04 06:04:00-04:00,LLY,neutral
766487.0,"Stocks Which Set New 52-Week High Yesterday, October 2nd",2018-10-03 12:59:00-04:00,LLY,neutral
766488.0,10 Biggest Price Target Changes For Wednesday,2018-10-03 09:51:00-04:00,LLY,neutral
766489.0,"The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares",2018-10-03 07:54:00-04:00,LLY,positive
766490.0,"BMO Capital Maintains Market Perform on Eli Lilly, Raises Price Target to $107",2018-10-03 07:28:00-04:00,LLY,neutral
766491.0,Results From Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint In People With Type 1 And Type 2 Diabetes,2018-10-02 06:01:00-04:00,LLY,neutral
766492.0,Leerink: Improving Fundamentals Drive Teva Upgrade,2018-10-01 14:01:00-04:00,LLY,positive
766493.0,"The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results",2018-09-28 08:10:00-04:00,LLY,positive
766494.0,Lilly's Emgality Receives FDA Approval for the Preventive Treatment of Migraine in Adults,2018-09-27 19:57:00-04:00,LLY,positive
766495.0,US Judge Has Dismissed Patent Suits By Teva Against Eli Lilly Related To Its Migraine Drug,2018-09-27 14:13:00-04:00,LLY,neutral
766496.0,"The Daily Biotech Pulse: Hologic Goes Shopping, Johnson & Johnson Snaps Ties With Geron",2018-09-27 08:20:00-04:00,LLY,neutral
766497.0,JPMorgan Resumes Coverage Of Eli Lilly: 'One Of The Best-Positioned Names In Our Group',2018-09-26 13:19:00-04:00,LLY,neutral
766498.0,"From Earlier, JP Morgan Reinstated Eli Lilly at Overweight, Announces $117 Price Target",2018-09-26 13:13:00-04:00,LLY,neutral
766499.0,Lilly Receives Positive CHMP Opinion for Emgality for the Prophylaxis of Migraine in Adults,2018-09-21 07:47:00-04:00,LLY,positive
766500.0,Elanco Animal Health Shares Indicated $26 on 750K Shares; IPO Priced at $24/Share,2018-09-20 09:54:00-04:00,LLY,positive
766501.0,"The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut",2018-09-20 09:02:00-04:00,LLY,positive
766502.0,Elanco Animal Health Prices $62.9M Share IPO @$24/Share,2018-09-20 04:11:00-04:00,LLY,positive
766503.0,"Eli Lilly And Company Subsidiary, Elanco, Prices IPO Of 62.9M Shares At $24/Share; Shares Expected To Open For Trade Thursday On NYSE Under Symbol 'ELAn'",2018-09-19 17:14:00-04:00,LLY,positive
766504.0,10 Biggest Price Target Changes For Tuesday,2018-09-18 10:23:00-04:00,LLY,neutral
766505.0,"Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $112",2018-09-18 07:19:00-04:00,LLY,negative
766506.0,"Credit Suisse Lifts Teva Price Target, Says Execution Is Key For Migraine Drug",2018-09-17 15:07:00-04:00,LLY,positive
766507.0,Teva's Preventive Migraine Treatment Approved By FDA,2018-09-17 09:08:00-04:00,LLY,positive
766508.0,"The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-09-16 14:22:00-04:00,LLY,neutral
766509.0,"The IPO Outlook For The Week: Eventbrite, Animal Health And Luxury Fashion",2018-09-14 14:45:00-04:00,LLY,neutral
766510.0,"The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet",2018-09-11 08:25:00-04:00,LLY,negative
766511.0,"Stocks Which Set New 52-Week High Friday, September 7th",2018-09-10 16:36:00-04:00,LLY,neutral
766512.0,Eli Lilly Initiates IXORA-R Head-To-Head Clinical Trial Comparing Taltz And Tremfya,2018-09-10 09:03:00-04:00,LLY,neutral
766513.0,"Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $107",2018-09-07 07:16:00-04:00,LLY,negative
766514.0,New Class of Migraine Drug Creates Four-Way Pharma Development Race,2018-09-06 15:58:00-04:00,LLY,positive
766515.0,Eli Lilly's Elanco Sets IPO Of 62.9M Shares In $20-$23/Share Range,2018-09-06 06:17:00-04:00,LLY,positive
766516.0,Eli Lilly Says Phase 3 Results In Flortaucipir PET Imaging Agent Showed That Flortaucipir Demonstrated Statistically Significant Sensitivity And specificity For Detecting A High Level Of Total Alzheimer's Disease Neuropathologic Change,2018-09-05 14:03:00-04:00,LLY,positive
766517.0,Zymeworks Reports IND-Submission Milestone Achieved In Eli Lilly Collaboration; Co. Will Receive $2M Milestone Payment For Eli Lily's  Submission Of IND Application For Bispecific Antibody Enabled By Zymeworks' Azymetric Platform,2018-09-04 17:02:00-04:00,LLY,neutral
766518.0,Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates,2018-08-31 15:06:00-04:00,LLY,neutral
766519.0,"UPDATE: Adocia Notes Eli Lilly Filed Counterclaims Against Co. Seeking ~$188M, Including Prejudgment Interest",2018-08-30 12:04:00-04:00,LLY,positive
766520.0,"French Biopharma Co. Focused On Treatment For Diabetes, Etc, Adocia, Issues Press Release Highlighting Update To Amount Of Damages In Case Against Eli Lilly To ~$1.8B",2018-08-30 12:03:00-04:00,LLY,negative
766521.0,"The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic",2018-08-28 08:13:00-04:00,LLY,neutral
766522.0,"Stocks That Made New 52-Week Highs So Far Today Include: IHS Markit, Cooper Cos., IDEXX Labs, Motorola Solutions, Emerson, Sherwin-Williams, Kansas City Southern, Norfolk Southern, Archer-Daniels, Verisk, Illumina, CSX, AMD, Eli Lilly, & Union Pacific",2018-08-27 13:24:00-04:00,LLY,positive
766523.0,"Barron's Picks And Pans: Electronic Arts, GlaxoSmithKline, Microsoft, Tesla And More",2018-08-25 18:16:00-04:00,LLY,neutral
766524.0,"The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows",2018-08-21 08:40:00-04:00,LLY,positive
766525.0,"Stocks Which Set New 52-Week High Yesterday, August 16th",2018-08-17 10:39:00-04:00,LLY,neutral
766526.0,"The Daily Biotech Pulse: Aveo Slips On Stock Offering, FDA Greenlights Generic EpiPen, Pfenex Exec Resigns",2018-08-17 08:15:00-04:00,LLY,negative
766527.0,"Stocks That Made New 52-Week Highs So Far Today Include: Ingersoll-Rand, Dollar General, Progressive, SunTrust Banks, Eli Lilly, Express Scripts, CenturyLink, Cintas, Fastenal, Aetna, O'Reilly Automotive, Darden Restaurants, Chipotle, and Centene",2018-08-16 11:26:00-04:00,LLY,neutral
766528.0,"Stocks Trading Ex Dividend Today, August 14th",2018-08-14 09:06:00-04:00,LLY,neutral
766529.0,"Stocks That Will Be Trading Ex Dividend Tomorrow, August 14th",2018-08-13 14:12:00-04:00,LLY,neutral
766530.0,"Stocks Which Set New 52-Week High Yesterday, August 7th",2018-08-08 11:01:00-04:00,LLY,neutral
766531.0,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict",2018-08-08 08:15:00-04:00,LLY,positive
766532.0,"Stocks That Made New 52-Week Highs Earlier Today Include: SL Green Realty, Verisk Analytics, Medtronics, Pfizer, Conoco Phillips, Archer-Daniels, Eli Lilly, Merck, Phillips 66, Costco, Advance Auto Parts, Norfolk Southern, CSX, Zoetis, Apple, and Disney",2018-08-07 11:49:00-04:00,LLY,neutral
766533.0,"Stocks Which Set New 52-Week High Yesterday, August 6th",2018-08-07 11:27:00-04:00,LLY,neutral
766534.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,LLY,negative
766535.0,"Stocks Which Set New 52-Week Highs Friday, August 3rd",2018-08-06 13:02:00-04:00,LLY,neutral
766536.0,"Stocks Which Set New 52-Week High Yesterday, August 2nd",2018-08-03 11:16:00-04:00,LLY,neutral
766537.0,"The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings",2018-08-03 07:52:00-04:00,LLY,neutral
766538.0,Elanco Animal Health F-1 Shows Registration For $100M IPO; Co. Planning To List On NYSE Under Symbol 'ELAN'; BZ NOTE: Co. Is Eli Lilly's Animal Health Unit,2018-08-02 17:29:00-04:00,LLY,positive
766539.0,"Stocks That Made New 52 Week Highs So Far Today Include: PerkinElmer, Eli Lilly, Zoetis, Apple, Simon Property Group, Global Payments, and Church & Dwight",2018-08-02 11:09:00-04:00,LLY,neutral
766540.0,"Stocks Which Set New 52-Week High Yesterday, August 1st",2018-08-02 10:56:00-04:00,LLY,neutral
766541.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,LLY,positive
766542.0,"Stocks That Have Made New 52 Week Highs Thus Far Today Include: Robert Half, Eli Lilly, Pfizer, Phillips 66, Humana, HCA Healthcare, Genworth, Republic Services, Illumina, Aflac, Medtronic, Waste Management, and Apple",2018-08-01 13:32:00-04:00,LLY,negative
766543.0,"Stocks Which Set New 52-Week High Yesterday, July 31",2018-08-01 12:04:00-04:00,LLY,neutral
766544.0,"Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial",2018-08-01 09:01:00-04:00,LLY,negative
766545.0,Dan Nathan Sees Unusual Options Activity In Eli Lilly,2018-08-01 07:39:00-04:00,LLY,neutral
766546.0,"Morgan Stanley Maintains Equal-Weight on Eli Lilly, Raises Price Target to $102",2018-07-31 09:40:00-04:00,LLY,neutral
766547.0,"Stocks Which Set New 52-Week High Yesterday, July 30th",2018-07-31 09:20:00-04:00,LLY,neutral
766548.0,"Stocks That Made New 52 Week Highs So Far Today Include: AMD, Ingersoll-Rand, Aflac, Fortiv, Kansas City Southern, Union Pacific, HCA Healthcare, ConocoPhillips, Waste Management, and EOG Resources",2018-07-30 13:03:00-04:00,LLY,negative
766549.0,"Stocks Which Set New 52-Week High Friday, July 27th",2018-07-30 12:05:00-04:00,LLY,neutral
766550.0,Eli Lilly Announces a 3 Year Extension of its Cancer Research Collaboration with Dana-Farber Cancer Institute,2018-07-30 06:50:00-04:00,LLY,negative
766551.0,"Barron's Picks And Pans: Amazon, Eli Lilly, Fiat Chrysler And More",2018-07-29 17:29:00-04:00,LLY,positive
766552.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,LLY,neutral
766553.0,"Stocks Which Set New 52-Week High Yesterday, July 26th:",2018-07-27 10:42:00-04:00,LLY,neutral
766554.0,"Stocks Which Set New 52-Week High Yesterday, July 25th",2018-07-26 11:00:00-04:00,LLY,neutral
766555.0,"Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold",2018-07-26 08:40:00-04:00,LLY,negative
766556.0,"Stocks That Made New 52-Week Highs Earlier Include: Adobe, S&P Global, Baxter, Salesforce, Microsoft, Biogen, Becton, Norfolk Southern, Target, IHS Markit, Tiffany, Eli Lilly, Thermo Fisher, Facebook, FLIR Systems, Medtronic, and Mastercard",2018-07-25 12:25:00-04:00,LLY,neutral
766557.0,"Stocks Which Set New 52-Week High Yesterday, July 24th:",2018-07-25 12:14:00-04:00,LLY,neutral
766558.0,"BMO Capital Maintains Market Perform on Eli Lilly, Raises Price Target to $90",2018-07-25 10:20:00-04:00,LLY,neutral
766559.0,"Credit Suisse Maintains Underperform on Eli Lilly, Raises Price Target to $86",2018-07-25 10:11:00-04:00,LLY,positive
766560.0,"Concerns About Trade Picture Overshadowing Earnings As GM, Boeing Report",2018-07-25 09:55:00-04:00,LLY,neutral
766561.0,10 Biggest Price Target Changes For Wednesday,2018-07-25 09:52:00-04:00,LLY,neutral
766562.0,"Benzinga's Top Upgrades, Downgrades For July 25, 2018",2018-07-25 09:02:00-04:00,LLY,positive
766563.0,Berenberg Downgrades Eli Lilly to Hold,2018-07-25 08:17:00-04:00,LLY,neutral
766564.0,"Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $110",2018-07-25 07:25:00-04:00,LLY,negative
766565.0,Earnings Season Optimism Seems To Help Lift Market,2018-07-24 10:36:00-04:00,LLY,positive
766566.0,"From Eli Lilly Q2 Earnings Conference Call, Co. Says It Is 'Preparing For All Scenarios' Regarding Trump Administration's Plans To Address Rising Healthcare Costs",2018-07-24 09:29:00-04:00,LLY,neutral
766567.0,Benzinga Pro's 5 Stocks To Watch Today,2018-07-24 09:15:00-04:00,LLY,neutral
766568.0,"Benzinga's Daily Biotech Pulse: Celgene's Lymphoma Trial Meets Endpoint, Merit Medical's Strong Q2, Bluebird Bio Offering",2018-07-24 08:53:00-04:00,LLY,positive
766569.0,25 Stocks Moving In Tuesday's Pre-Market Session,2018-07-24 08:02:00-04:00,LLY,neutral
766570.0,A Peek Into The Markets: US Stock Futures Rise Ahead Of Earnings,2018-07-24 07:06:00-04:00,LLY,neutral
766571.0,Eli Lilly Raises FY18 Sales Outlook From $23.7B-$24.2B To $24.0B-$24.5B vs $23.99B Est.,2018-07-24 06:30:00-04:00,LLY,neutral
766572.0,Eli Lilly Raises FY18 Adj. EPS Outlook From $5.10-$5.20 To $5.40-$5.50 vs $5.15 Est.,2018-07-24 06:29:00-04:00,LLY,neutral
766573.0,Eli Lilly Revises FY18 Outlook,2018-07-24 06:27:00-04:00,LLY,neutral
766574.0,"Eli Lilly Q2 Adj. EPS $1.50 Beats $1.30 Estimate, Sales $6.36B Beat $6.05B Estimate",2018-07-24 06:26:00-04:00,LLY,neutral
766575.0,"Lilly to Separate Elanco Animal Health with IPO, Offering Is Expected To Represent An Ownership Stake Of Less Than 20% And Process Will Be Complete During Second Half Of 2018",2018-07-24 06:23:00-04:00,LLY,neutral
766576.0,"12 Stocks To Watch For July 24, 2018",2018-07-24 05:05:00-04:00,LLY,neutral
766577.0,"Earnings Scheduled For July 24, 2018",2018-07-24 04:20:00-04:00,LLY,neutral
766578.0,Eli Lilly's Q2 Earnings Preview,2018-07-23 15:52:00-04:00,LLY,neutral
766579.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-07-22 17:03:00-04:00,LLY,neutral
766580.0,Eli Lilly And Incyte Late Thursday Announced Study Results Showing Benefit Of Baricitinib 4 mg For Treatment Of Systemic Lupus Erythematosus (SLE) Were Published In The Lancet,2018-07-20 09:01:00-04:00,LLY,positive
766581.0,Boehringer Ingelheim and Lilly Announce Tradjenta's CARMELINA Outcome Trial Meets Primary Endpoint,2018-07-19 08:03:00-04:00,LLY,neutral
766582.0,"BMO Capital Maintains Market Perform on Eli Lilly, Raises Price Target to $80",2018-07-19 08:02:00-04:00,LLY,neutral
766583.0,"Eli Lilly Reports Once-Weekly Trulicity Label Updated To Include Data Showing Benefits For Adults With Type 2 Diabetes, Chronic Kidney Disease",2018-07-19 06:47:00-04:00,LLY,positive
766584.0,"Stocks That Made New 52-Week Highs Today Include: Alphabet (Both Classes), Facebook, Amazon, Eli Lilly, Intercontinental Exchange, Adobe, TripAdvisor, Darden Restaurants, Citrix, Marsh & McLennan, Norfolk Southern, Motorola, TJX, Intuit, Visa, and CSX",2018-07-18 14:25:00-04:00,LLY,positive
766585.0,"Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares",2018-07-18 08:42:00-04:00,LLY,positive
766586.0,"PFizer, Eli Lilly Report Phase 3 Trial Of Tanezumab Met All Thre Co-Primary Endpoints",2018-07-18 06:46:00-04:00,LLY,neutral
766587.0,"Stocks That Made New 52-Week Highs Today Include: Citrix, TripAdvisor, Microsoft, Alphabet (Both Classes), Medtronic, Accenture, Facebook, NetApp, S&P Global, Amazon, VeriSign, Motorola Solutions, Marsh & McLennan, IDEXX Labs, Eli Lilly, Sysco, and VF",2018-07-17 13:30:00-04:00,LLY,positive
766588.0,Health Care Sector Outlook: Checking In Ahead Of Q2 Earnings Reports,2018-07-09 14:39:00-04:00,LLY,positive
766589.0,A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year,2018-07-05 12:25:00-04:00,LLY,neutral
766590.0,"UPDATE: Lilly Will Engage 40K People With Migraine In US Over Next 2 Years, Will Be Conducted By Kantar Health On Behalf Of Co.",2018-06-29 06:47:00-04:00,LLY,positive
766591.0,"Eli Lilly Reports Initiation Of OVERCOME Study To Advance Understanding Of Burden, Impact, Epidemiology Of Migraine",2018-06-29 06:46:00-04:00,LLY,negative
766592.0,"Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut",2018-06-28 08:26:00-04:00,LLY,positive
766593.0,Eli Lilly Reports Taltz Met Primary and Secondary Endpoints in a Phase 3 Study,2018-06-28 06:47:00-04:00,LLY,neutral
766594.0,Eli Lilly Reports Intended Brand Name For Episodic Cluster Headache Treatment Approved As Emgality,2018-06-27 16:30:00-04:00,LLY,positive
766595.0,Eli Lilly Announces Results Of Phase 3 Study Of Emgailty Which Met Primary and Secondary Endpoint,2018-06-27 16:30:00-04:00,LLY,neutral
766596.0,Boehringer Ingelheim and Lilly Report EASE Phase III Program Met Primary Endpoint For All Investigated Doses Of empagliflozin,2018-06-25 08:01:00-04:00,LLY,positive
766597.0,Lilly Announces Investigational Doses of Once-Weekly Trulicity Show Promise in Delivering Powerful Efficacy in People with Type 2 Diabetes at #ADA2018,2018-06-23 19:14:00-04:00,LLY,positive
766598.0,Lily Announces Jardiance Reduced Risk of Kidney Disease Progression in Adults With Type 2 Diabetes and Established Cardiovascular (Cv) Disease Independent of Control of Conventional Cv Risk Factors,2018-06-23 19:00:00-04:00,LLY,negative
766599.0,Lilly Announces New Data Presented at #ADA2018 Reinforce Potential of Ultra Rapid Lispro in People with Type 1 and Type 2 Diabetes,2018-06-23 18:58:00-04:00,LLY,neutral
766600.0,"UPDATE: In Separate Decision June 15th District Court Ruled In Favor Of Eli Lilly Against Dr. Reddy's and Hospira, Preventing Them From Launching Alternative Salt Forms Of Pemetrexed Until Lilly's Patent Expires",2018-06-22 15:56:00-04:00,LLY,positive
766601.0,U.S. District Court Rules In Favor Of Eli Lilly Against Dr. Reddy's Laboratories In Alimta Vitamin Regimen Patent Lawsuit,2018-06-22 15:51:00-04:00,LLY,positive
766602.0,"Benzinga's Top Upgrades, Downgrades For June 22, 2018",2018-06-22 09:14:00-04:00,LLY,positive
766603.0,"The Market In 5 Minutes: Stress Test Results, More Trade Talks, Viacom's Unexpected Risk",2018-06-22 09:00:00-04:00,LLY,negative
766604.0,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street,2018-06-22 07:23:00-04:00,LLY,neutral
766605.0,DZ Bank Downgrades Eli Lilly to Hold,2018-06-22 06:39:00-04:00,LLY,neutral
766606.0,"Credit Suisse Maintains Underperform on Eli Lilly, Raises Price Target to $84",2018-06-21 07:44:00-04:00,LLY,positive
766607.0,Pop Star Pink Confronts SeaWorld On PETA's Behalf During Shareholder Meeting,2018-06-13 16:20:00-04:00,LLY,negative
766608.0,"Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate",2018-06-12 08:47:00-04:00,LLY,positive
766609.0,"Eli Lilly, AstraZeneca Discontinuing Global Phase 3 Clinical Trials of Lanabecestat",2018-06-12 03:44:00-04:00,LLY,neutral
766610.0,"Eli Lilly Division, Elanco Animal Health, Introduces New Respiratory PRRS Vaccine",2018-06-11 07:11:00-04:00,LLY,neutral
766611.0,Eli Lilly Reports Its Elanco Animal Health Unit Received Licensing Of Prevacent PRRS By USDA Shown To Be Effective In Reducing PRRS In Piglets 2 Weeks Or Older,2018-06-11 07:04:00-04:00,LLY,positive
766612.0,"Pharma Stock Roundup: Merck, Eli Lilly, AbbVie And More",2018-06-08 16:33:00-04:00,LLY,neutral
766613.0,"The Market In 5 Minutes: China, ZTE, McDonald's And More",2018-06-08 09:00:00-04:00,LLY,neutral
766614.0,"Benzinga's Top Upgrades, Downgrades For June 8, 2018",2018-06-08 08:58:00-04:00,LLY,positive
766615.0,"Cantor Fitzgerald Initiates Coverage On Eli Lilly with Overweight Rating, Announces $100 Price Target",2018-06-08 06:18:00-04:00,LLY,negative
766616.0,"Eli Lilly CEO Calls For Uniform Prices, Better Use Of Technology In Health Care",2018-06-07 16:24:00-04:00,LLY,positive
766617.0,"Lilly CEO Ricks, When Asked If Co. Will Participate In Right-To-Try Initiative, Tells Benzinga, Co. Has Supplied Medication To That Patient Population 'For Years,' Notes Co. Was Full Participant In Expanded Access Program, But Does Not Answer Directly",2018-06-07 13:57:00-04:00,LLY,neutral
766618.0,"Lilly CEO Ricks Positive On JP Morgan, Berkshire, Amazon Health Care Coalition, Says 'If these 3 large cos. can use their scale, technology to create real change and move to value-based payments, it could move [health care] system forward'",2018-06-07 13:29:00-04:00,LLY,positive
766619.0,"Eli Lilly CEO David Ricks Currently Speaking At Detroit Economic Club, Highlights Co. Launching Recently-Approved RA Drug Olumiant At 60% Discount To Competitors",2018-06-07 13:11:00-04:00,LLY,neutral
766620.0,UPDATE: Eli Lilly Reports Will Initiate Phase 3 Trial In Moderate To Severe Ulcerative Colitis In 2018,2018-06-05 10:17:00-04:00,LLY,negative
766621.0,"Eli Lilly Offers New Safety, Efficacy Data From Phase 2 Study Evaluating Mirikizumab In Patients With Moderate To Severe Ulcerative Colitis: Showed Achivement Of Greater Rates Of Clinical Remission At 12 Weeks vs Placebo",2018-06-05 10:16:00-04:00,LLY,positive
766622.0,"FDA Expands Eli Lilly's ALIMTA (pemetrexed) Label To Include Combination With KEYTRUDA (pembrolizumab) And Carboplatin As First-Line Treatment For Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective Of PD-L1 Expression",2018-06-05 06:47:00-04:00,LLY,negative
766623.0,"Donald Trump Tweets: 'We had Repeal & Replace done (and the saving to our country of one trillion dollars) except for one person, but it is getting done anyway'...'less expensive plans will be announced this month. Drug prices coming down & Right to Try!'",2018-06-04 08:22:00-04:00,LLY,neutral
766624.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,LLY,negative
766625.0,Eli Lilly Press Release Confirms Earlier News Of FDA Approval For Olumiant,2018-06-01 12:05:00-04:00,LLY,positive
766626.0,Eli Lilly And Co.'s Olumiant Wins FDA Approval,2018-06-01 11:23:00-04:00,LLY,positive
766627.0,Eli Lilly Says Will Present New Data Evaluating Mirikizumab Fro Treatment Of Moderate To Severe Ulcerative Colitis At Digestive Disease Week Jun. 2-5,2018-06-01 06:45:00-04:00,LLY,negative
766628.0,Eli Lilly Announces FDA Approval for its Taltz to Include Psoriasis Involving the Genital Area on its Label,2018-05-22 08:32:00-04:00,LLY,positive
766629.0,Lilly's Taltz® (ixekizumab) Receives First U.S. FDA Approval For Label Update To Include Data For Psoriasis Involving Genital Area,2018-05-22 08:32:00-04:00,LLY,positive
766630.0,"Eli Lilly To Buy AurKa Pharma For $110M Upfront Payment, Plus Eligibility To Receive Up To $465M In Regulatory, Sales Milestones Related To AK-01",2018-05-14 07:45:00-04:00,LLY,neutral
766631.0,55 Biggest Movers From Yesterday,2018-05-11 04:39:00-04:00,LLY,neutral
766632.0,UPDATE: Eli Lilly Announces Tender Offer for HBM-Portfolio Company ARMO BioSciences for $1.6B,2018-05-11 03:52:00-04:00,LLY,neutral
766633.0,Mid-Afternoon Market Update: Prestige Brands Gains On Earnings Beat; MDC Partners Shares Slide,2018-05-10 14:36:00-04:00,LLY,positive
766634.0,40 Stocks Moving In Thursday's Mid-Day Session,2018-05-10 12:43:00-04:00,LLY,neutral
766635.0,Mid-Day Market Update: Dow Rises 150 Points; Hudson Technologies Shares Plunge,2018-05-10 12:13:00-04:00,LLY,positive
766636.0,Mid-Morning Market Update: Markets Open Higher; Magna Tops Q1 Views,2018-05-10 10:14:00-04:00,LLY,positive
766637.0,"Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results",2018-05-10 09:44:00-04:00,LLY,neutral
766638.0,32 Stocks Moving In Thursday's Pre-Market Session,2018-05-10 08:08:00-04:00,LLY,neutral
766639.0,Lilly Announces Agreement To Acquire ARMO BioSciences For $50/Share Or ~$1.6B,2018-05-10 07:30:00-04:00,LLY,positive
766640.0,What's In Store For Radius Health In Q1 Earnings?,2018-05-07 13:56:00-04:00,LLY,neutral
766641.0,Eli Lilly and NCCD of China Collaborate to Advance Care for People Living with Diabetes and Cardiovascular Disease,2018-04-25 06:51:00-04:00,LLY,positive
766642.0,19 Companies Google Could Buy With Its $102 Billion In Cash,2018-04-24 15:56:00-04:00,LLY,neutral
766643.0,Goldman Sachs Neutral On Alder Biopharma As Launch Of Migraine Treatment Approaches,2018-04-24 12:49:00-04:00,LLY,neutral
766644.0,"Eli Lilly Says It Is Looking To Do More Deals In Oncology, Including Immuno-Oncology And Other Cancer Drugs",2018-04-24 09:42:00-04:00,LLY,negative
766645.0,28 Stocks Moving In Tuesday's Pre-Market Session,2018-04-24 08:01:00-04:00,LLY,neutral
766646.0,"UPDATE: Eli Lilly Raises FY18 Adj. EPS Outlook From $4.81-$4.91 To $5.10-$5.20 vs $4.88 Est., Sales From $23B-$23.5B To $23.7B-$24.2B vs $23.4B Est.",2018-04-24 06:27:00-04:00,LLY,neutral
766647.0,Eli Lilly Raises FY18 Outlook,2018-04-24 06:25:00-04:00,LLY,neutral
766648.0,"Eli Lilly Q1 Adj. EPS $1.34 Beats $1.14 Est., Sales $5.7B Beats $5.49B Est.",2018-04-24 06:25:00-04:00,LLY,neutral
766649.0,Lilly Reports Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies at #AAN2018,2018-04-24 06:04:00-04:00,LLY,negative
766650.0,"12 Stocks To Watch For April 24, 2018",2018-04-24 05:01:00-04:00,LLY,neutral
766651.0,"Earnings Scheduled For April 24, 2018",2018-04-24 04:14:00-04:00,LLY,neutral
766652.0,"Lilly, Incyte Announce FDA Advisory Committee Recommends Approval of Baricitinib 2mg, Not 4mg, for Treatment of Moderately-to-Severely Active RA",2018-04-24 03:56:00-04:00,LLY,positive
766653.0,"Top Ideas From The 2018 Sohn Conference: Box, Bitcoin, Facebook, Palo Alto And More",2018-04-23 18:23:00-04:00,LLY,positive
766654.0,Earnings Preview: Verizon And AT&T Report Q1 Results This Week,2018-04-23 13:04:00-04:00,LLY,neutral
766655.0,"Upcoming Earnings: CAT, LLY And BA Report This Week",2018-04-23 11:58:00-04:00,LLY,neutral
766656.0,"From Sohn Conference: Ecor1's Nodelman On Ascendis Pharma Highlighted 10 Potential Buyers Of Co., Including Eli Lilly, Pfizer",2018-04-23 10:58:00-04:00,LLY,neutral
766657.0,"The Week Ahead: Sohn Conference, FANG Earnings, DocuSign IPO",2018-04-23 10:44:00-04:00,LLY,neutral
766658.0,REMINDER: Eli Lilly and Incyte Have FDA AdCom Meeting For Baricitinib Today,2018-04-23 06:59:00-04:00,LLY,neutral
766659.0,"Eli Lilly Reports Add'l Topline Results From CYRAMZA Phase 3 RANGE Study, Positive Trend Seen In Secondary Endpoint But Did Not Reach Statistical Significance",2018-04-20 14:52:00-04:00,LLY,neutral
766660.0,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More",2018-04-20 14:00:00-04:00,LLY,neutral
766661.0,"FDA Staff Review Of Eli Lilly's Rheumatoid Arthritis Treatment Says Supportive Of 2mg Dose, But Not 4mg Dose",2018-04-19 07:58:00-04:00,LLY,positive
766662.0,"Benzinga's Bulls & Bears Of The Week: Caterpillar, Facebook, Starbucks, Tesla And More",2018-04-16 10:05:00-04:00,LLY,neutral
766663.0,"Benzinga's Top Analyst Calls From April 13, 2018",2018-04-13 13:09:00-04:00,LLY,positive
766664.0,BMO's Bearish Stance On Eli Lilly Comes To An End,2018-04-13 11:00:00-04:00,LLY,neutral
766665.0,"Benzinga's Top Upgrades, Downgrades For April 13, 2018",2018-04-13 09:28:00-04:00,LLY,positive
766666.0,BMO Capital Upgrades Eli Lilly to Market Perform,2018-04-13 07:31:00-04:00,LLY,neutral
766667.0,"Eli Lilly To Report Q1 Earnings On Tues., Apr. 24 Before Market Open",2018-04-04 16:57:00-04:00,LLY,neutral
766668.0,"UPDATE: As A Result Of Lilly's Transaction, The Co. Will Incur An Acquired In-Process Research And Development Charge To Earnings Of ~$0.05/Share In Q2",2018-04-04 07:03:00-04:00,LLY,neutral
766669.0,"Lilly, Sigilon Therapeutics Report Strategic Partnership to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes; Sigilon To Receive $63M Up Front And Lilly To Make An Undisclosed Equity Investment In Sigilon",2018-04-04 07:02:00-04:00,LLY,neutral
766670.0,Lilly Announces CYRAMZA Phase 3 Reach-2 Study Met Overall Survival Endpoint And Secondary Endpoint Of Progression-Free Survival,2018-04-04 06:46:00-04:00,LLY,neutral
766671.0,Terns Pharmaceutical Acquires Global Exclusive Rights To Develop And Commercialize 3 NASH Assets From Eli Lilly,2018-04-04 06:02:00-04:00,LLY,positive
766672.0,Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates,2018-04-03 08:14:00-04:00,LLY,neutral
766673.0,Checking In On The Healthcare Sector Ahead Of Q1 Earnings Season,2018-03-20 11:29:00-04:00,LLY,neutral
766674.0,"Jim Cramer Shares His Thoughts On Merck, Five Below And More",2018-03-15 07:21:00-04:00,LLY,positive
766675.0,"Citigroup, Eli Lilly, Square, Target: 'Fast Money' Picks For March 14",2018-03-14 07:44:00-04:00,LLY,neutral
766676.0,Height Casts 65% Odds That Congress Rolls Back Pharma Discounts,2018-03-07 11:31:00-05:00,LLY,neutral
766677.0,Dear Activists: Buying Stock Can Effect More Change Than Selling It,2018-03-06 15:06:00-05:00,LLY,positive
766678.0,Boehringer Ingelheim and Eli Lilly Expand Their Heart Failure Program for Jardiance with New Exercise Capacity Trials,2018-03-06 08:09:00-05:00,LLY,negative
766679.0,Benzinga Pro's 5 Stocks To Watch Today,2018-02-27 08:14:00-05:00,LLY,neutral
766680.0,"UPDATE: Eli Lilly Says 'New indication based on MONARCH 3 trial can help more women living with HR+, HER2- advanced breast cancer'",2018-02-26 17:22:00-05:00,LLY,negative
766681.0,Eli Lilly Reports Received Added FDA Approval For Verzenio As Initial Treatment For Advanced Breast Cancer,2018-02-26 17:21:00-05:00,LLY,negative
766682.0,Eli Lilly's Says Trulicity in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes,2018-02-26 06:50:00-05:00,LLY,positive
766683.0,"Eli Lilly Shares Near Session Highs, Up 0.4%; Traders Circulating Takeover Chatter Out Of Chat",2018-02-22 10:10:00-05:00,LLY,positive
766684.0,A Peek Into The Markets: U.S. Stock Futures Down; Crude Oil Falls,2018-02-13 07:12:00-05:00,LLY,negative
766685.0,Eli Lilly Says its Top-Line Phase 3 Study of Taltz Met the Primary and All Key Secondary Endpoints,2018-02-13 06:46:00-05:00,LLY,neutral
766686.0,The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease,2018-02-08 09:41:00-05:00,LLY,negative
766687.0,Array's Melanoma Combo Shows Positive Overall Survival Data,2018-02-07 11:31:00-05:00,LLY,positive
766688.0,"Treasury Bounce, Boeing Results Appear To Give Slumping Market New Life",2018-01-31 10:04:00-05:00,LLY,positive
766689.0,A Peek Into The Markets: U.S. Stock Futures Rise; Fed Decision In Focus,2018-01-31 07:27:00-05:00,LLY,neutral
766690.0,"Eli Lilly Raises FY18 Adj. EPS Guidance From $4.60-$4.70 to $4.81-$4.91 vs $4.68 Est., Reaffirms Sales Guidance",2018-01-31 06:27:00-05:00,LLY,neutral
766691.0,"Eli Lilly Reports Q4 Adj. EPS $1.14 vs $1.07 Est., Sales $6.16B vs $5.94B Est.",2018-01-31 06:26:00-05:00,LLY,neutral
766692.0,"15 Stocks To Watch For January 31, 2018",2018-01-31 04:52:00-05:00,LLY,neutral
766693.0,"Earnings Scheduled For January 31, 2018",2018-01-31 04:22:00-05:00,LLY,neutral
766694.0,Hang On: Rate Fears In Focus As Futures Point Lower After Monday's Big Losses,2018-01-30 10:47:00-05:00,LLY,negative
766695.0,"The Week Ahead: Big Tech Earnings, Fed Rate Decision Likely To Dominate Headlines",2018-01-29 14:45:00-05:00,LLY,negative
766696.0,"Analyst: Radius Health Could Advance 50% With Osteoporosis Treatment, Breast Cancer Pipeline",2018-01-29 11:50:00-05:00,LLY,negative
766697.0,"PFE, LLY, MRK Write Up 'Scripts For Q4",2018-01-29 10:52:00-05:00,LLY,neutral
766698.0,"Fed, Earnings Are Meaty Filling Between Slices Of Job, Price Data",2018-01-29 09:55:00-05:00,LLY,neutral
766699.0,Jefferies On Gilead: 'We See Better Days Ahead',2018-01-26 13:48:00-05:00,LLY,positive
766700.0,Lilly receives EU Marketing Authorisation for Taltz for the Treatment of Active Psoriatic Arthritis,2018-01-25 04:50:00-05:00,LLY,positive
766701.0,Eli Lilly's Challenges Leaves Credit Suisse With A 'Sour Taste',2018-01-22 10:44:00-05:00,LLY,positive
766702.0,"Benzinga's Top Upgrades, Downgrades For January 22, 2018",2018-01-22 10:14:00-05:00,LLY,positive
766703.0,"The Market In 5 Minutes: Celgene Buys Juno, Netflix Earnings Preview, Eagles And Patriots Advance To Super Bowl",2018-01-22 09:00:00-05:00,LLY,positive
766704.0,Eli Lilly Announces FDA Approval of Credelio to Treat and Protect Against Ticks and Fleas,2018-01-22 08:06:00-05:00,LLY,positive
766705.0,Credit Suisse Downgrades Eli Lilly to Underperform,2018-01-22 07:09:00-05:00,LLY,positive
766706.0,"Benzinga's Weekly Bulls & Bears: Apple, Eli Lilly, GE, Nike And More",2018-01-20 16:50:00-05:00,LLY,neutral
766707.0,The Top 10 Value Stocks In The S&P 500,2018-01-19 13:12:00-05:00,LLY,positive
766708.0,"Eli Lilly's Risks Could Be Underappreciated, Goldman Sachs Says In Downgrade",2018-01-16 12:06:00-05:00,LLY,negative
766709.0,Goldman Sachs Downgrades Eli Lilly to Neutral,2018-01-16 08:42:00-05:00,LLY,neutral
766710.0,Innventure and Eli Lilly's Elanco Announce Strategic Initiative to Commercialize Disruptive Technologies for Animal Health,2018-01-16 08:09:00-05:00,LLY,negative
766711.0,"BZ NOTE: Eli Lilly's PDUFA Date For Amemaciclib-MONARCH 1 & 2 Estimated At Jan. 10 By Biotech Research Site; However, That NDA Was Approved Oct. 4, Separate NDA For This Drug Remains Under Review With Estimated Action In April",2018-01-11 13:56:00-05:00,LLY,positive
766712.0,Alzheimer's Takes Another Hit As Pfizer Ends Research In The Area,2018-01-08 12:22:00-05:00,LLY,neutral
766713.0,"The Week Ahead: Conferences Take Center Stage, Earnings Begin To Trickle In",2018-01-08 11:46:00-05:00,LLY,neutral
766714.0,"Argus Shares Eli Lilly's Optimism, Upgrades To Buy",2018-01-05 13:54:00-05:00,LLY,positive
766715.0,"Benzinga's Top Upgrades, Downgrades For January 5, 2018",2018-01-05 09:11:00-05:00,LLY,positive
766716.0,"Eli Lilly To Report Q4 Earnings On Wed., Jan. 31 Before Market Open",2018-01-05 09:03:00-05:00,LLY,neutral
766717.0,Argus Upgrades Eli Lilly to Buy,2018-01-05 07:42:00-05:00,LLY,neutral
766718.0,"Goldman Sachs Healthcare CEOs Unscripted Conference Taking Place Today; Presenters Include Agilent, Bluebird Bio, Boston Scientific, Alexion, Eli Lilly, and Alnylam",2018-01-04 06:54:00-05:00,LLY,neutral
766719.0,"PETA Leverages Shareholder Power, Calls On SeaWorld To End All Animal Breeding",2017-12-21 08:09:00-05:00,LLY,neutral
766720.0,3 Biotech Pipeline Areas To Keep An Eye On In 2018,2017-12-20 12:37:00-05:00,LLY,neutral
766721.0,Entrega to Receive $5M Investment from Lilly To Advance Proprietary Oral Delivery Technology for Peptides,2017-12-19 03:59:00-05:00,LLY,neutral
766722.0,Eli Lilly Shares Volatile Over Last Few Mins. As Traders Circulate Chatter Co. Hired Bankers Related To Consideration Of Alternatives For Its Animal Health Unit,2017-12-18 09:50:00-05:00,LLY,positive
766723.0,"Lightning Round: Jim Cramer Shares His Thoughts On T-Mobile, Electronic Arts, And More",2017-12-15 07:33:00-05:00,LLY,positive
766724.0,"Eli Lilly Issues Guidance For 2018, New Drugs To Drive Top Line",2017-12-14 12:33:00-05:00,LLY,positive
766725.0,Eli Lilly Sees FY2018 EPS $4.60-4.70 vs $4.64 Est; Sees Sales $23.0B-23.50B vs $23.10B Est,2017-12-13 06:47:00-05:00,LLY,neutral
766726.0,Eli Lilly Sees FY2017 EPS $4.15-4.25 vs $4.21 Est,2017-12-13 06:46:00-05:00,LLY,neutral
766727.0,Eli Lilly Raises Qtr. Dividend From $0.52/Share to $0.5625/Share,2017-12-11 15:31:00-05:00,LLY,neutral
766728.0,A Peek Into The Markets: U.S. Stock Futures Signal Higher Start On Wall Street,2017-12-11 07:17:00-05:00,LLY,neutral
766729.0,Eli Lilly Reports FDA Accepted BLA For Galcanezumab Review For Prevention Of Migraine In Adults,2017-12-11 06:45:00-05:00,LLY,positive
766730.0,"Eli Lilly Reports Top-Line Results From CYRAMZA Phase 3 Study: Met Endpoint Of PFS, But Did Not Improve A Secondary Endpoint Of Overall Survival",2017-12-08 17:05:00-05:00,LLY,negative
766731.0,"Juno Therapeutics Signs Licensing Agreements with Lilly, OncoTracker, and Fred Hutchinson Cancer Research Center to Advance Its BCMA-Directed Engineered T Cell Program in Multiple Myeloma with Gamma Secretase Inhibition",2017-12-06 09:03:00-05:00,LLY,negative
766732.0,Eli Lilly's Taltz Gets Approval For Label Expansion in US,2017-12-04 12:39:00-05:00,LLY,positive
766733.0,Eli Lilly Receives FDA Approval For Taltz,2017-12-01 17:02:00-05:00,LLY,positive
766734.0,Lilly Option Alert: Dec 15 $81 Calls Sweep (27) at the Ask: 639 @ $3.847 vs 0 OI; Ref=$84.7,2017-11-27 11:04:00-05:00,LLY,positive
766735.0,"Morgan Stanley Earlier Maintained Equal-Weight Rating on Eli Lilly, Raised Price Target from $86.00 to $90.00",2017-11-21 14:10:00-05:00,LLY,neutral
766736.0,Dexcom Reports Development Agreement with Lilly to Integrate Dexcom CGM into Connected Diabetes Ecosystem,2017-11-21 10:33:00-05:00,LLY,positive
766737.0,Who Is The Former Pharma Exec Trump Nominated To Lead HHS?,2017-11-14 12:02:00-05:00,LLY,neutral
766738.0,Stocks Going Ex Dividend The Third Week of November,2017-11-13 12:29:00-05:00,LLY,neutral
766739.0,Eli Lilly Thursday Reported Positive New Data On FORTEO Showing Statistically Significant Reduced Risk For Fractures,2017-11-10 09:30:00-05:00,LLY,positive
766740.0,Pharma ETFs Down Post Q3 Earnings,2017-11-09 12:34:00-05:00,LLY,neutral
766741.0,Eli Lilly Says Taltz Demonstrated Improvement In Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors; Also Showed Improvements In Secondary Measures At 52 Week Mark,2017-11-08 09:03:00-05:00,LLY,positive
766742.0,"Evercore Out With A Note Saying Teva Is Suing Eli Lilly, Firm Says They Found A Lawsuit Where Teva Believes Other CGRP Mabs Like Lilly Are Infringing On Its Intellectual Property",2017-10-25 11:19:00-04:00,LLY,positive
766743.0,14 Technical Levels Discussed On Tuesday's PreMarket Prep,2017-10-24 10:08:00-04:00,LLY,neutral
766744.0,"A Peek Into The Markets: U.S. Stock Futures Gain; McDonald's, General Motors Earnings In Focus",2017-10-24 07:15:00-04:00,LLY,positive
766745.0,"Eli Lilly Says it is Considering Strategic Alternatives for its Elanco Animal Health Unit, Including IPO or Sale",2017-10-24 06:30:00-04:00,LLY,neutral
766746.0,"Eli Lilly Q3 EPS $1.05 vs $1.03 Est., Sales $5.66B vs $5.52B Est.",2017-10-24 06:29:00-04:00,LLY,neutral
766747.0,"12 Stocks To Watch For October 24, 2017",2017-10-24 04:59:00-04:00,LLY,neutral
766748.0,"Earnings Scheduled For October 24, 2017",2017-10-24 04:09:00-04:00,LLY,neutral
766749.0,Buy Sierra Oncology Ahead Of A 2018 Full Of Catalysts,2017-10-23 11:49:00-04:00,LLY,neutral
766750.0,The Week Ahead: Earnings Season Starts In Earnest,2017-10-23 09:00:00-04:00,LLY,positive
766751.0,Eli Lilly Announces a $72M Investment in Insulin Manufacturing in Indianapolis,2017-10-23 06:48:00-04:00,LLY,neutral
766752.0,Upcoming Earnings: Heavy-Equipment Maker Caterpillar And Pharma Giant Eli Lilly Report On Tuesday,2017-10-20 13:44:00-04:00,LLY,neutral
766753.0,"Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever",2017-10-18 09:07:00-04:00,LLY,positive
766754.0,"Eli Lilly, CureVac Report Global Collaboration For Development Of mRNA Cancer Vaccines",2017-10-18 06:46:00-04:00,LLY,negative
766755.0,Eli Lilly Gives an Update on its CYRAMZA Trial,2017-10-16 06:47:00-04:00,LLY,neutral
766756.0,"Pharma Stock Roundup: Pfizer Mulls Options For Consumer Healthcare, Eli Lilly's Pipeline Setback",2017-10-13 12:19:00-04:00,LLY,neutral
766757.0,Eli Lilly Granted Priority Review for Verzenio for Advanced Breast Cancer,2017-10-12 06:45:00-04:00,LLY,negative
766758.0,5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings,2017-10-10 12:52:00-04:00,LLY,positive
766759.0,7 Catalysts For Eli Lilly Over The Next Year,2017-10-10 10:33:00-04:00,LLY,neutral
766760.0,"Benzinga's Top Upgrades, Downgrades For October 10, 2017",2017-10-10 09:16:00-04:00,LLY,positive
766761.0,"The Market In 5 Minutes: Nvidia's Drive, Russia And Cryptos, And Carbon Emission Limits",2017-10-10 08:31:00-04:00,LLY,neutral
766762.0,A Peek Into The Markets: U.S. Stock Futures Gain Ahead Of Fed Speakers,2017-10-10 07:08:00-04:00,LLY,positive
766763.0,"UPDATE: Eli Lilly Says 'analysis of the secondary study endpoints of both PFS, ORR showed evidence of monotherapy activity in the abemaciclib arm'",2017-10-10 06:47:00-04:00,LLY,neutral
766764.0,Eli Lilly Reports Topline Results From Phase 3 JUNIPER Trial Evaluating Verzenio In KRAS-Mutated Advanced NSCLC: 'did not meet its primary endpoint of overall survival',2017-10-10 06:46:00-04:00,LLY,positive
766765.0,Credit Suisse Downgrades Eli Lilly to Neutral,2017-10-10 06:31:00-04:00,LLY,positive
766766.0,Health Care Sector Back In Focus In Congress Ahead Of Q3 Earnings Result,2017-10-09 15:56:00-04:00,LLY,positive
766767.0,"Teva Pharmaceuticals Responds To Patent Office Decision In Eli Lilly's Favor, Tells Benzinga: 'We are disappointed with the court's decision and evaluating our options to appeal'",2017-10-06 08:59:00-04:00,LLY,negative
766768.0,Eli Lilly Shares Spike On Patent Victory,2017-10-05 17:07:00-04:00,LLY,positive
766769.0,Eli Lilly Reports US PTO Ruled In Favor Of Co.'s Alimta Vitamin Regimen Patent,2017-10-05 16:14:00-04:00,LLY,positive
766770.0,UPDATE: Eli Lilly Prevails In IPR Review Of '209 Patent For Alimta,2017-10-05 14:12:00-04:00,LLY,neutral
766771.0,Watching Shares Of Eli Lilly As Traders Pass Unconfirmed Chatter Of Favorable Patent Case Decision,2017-10-05 14:09:00-04:00,LLY,positive
766772.0,"Eli Lilly Has Said List Price For Its New Breast Cancer Treatment Verzenio Will Be ~$11K/Month, Will Be Available In US By End Of Oct.",2017-09-28 16:19:00-04:00,LLY,negative
766773.0,Johnson & Johnson Downgraded On Hefty Valuation Compared To Peers,2017-09-20 11:49:00-04:00,LLY,neutral
766774.0,"Wall Street's M&A Chatter From September 18: Walgreens-Rite Aid, Northrup Grumman-Orbital ATK, Itron-Silver Spring Networks",2017-09-19 09:13:00-04:00,LLY,neutral
766775.0,Eli Lilly's Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis,2017-09-14 09:06:00-04:00,LLY,neutral
766776.0,This Analyst Predicts Bullish Growth Outlook For Incyte,2017-09-12 09:28:00-04:00,LLY,positive
766777.0,Eli Lilly Says Jardiance Tablets Reduced the Risk of Cardiovascular Death in People with Type 2 Diabetes,2017-09-12 07:05:00-04:00,LLY,negative
766778.0,Array BioPharma And Others Shine At The ESMO 2017 Congress,2017-09-11 13:30:00-04:00,LLY,neutral
766779.0,Lilly Announces Presentation of Phase 3 RANGE Data for CYRAMZA Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer at ESMO 2017,2017-09-10 09:46:00-04:00,LLY,neutral
766780.0,What Pharmaceuticals Spend On Lobbying To Influence Trump,2017-09-09 16:28:00-04:00,LLY,negative
766781.0,Data Showing Lilly's Lasmiditan Significantly Reduces Pain in Patients with Migraine to be Presented at IHC 2017,2017-09-09 15:31:00-04:00,LLY,negative
766782.0,"UPDATE: Eli Lilly Says Galcanezumab Showed 'statistically significant reduction in the number of monthly migraine headache days with both doses (5.6 days for 120 mg and 6.5 days for 240 mg, p<0.001 for both dosing groups)'",2017-09-08 06:52:00-04:00,LLY,positive
766783.0,"Eli Lilly Reports Treatment With Self-Administered Galcanezumab For Up To 12 Months Showed Positive Safety, Tolerability Profile In Patients With Migraine",2017-09-08 06:52:00-04:00,LLY,positive
766784.0,"UPDATE: Eli Lilly Sees Incurring ~$1.2B Pre-Tax Charge Related to Streamlining Of Operations, Or About $0.80/Share After Tax",2017-09-07 09:18:00-04:00,LLY,neutral
766785.0,"UPDATE: Eli Lilly Says Streamlining Of Operations Will Impact ~8% Of Workforce, Or About 3,500 Jobs",2017-09-07 09:17:00-04:00,LLY,neutral
766786.0,"Eli Lilly Unveils Actions To Streamline Operations, Sees Annualized Savings Of ~$500M",2017-09-07 09:15:00-04:00,LLY,neutral
766787.0,"UPDATE: Lilly, Incyte Expect FDA To Classify NDA For Baricitinib As Class I Resubmission, Which Will Start A New 6-Month Review Cycle",2017-08-30 06:47:00-04:00,LLY,neutral
766788.0,"Eli Lilly, Incyte Report Will Resubmit NDA For Baricitinib Before End Of Jan. '18",2017-08-30 06:45:00-04:00,LLY,neutral
766789.0,Shares of Lilly Fall on Positive Novo Nordisk SUSTAIN 7 Trial Results,2017-08-16 14:08:00-04:00,LLY,positive
766790.0,13F From Farallon Capital Shows Liquidated ~1.6M Share Stake In Eli Lilly,2017-08-14 13:58:00-04:00,LLY,positive
766791.0,Eli Lilly Reports Results From Second Phase 3 Study Of Lasmiditan For Acute Treatment Of Migraine; Met Its Primary Endpoint In SPARTAN,2017-08-04 06:46:00-04:00,LLY,neutral
766792.0,Eli Lilly Says California and Florida AGs Have Requested Info On Co.'s Insulin Products,2017-07-28 11:51:00-04:00,LLY,neutral
766793.0,"On, Wisconsin: University Wins Half Billion In iPhone Patent Suit, Another Sign Schools Are Research Cash Cows",2017-07-27 16:11:00-04:00,LLY,positive
766794.0,"Samsung, Amazon — Everyone Is Getting Into Pharmaceuticals",2017-07-27 08:36:00-04:00,LLY,positive
766795.0,Zoetis Investors May Need Patience To See Bull Thesis Play Out,2017-07-26 11:08:00-04:00,LLY,positive
766796.0,"Intense Competition Pressures Eli Lilly, Leerink Downgrades",2017-07-26 10:58:00-04:00,LLY,negative
766797.0,"19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug",2017-07-26 10:09:00-04:00,LLY,positive
766798.0,"Benzinga's Top Upgrades, Downgrades For July 26, 2017",2017-07-26 09:25:00-04:00,LLY,positive
766799.0,Leerink Swann Downgrades Eli Lilly to Market Perform,2017-07-26 07:47:00-04:00,LLY,neutral
766800.0,"Eli Lilly Raises FY 2017 Guidance, Sees EPS $4.10-$4.20 from $4.05-$4.15 vs $4.12 Est., Sees Sales $22.0B-$22.5B from $21.8B-$22.3B vs $22.1B Est.",2017-07-25 06:27:00-04:00,LLY,neutral
766801.0,"Eli Lilly Q2 EPS $1.11 vs $1.05 Est., Sales $5.82B vs $5.60B Est.",2017-07-25 06:25:00-04:00,LLY,neutral
766802.0,Eli Lilly and Incyte's Re-submission of a New Drug Application to the FDA Will be Delayed Beyond 2017,2017-07-25 06:16:00-04:00,LLY,negative
766803.0,"12 Stocks To Watch For July 25, 2017",2017-07-25 05:58:00-04:00,LLY,neutral
766804.0,"Earnings Scheduled For July 25, 2017",2017-07-25 05:52:00-04:00,LLY,neutral
766805.0,2 Ways To Trade This Week's Healthcare Earnings,2017-07-24 11:51:00-04:00,LLY,neutral
766806.0,Eli Lilly and Nektar Therapeutics to Partner for Development and Commercialization of NKTR-358,2017-07-24 07:34:00-04:00,LLY,neutral
766807.0,"Adimab Reports Deal With Eli Lilly To Transfer Co.'s Platform To Lilly For Discovery, Optimization Of Antibody-Based Drugs In Therapeutic Areas",2017-07-18 09:13:00-04:00,LLY,positive
766808.0,"Shares of Eli Lilly, AstraZeneca, Merck, Gilead, Abbvie, Other Large Cap Biotech Spiking Higher",2017-07-13 14:43:00-04:00,LLY,positive
766809.0,6 Biggest Price Target Changes For Thursday,2017-07-13 10:06:00-04:00,LLY,neutral
766810.0,"Delta, United, Eli Lilly, General Electric: Fast Money Picks For July 13",2017-07-13 07:09:00-04:00,LLY,positive
766811.0,"Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation, Cialis Exclusivity Expected To End At Earliest On Sept. 27th 2018",2017-07-12 10:01:00-04:00,LLY,positive
766812.0,Eli Lilly's Abemaciclib is Granted Priority Review by the FDA for the Treatment of Breast Cancer,2017-07-10 06:47:00-04:00,LLY,negative
766813.0,"UK Supreme Court Rules In Favor Of Eli Lilly's Alimta Vitamin Regimen Patents, Also Affirmed Indirect Infringement Finding By UK Court Of Appeal",2017-07-07 07:50:00-04:00,LLY,positive
766814.0,Merck Falls As FDA Puts Hold On 3 Keytruda Myeloma Studies,2017-07-06 15:09:00-04:00,LLY,neutral
766815.0,UPDATE: Lilly Says Japanese Marketing Authorization Of Olumiant Triggered $15M Milestone Payment From Lilly To Incyte,2017-07-03 08:02:00-04:00,LLY,neutral
766816.0,Eli Lilly and Incyte Announce Japan's Ministry of Health Grants Marketing Approval for Olumiant,2017-07-03 08:02:00-04:00,LLY,positive
766819.0,Attention To Details: Neos' ADHD Portfolio,2017-06-26 09:05:00-04:00,LLY,neutral
766822.0,"Jim Cramer Shares His Thoughts On Helmerich & Payne, Tailored Brands And Eli Lilly",2017-06-26 07:35:00-04:00,LLY,positive
766825.0,Eli Lilly Unveils Expanded Biotechnology Center in San Diego As Part Of $850M  U.S. Capital Investment In 2017,2017-06-21 11:01:00-04:00,LLY,neutral
766826.0,Eli Lilly Receives FDA Orphan Designation for Humanized Immunoglobulin G4-Variant Monoclonal Antibody Directed Against P19 Subunit of Interleukin (IL)-23 in  Treatment Of UC in Pediatric Patients,2017-06-18 21:58:00-04:00,LLY,neutral
766829.0,"Lilly, Incyte Announce Results from Long-term Extension of Phase 3 Studies Show Treatment With Baricitinib Slows Progression of Joint Damage, Controls Disease Activity over 2 Years #EULAR2017",2017-06-16 04:24:00-04:00,LLY,negative
766830.0,"Regeneron Lower Day After 8-K Filing, Increased Competition For Pain Remedy",2017-06-15 15:09:00-04:00,LLY,negative
766832.0,"Eli Lilly's Talz Showed Significant Improvements In Disease Signs, Symptoms At 24 Weeks Among Patients With Active Psoriatic Arthritis Who Had Prior Inadequate Response Or Intolerance To TNF Inhibitors",2017-06-15 10:37:00-04:00,LLY,positive
766835.0,"Lilly, Incyte Announce Presentation of New Data on Olumiant in RA, Taltz in PsA at #EULAR 2017",2017-06-13 18:07:00-04:00,LLY,neutral
766836.0,"UPDATE: Lilly Says 'Analysis of 12,500 adults with type 2 diabetes from 19 studies showed amputations and fractures were not increased with Jardiance compared with placebo'",2017-06-13 14:03:00-04:00,LLY,negative
766837.0,Eli Lilly Reports Jardiance Analysis Reinforces Established Safety Profile,2017-06-13 14:02:00-04:00,LLY,positive
766841.0,"Pfizer, Eli Lilly Report Tanezumab Received FDA Fast Track Designation",2017-06-13 08:01:00-04:00,LLY,neutral
766843.0,"Eli Lilly, Boehringer Ingelheim Announce Plans To Conduct New, Large Clinical Outcomes Trial Investigating Jardance For Treatment Of Chronic Kidney Disease",2017-06-12 08:06:00-04:00,LLY,neutral
766844.0,Lilly Announces Results Showing Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine Presented at AHS,2017-06-11 11:54:00-04:00,LLY,positive
766845.0,Eli Lilly and the International Diabetes Federation Announce Second Phase of BRIDGES 2 Program,2017-06-09 06:34:00-04:00,LLY,neutral
766848.0,Eli Lilly to Collaborate with KeyBioscince on Dual Amylin Calcitonin Receptor Agonists,2017-06-08 06:34:00-04:00,LLY,neutral
766849.0,Lilly Announces Initiation of MonarchE Global Phase 3 Study of Abemaciclib as Adjuvant Therapy in Early Breast Cancer #ASCO17,2017-06-03 15:42:00-04:00,LLY,negative
766850.0,"Eli Lilly Announces Derica Rice to Retire as CFO; Co. is Considering Internal, External Candidates",2017-06-01 06:52:00-04:00,LLY,neutral
766851.0,"Bernstein Strategic Decisions Conference Begins Today, Presenters Include: Eli Lilly, Clorox, Celgene, Discovery Communications, Mastercard, Biogen, Nasdaq, Motorola, And Yum Brands",2017-05-31 09:32:00-04:00,LLY,neutral
766852.0,A Peek Into The Markets: U.S. Stock Futures Up Ahead Of Beige Book,2017-05-31 07:33:00-04:00,LLY,neutral
766853.0,Eli Lilly Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA Meets Primary Endpoint,2017-05-31 06:48:00-04:00,LLY,negative
766854.0,Monday's Market In 5 Minutes,2017-05-30 08:31:00-04:00,LLY,neutral
766855.0,A Look At Nvidia's Largest Shareholders And What Their Presence Means,2017-05-25 10:29:00-04:00,LLY,neutral
766856.0,"Zymeworks: Early But Compelling Data, Large Biopharma Partners And A Potential June Catalyst",2017-05-23 14:09:00-04:00,LLY,positive
766857.0,Watch These 5 Huge Put Purchases In Wednesday Trade,2017-05-17 04:32:00-04:00,LLY,positive
766858.0,Benzinga's Option Alert Recap From May 16,2017-05-16 16:59:00-04:00,LLY,positive
766859.0,Option Alert: Lilly Jun 77.5 Puts Sweep: 1000 @  ASK  $1.008: 4230 traded vs 2903 OI:  Earnings 7/25 Before Open  $78.97 Ref,2017-05-16 14:06:00-04:00,LLY,positive
766860.0,Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine,2017-05-12 07:02:00-04:00,LLY,positive
766861.0,"Incyte, Lilly Disagree With FDA CRL for Baricitinib; Expects Lilly to Engage With FDA to Discuss Agency's Concerns, Determine Potential Path Forward",2017-05-04 07:15:00-04:00,LLY,negative
766862.0,"10-K Just Recently Out from Eli Lilly Shows Co. Received CID from State of Washington's Office of AG Related to Pricing of Insulin Products, Relationships with PBMs",2017-05-01 12:14:00-04:00,LLY,neutral
766863.0,"Companies Holding Shareholder Meetings Today Include: American Express, Dish Network, Eli Lilly, And Zynga",2017-05-01 09:07:00-04:00,LLY,neutral
766864.0,"Analyst Sees Eli Lilly Fairly Valued At $81 Per Share, Downgrades To Hold",2017-04-27 10:06:00-04:00,LLY,positive
766865.0,"Benzinga's Top Upgrades, Downgrades For April 27, 2017",2017-04-27 09:24:00-04:00,LLY,positive
766866.0,Argus Research Downgrades Eli Lilly to Hold,2017-04-27 07:53:00-04:00,LLY,neutral
766867.0,Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates,2017-04-25 13:44:00-04:00,LLY,positive
766868.0,"Eli Lilly Reaffirms FY 2017 Sales Guidance, Sees $21.8b to $22.3B vs $22.1B Est",2017-04-25 06:28:00-04:00,LLY,neutral
766869.0,"Eli Lilly Reaffirms FY 2017 Adj EPS Guidance, Sees $4.05 to $4.15 vs $4.11 Est",2017-04-25 06:27:00-04:00,LLY,neutral
766870.0,"Eli Lilly Q1 EPS $0.98 vs $0.96 Est, Sales $5.23B vs $5.21B Est",2017-04-25 06:26:00-04:00,LLY,neutral
766871.0,"15 Stocks To Watch For April 25, 2017",2017-04-25 05:46:00-04:00,LLY,neutral
766872.0,"Earnings Scheduled For April 25, 2017",2017-04-25 05:03:00-04:00,LLY,neutral
766873.0,"Earnings: Caterpillar, Lockheed Martin, and Eli Lilly Report Tomorrow",2017-04-24 13:45:00-04:00,LLY,neutral
766874.0,Eli Lilly Announces Phase 3 study Comparing Abemaciclib in Combination with an aromatase Met its Primary Endpoint,2017-04-24 06:50:00-04:00,LLY,neutral
766875.0,What Would A $5.8 Billion NIH Cut Look Like? Devastation,2017-04-20 13:38:00-04:00,LLY,negative
766876.0,15 Biggest Mid-Day Losers For Monday,2017-04-17 13:08:00-04:00,LLY,negative
766877.0,Hearing Leerink Defending Eli Lilly,2017-04-17 10:00:00-04:00,LLY,neutral
766878.0,"Benzinga's Top Upgrades, Downgrades For April 17, 2017",2017-04-17 09:34:00-04:00,LLY,positive
766879.0,20 Stocks Moving In Monday's Pre-Market Session,2017-04-17 08:24:00-04:00,LLY,neutral
766880.0,BMO Capital Downgrades Eli Lilly to Underperform,2017-04-17 08:17:00-04:00,LLY,neutral
766881.0,Morgan Stanley Downgrades Eli Lilly to Equal-Weight,2017-04-17 08:15:00-04:00,LLY,neutral
766882.0,"Eli Lilly -4.7% Premarket @ $81.88, Incyte -12.7% @ $123; FDA on Friday Declined to Approve, Lilly, Incyte Arthritis Drug Olumiant",2017-04-17 06:29:00-04:00,LLY,neutral
766883.0,"Lilly Reaffirms Financial Guidance for 2017, Mid-term Guidance for Remainder of this Decade",2017-04-14 09:03:00-04:00,LLY,neutral
766884.0,"Lilly, Incyte Announce FDA Issues CRL for Baricitinib",2017-04-14 09:02:00-04:00,LLY,neutral
766885.0,Healthcare Sector Earnings: Making A Comeback In Q1 2017?,2017-04-12 11:46:00-04:00,LLY,neutral
766886.0,Endpoint Reporter John Carroll Tweets: $LLY spokesperson says they are not disclosing the exact date on bari PDUFA. Really? What's the point of that?,2017-04-12 11:24:00-04:00,LLY,neutral
766887.0,FDA Warns Of Dangerous Hidden Ingredient In 5 OTC Male Sexual Enhancement Supplements,2017-04-07 12:25:00-04:00,LLY,negative
766888.0,"Eli Lilly Spokesperson, Asked If 3-Month Delay In Baricitinib PDUFA Date Announced Jan. 13 Sets New PDUFA Date At Apr. 13, Tells Benzinga 'We Are Not Disclosing A Specific Date For PDUFA'",2017-04-05 08:27:00-04:00,LLY,negative
766889.0,Eli Lilly Endowment Reports Open Market Sale Of 210K Shares Of Common Stock At $84.67 Per SEC Filing,2017-03-31 11:16:00-04:00,LLY,positive
766890.0,"If Gender Confirmation Becomes A Legal Human Right, Which Corporations Could Benefit?",2017-03-28 13:05:00-04:00,LLY,positive
766891.0,IntelGenx Reports Eli Lilly Granted Co. VersaFilm an Exclusive License for Tadalafil Film Under ED Dosing Patent,2017-03-28 08:10:00-04:00,LLY,positive
766892.0,Eli Lilly Announces Plans To Invest $850M In U.S. Operations In 2017,2017-03-24 08:01:00-04:00,LLY,neutral
766893.0,"Ignyta Announces Exploration Of Strategic Options For Taladegib, Enalbed By New License Agreement With Eli Lilly",2017-03-23 16:18:00-04:00,LLY,positive
766894.0,Leerink Presents: Your 2017 Biopharma Catalyst Tracker,2017-03-20 09:17:00-04:00,LLY,neutral
766895.0,Eli Lilly Announces MONARCH 2 Trial of Abemaciclib Met Primary Endpoint of Progression Free Survival,2017-03-20 06:49:00-04:00,LLY,positive
766896.0,"Eli Lilly, Boehringer Ingelheim Report 'EMPEROR HF clinical trial program will evaluate the efficacy and safety of empagliflozin in patients with chronic heart failure, including those with and without type 2 diabetes'",2017-03-17 08:02:00-04:00,LLY,negative
766897.0,Lilly Drops to Low of $84.16 on Volume,2017-03-16 11:44:00-04:00,LLY,negative
766898.0,"Cowen Annual Healthcare Conference Continues Today; Presenters Include Regulus, Eli Lilly, Oculus, DexCom, Illumina, Allergan, Kite Pharma, Pfizer, and bluebird bio",2017-03-07 08:59:00-05:00,LLY,neutral
766899.0,New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz vs Stelara in Patients with Moderate-to-Severe Plaque Psoriasis,2017-03-05 13:05:00-05:00,LLY,neutral
766900.0,Chi-Med Announces Positive Top-Line Results for FRESCO Phase III Pivotal Registration Trial of Fruquintinib in Patients with Locally Advanced or Metastatic Colorectal Cancer,2017-03-03 04:23:00-05:00,LLY,positive
766901.0,Carl Icahn's Track Record In Big Pharma,2017-02-24 09:40:00-05:00,LLY,neutral
766902.0,"After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?",2017-02-16 16:13:00-05:00,LLY,negative
766903.0,Border Tax Polarizes U.S Companies As Exporters Take Side With Trump Team,2017-02-16 09:17:00-05:00,LLY,neutral
766904.0,Eli Lilly & Incyte Announce Add'l Results From Pivotal RA-BEAM Study In New England Journal Of Medicine,2017-02-15 18:00:00-05:00,LLY,neutral
766905.0,"UPDATE: Eli Lilly Says, As a Result of Olumiant Approval by EC, Incyte Becomes Eligible to Receive $65M Milestone Payment",2017-02-13 16:24:00-05:00,LLY,positive
766906.0,Eli Lilly Reports EC Approved Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active RA,2017-02-13 16:23:00-05:00,LLY,positive
766907.0,Eli Lilly Reports Trulicity Label Updated to Include Use in Combo with Basal Insulin for Adults with Type 2 Diabetes,2017-02-08 06:46:00-05:00,LLY,neutral
766908.0,Eli Lilly Reprots Japan IP High Court Rules In Favor In Invalidation Trials Initiated By Sawai Regarding Vitamin Regimen Patents For Alimta,2017-02-02 09:02:00-05:00,LLY,positive
766909.0,"Eli Lilly CEO Says Too Early To Say If Amyloid-Beta Hypothesis For Alzheihmer's Is Wrong, Believes BACE Inhibitors Data Will Shed More Light",2017-01-31 12:11:00-05:00,LLY,negative
766910.0,"Eli Lilly CEO Says President Trump Didn't Get Into Collaborative Policy Detail In Terms Of U.S. Pricing Environment, Left Meeting With Confidence In People Who Would Work Closely With Legislation Moving Forward",2017-01-31 12:05:00-05:00,LLY,positive
766911.0,Eli Lilly Says Quarterly Rev. Growth Led By Volume On Conf. Call,2017-01-31 11:53:00-05:00,LLY,positive
766912.0,US Commercial News Managing Editor Mandy Jackson Tweets: $LLY terminated EXPEDITION PRO study in prodromal Alzheimer's disease.,2017-01-31 11:40:00-05:00,LLY,neutral
766913.0,"President Trump Doubles Down On Healthcare Criticism, Says Drug Prices Are 'Astronomical'",2017-01-31 10:57:00-05:00,LLY,negative
766914.0,"Fed Meeting Starts Today, But Focus Remains On Key Earnings Data",2017-01-31 10:20:00-05:00,LLY,neutral
766915.0,"CNBC's Meg Tirrell Tweets: $LLY CEO tells Trump tax, deregulation could really help us expand operations",2017-01-31 09:51:00-05:00,LLY,positive
766916.0,"The Market In 5 Minutes: Under Armour's Miss, Apple's Q1 Primer",2017-01-31 09:04:00-05:00,LLY,negative
766917.0,"Healthcare Q4: Eli Lilly Beats, Pfizer Misses",2017-01-31 08:57:00-05:00,LLY,negative
766918.0,A Peek Into The Markets: U.S. Stock Futures Down; Apple Earnings In Focus,2017-01-31 07:47:00-05:00,LLY,neutral
766919.0,Lilly Reaffirms FY17 Adj. EPS Outlook $4.05-$4.15 vs $4.10 Est.,2017-01-31 06:26:00-05:00,LLY,neutral
766920.0,"Eli Lilly Reports Q4 EPS $0.95 vs $0.98 Est., Sales $5.761B vs $5.55B Est.",2017-01-31 06:25:00-05:00,LLY,neutral
766921.0,15 Stocks You Should Be Watching Today,2017-01-31 05:27:00-05:00,LLY,neutral
766922.0,Jaguar Animal Health +60% Premarket @$0.85 After Announcement of Deal with Lilly Subsidiary,2017-01-31 05:08:00-05:00,LLY,neutral
766923.0,"Earnings Scheduled For January 31, 2017",2017-01-31 05:08:00-05:00,LLY,neutral
766924.0,"Jaguar Animal Health, Elanco Announce Global Collaboration for Development, Co-Promotion of Canalevia; Jaguar to Receive Upfront Payment of $1.5M",2017-01-31 05:05:00-05:00,LLY,neutral
766925.0,"Recent Weakness In Eli Lilly, Novo Nordisk, Sanofi Due To New York Times Reporting Drug Makers Accused Of Fixing Drug Prices On Insulin",2017-01-30 14:45:00-05:00,LLY,negative
766926.0,Taking A Clinical Road Less Traveled: Neurotrope Hopes To Succeed In Alzheimer's Where Competitors Fail,2017-01-30 14:04:00-05:00,LLY,positive
766927.0,"A Mixed Bag of Earnings Ahead: Eli Lilly, Pfizer, Exxon Mobil, And Under Armour",2017-01-30 12:26:00-05:00,LLY,neutral
766928.0,"Mixing It Up: Markets Await Host Of Economic Data, Key Earnings, And Fed Meeting",2017-01-30 10:07:00-05:00,LLY,positive
766929.0,"Barron's Sees Dow At 30,000",2017-01-29 16:31:00-05:00,LLY,neutral
766930.0,Eli Lilly Reports Jardiance Is First Type 2 Diabetes Medicine In EU To Include Cardiovascular Death Reduction Data In Label,2017-01-26 08:23:00-05:00,LLY,negative
766931.0,Which Pharma Players Dominate The Lung Cancer Space?,2017-01-25 14:40:00-05:00,LLY,negative
766932.0,"Elanco Animal Health, A Division of Eli Lilly and Aratana, Announces Galliprant Available For Canine Osteoarthritis",2017-01-24 16:38:00-05:00,LLY,neutral
766933.0,Mid-Afternoon Market Update: Crude Oil Down 2.5%; Gigamon Shares Drop After Issuing Lower Forecast,2017-01-18 14:31:00-05:00,LLY,negative
766934.0,15 Biggest Mid-Day Gainers For Wednesday,2017-01-18 12:37:00-05:00,LLY,neutral
766935.0,Mid-Day Market Update: CoLucid Jumps On Acquisition News; Pearson Shares Tumble,2017-01-18 12:12:00-05:00,LLY,positive
766936.0,Mid-Morning Market Update: Markets Mixed; Goldman Sachs Profit Beats Views,2017-01-18 10:19:00-05:00,LLY,positive
766937.0,"The Market In 5 Minutes: Goldman Sachs, Chelsea Manning And Jerry Seinfeld",2017-01-18 09:03:00-05:00,LLY,neutral
766938.0,18 Stocks Moving In Wednesday's Pre-Market Session,2017-01-18 08:25:00-05:00,LLY,neutral
766939.0,"A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Economic Data, Yellen Speech",2017-01-18 07:56:00-05:00,LLY,neutral
766940.0,CoLUcid Pharma to be Acquired by Eli Lilly for $46.50/Share Cash,2017-01-18 06:46:00-05:00,LLY,neutral
766941.0,"Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse",2017-01-17 09:14:00-05:00,LLY,positive
766942.0,"Incyte PDUFA Date Pushed Back, JMP Discusses Impact",2017-01-17 08:13:00-05:00,LLY,neutral
766943.0,"Eli Lilly And Incyte Report FDA Has Extended Review Period For Baricitinib, PUDFA Goal Date Has Been Extended By 3 Months",2017-01-13 16:53:00-05:00,LLY,neutral
766944.0,7 Biotech Catalysts Remaining In January,2017-01-13 14:08:00-05:00,LLY,neutral
766945.0,Watch These 5 Huge Put Purchases In Friday Trade,2017-01-13 04:20:00-05:00,LLY,positive
766946.0,"Eli Lilly Releases PR On Earlier Report, Says U.S. Court of Appeals Rules In Lilly's Favor On Alimta Vitamin Regimen Patent",2017-01-12 11:08:00-05:00,LLY,positive
766947.0,Teva 'Disappointed' In Court's Patent Decision,2017-01-12 10:50:00-05:00,LLY,neutral
766948.0,Option Alert: Lilly Jan 75.0 Puts Sweep: 710 @  ASK  $0.54: 740 traded vs 16k OI:  Earnings 1/31 Before Open  $76.22 Ref,2017-01-12 10:15:00-05:00,LLY,positive
766949.0,U.S. Appeals Court Rules For Eli Lilly Against Teva In Alimta Patent Case,2017-01-12 10:12:00-05:00,LLY,neutral
766950.0,"Lilly and Merck Expand Immuno-Oncology Collaboration, Financial Terms Not Disclosed",2017-01-11 06:45:00-05:00,LLY,positive
766951.0,The MedTech Group: 2017 Top Picks And Catalysts,2017-01-06 10:35:00-05:00,LLY,positive
766952.0,Zymeworks Announces Successful Achievement of Research Milestone with Lilly in Bispecific Antibody Collaboration,2017-01-05 05:03:00-05:00,LLY,positive
766953.0,"Eli Lilly, Boehringer Ingelheim Announce FDA Approval of sNDA to Include Landmark Data in Product Labels for Synjardy, Synjardy XR, Glyxambi Tablets",2017-01-04 17:11:00-05:00,LLY,positive
766954.0,"FTC Will Require Boehringer Ingelheim To Make Divestitures To Eli Lilly, Bayer AG As Conditions For Sanofi Deal",2016-12-28 14:14:00-05:00,LLY,neutral
766955.0,A Preview Of January PDUFA Dates,2016-12-28 11:10:00-05:00,LLY,neutral
766956.0,Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week,2016-12-27 14:32:00-05:00,LLY,positive
766957.0,6 Worst Biotech Stocks Of 2016,2016-12-23 11:50:00-05:00,LLY,negative
766958.0,Jefferies' 2017 Global Pharma Outlook,2016-12-19 10:56:00-05:00,LLY,neutral
766959.0,"Eli Lilly, Boehringer Welcome New Recommendation For Jardiance Tablets; Includes New Recommendations To consider JARDIANCE Use In People With Type 2 Diabetes and Established Cardiovascular Disease To Reduce Risk Of Cardiovascular Death",2016-12-16 14:11:00-05:00,LLY,negative
766960.0,"Eli Lilly Biochaperone Lispro U100 and Humalog Showed SImilar Safety Result, Well Tolerated",2016-12-16 12:02:00-05:00,LLY,positive
766961.0,"Eli Lilly's Guidance Supported By Short-Term Boosts, Not Better Fundamentals",2016-12-16 11:22:00-05:00,LLY,positive
766962.0,"The Market In 5 Minutes: Adobe, Oracle Take The Earnings Stage",2016-12-16 09:15:00-05:00,LLY,neutral
766963.0,7 Biggest Price Target Changes For Friday,2016-12-16 09:11:00-05:00,LLY,neutral
766964.0,"Morgan Stanley Upgrades Eli Lilly to Overweight, Raises Target to $82.00",2016-12-16 06:12:00-05:00,LLY,negative
766965.0,The Week In Guidance: 4 Companies That Gave Investors Their 2017 Outlook,2016-12-15 13:44:00-05:00,LLY,neutral
766966.0,18 Biggest Mid-Day Gainers For Thursday,2016-12-15 12:37:00-05:00,LLY,neutral
766967.0,Hearing Eli Lilly Added To Conviction Buy List At Goldman,2016-12-15 11:17:00-05:00,LLY,neutral
766968.0,Eli Lilly CFO Says They Do Not See U.S. Healthcare Reform Changes Impacting FY17 Sales,2016-12-15 10:11:00-05:00,LLY,neutral
766969.0,"Eli Lilly Announces Guidance, U.S. Insulin Release",2016-12-15 08:55:00-05:00,LLY,neutral
766970.0,Eli Lilly Holding Guidance Call Today 10am EST,2016-12-15 08:28:00-05:00,LLY,neutral
766971.0,18 Stocks Moving In Thursday's Pre-Market Session,2016-12-15 08:16:00-05:00,LLY,neutral
766972.0,A Peek Into The Markets: U.S. Stock Futures Mixed Ahead Of Economic Data,2016-12-15 07:49:00-05:00,LLY,neutral
766973.0,Eli Lilly's Basaglar Now Available in US,2016-12-15 07:01:00-05:00,LLY,neutral
766974.0,Eli Lilly and Company Common Stock Sees FY2017 EPS $4.05-4.15 vs $3.97 Est,2016-12-15 06:27:00-05:00,LLY,neutral
766975.0,Eli Lilly and Company Common Stock Sees FY2016 EPS $3.50-3.60 vs $3.52 Est,2016-12-15 06:26:00-05:00,LLY,neutral
766976.0,Heads Up! These 4 Companies Issuing Guidance This Week,2016-12-13 14:33:00-05:00,LLY,neutral
766977.0,Lilly Announces Program to Provide Insulin at Discounted Prices,2016-12-13 06:31:00-05:00,LLY,positive
766978.0,Eli Lilly Raises Qtr. Dividend from $0.51 to $0.52/Share,2016-12-12 18:01:00-05:00,LLY,neutral
766979.0,"Eli Lilly, Boehringer Ingelheim Report FDA Approved Synjardy XR Tablets for Adults with Type-2 Diabetes",2016-12-12 15:29:00-05:00,LLY,positive
766980.0,What We Know About Trump's Potential Pick To Head The FDA,2016-12-12 14:08:00-05:00,LLY,neutral
766981.0,AC Immune Out Positive On Crenezumab; What Does It Mean?,2016-12-12 10:05:00-05:00,LLY,positive
766982.0,AstraZeneca Higher Off Drug News And Upgrade,2016-12-09 11:47:00-05:00,LLY,neutral
766983.0,Eli Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease,2016-12-09 07:01:00-05:00,LLY,neutral
766984.0,Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at CTAD 2016 Meeting; Primary Endpoint was Not Met,2016-12-09 04:11:00-05:00,LLY,neutral
766985.0,UPDATE: Lilly Trial Met Primary Endpoint Of KI67 Expression Reduction After 2 Weeks Treatment,2016-12-08 08:32:00-05:00,LLY,neutral
766986.0,Lilly Presents neoMONARCH Phase 2 Data on Abemaciclib in Early-Stage Breast Cancer,2016-12-08 08:31:00-05:00,LLY,negative
766987.0,What If Trump Keeps Badmouthing Drug Pricing?,2016-12-07 13:38:00-05:00,LLY,neutral
766988.0,"Pfizer, J&J, Other Big Pharma Names Dip Lower Just After the Open",2016-12-07 09:34:00-05:00,LLY,negative
766989.0,Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell,2016-12-05 15:55:00-05:00,LLY,negative
766990.0,Eli Lilly Shares Spike Higher as FDA Has Approved Jardiance to Reduce CV Death in Adults with Type 2 Diabetes,2016-12-02 13:09:00-05:00,LLY,neutral
766991.0,Lilly Pops to High of $67.45 on Volume,2016-12-02 13:07:00-05:00,LLY,neutral
766992.0,"Eli Lilly Confirms It Will Provide Updated Guidance In Conf. Call Dec. 15, 10am EST",2016-12-02 10:31:00-05:00,LLY,neutral
766993.0,"Forbes Healthcare Summit Concludes Today; Presenters Include Express Scripts, Allergan, IBM, Bristol-Myers Squibb, Merck, Anthem, Eli Lilly, And Regeneron",2016-12-01 08:21:00-05:00,LLY,neutral
766994.0,The Difference Between Shareholders And Stakeholders,2016-11-29 08:40:00-05:00,LLY,neutral
766995.0,"Aside From The Recent Drug Failure, What Else Is Happening With Eli Lilly?",2016-11-25 11:09:00-05:00,LLY,negative
766996.0,Reasons To Be Optimistic On Biogen's Alzheimer's Treatment Prospects,2016-11-25 10:12:00-05:00,LLY,positive
766997.0,Atlantic Equities Earlier Downgraded Eli Lilly to Neutral,2016-11-25 10:10:00-05:00,LLY,neutral
766998.0,The Market In 5 Minutes: Black Friday Closes Shortened Trading Week,2016-11-25 09:33:00-05:00,LLY,neutral
766999.0,Benzinga's Top Downgrades,2016-11-25 09:19:00-05:00,LLY,positive
767000.0,Experts React To Concerning Alzheimer's News From Eli Lilly,2016-11-25 08:39:00-05:00,LLY,neutral
767001.0,A Peek Into The Markets: U.S. Stock Futures Gain On Black Friday,2016-11-25 07:36:00-05:00,LLY,positive
767002.0,"BMO Capital Downgrades Eli Lilly to Market Perform, Lowers Target to $64.00",2016-11-25 06:31:00-05:00,LLY,negative
767003.0,"Must Watch Stocks for November 25, 2016",2016-11-25 04:24:00-05:00,LLY,neutral
767004.0,A Tough Day For Some Biotech Bulls,2016-11-23 13:45:00-05:00,LLY,negative
767005.0,Eli Lilly's Solanezumab Failure: Alzheimer's Treatment Space Feels Aftershock,2016-11-23 13:22:00-05:00,LLY,negative
767006.0,18 Biggest Mid-Day Losers For Wednesday,2016-11-23 13:06:00-05:00,LLY,negative
767007.0,"Baird Analayst Says No Change To Axovant Sciences on Lilly's solanezumab Failure, Intepirdine Commercial Opportunity In AD Is Multiple Billions per Year",2016-11-23 12:44:00-05:00,LLY,negative
767008.0,Mid-Day Market Update: Eli Lilly Tumbles After Alzheimer's Study Fails To Meet Goals; Euroseas Shares Rise,2016-11-23 12:05:00-05:00,LLY,negative
767009.0,Stocks Hitting 52-Week Lows,2016-11-23 10:27:00-05:00,LLY,negative
767010.0,Adam Feuerstein Tweets: Check out @AF_biotech tweets laying out bear thesis on $PRTA as collateral damage from $LLY sola blowup. He knows his stuff.,2016-11-23 10:10:00-05:00,LLY,negative
767011.0,Mid-Morning Market Update: Markets Mostly Lower; Deere Tops Q4 Views,2016-11-23 10:08:00-05:00,LLY,positive
767012.0,"Biotech Down In Early Trading: PDL BioPharma 15%, Eli Lilly 13%, Biogen, 6%, Cellectis, Insys 5.5%, Dynavax, Kite 5%",2016-11-23 10:02:00-05:00,LLY,neutral
767013.0,Neurotrope Issues Statement On Eli Lilly's Solanezumab,2016-11-23 09:37:00-05:00,LLY,neutral
767014.0,"Credit Suisse Says Hard To Get Strong Read-Through Conclusions On Biogen From Lilly's Study Without More Details, Today's News Represents Negative Headline In A Time Where Positive Headlines Are Needed; Biotech Space Could Be Weak On This Headline News",2016-11-23 09:23:00-05:00,LLY,positive
767015.0,"JP Morgan Highlighting Downside in Biogen Shares This Morning (Down ~8%) Related to Lilly's Alzheimer Drug News; Sees Transient 5-15% Move Lower in Biogen Shares, But Sees Possibility Stock Recovers",2016-11-23 09:21:00-05:00,LLY,positive
767016.0,Eli Lilly's Solanezumab Failure Is Bad News For Biogen,2016-11-23 09:14:00-05:00,LLY,negative
767017.0,"AC Immune Shares Down 20% Amid Concerning Alzheimer Drug Data from Lilly; BZ NOTE: In an Oct. 18 Note, Leerink Estimated AC Immune Shares Could Be Down 60% if Data was Not Favorable",2016-11-23 09:07:00-05:00,LLY,positive
767018.0,"Morgan Stanley Calling For Biogen To End The Day Flat To Slightly Up Following Eli Lilly Data Results; Says aducanumab More Potent Than solanezumab, Believes Indication Of Activity/Trends Could Keep Amyloid Debate Alive",2016-11-23 09:00:00-05:00,LLY,positive
767019.0,Raymond James Out Saying They Would Be Buyers of Biogen On Weakness Following Eli Lilly's Failed EXPEDITION 3 Trail; May Actually Be Clearing Event With Respect To Any Takeout,2016-11-23 08:57:00-05:00,LLY,negative
767020.0,20 Stocks Moving In Wednesday's Pre-Market Session,2016-11-23 08:35:00-05:00,LLY,neutral
767021.0,"A Peek Into The Markets: U.S. Stock Futures Mixed Ahead Of Economic Data, Fed Minutes",2016-11-23 08:02:00-05:00,LLY,neutral
767022.0,Eli Lilly Plunges 15% After Alzheimer's Study Fails To Meet Goals,2016-11-23 07:45:00-05:00,LLY,negative
767023.0,Can You Guess This Chart?,2016-11-23 07:36:00-05:00,LLY,neutral
767024.0,"Adam Feuerstein Tweets: Worst thing: $LLY gamed sola study to win but still failed badly, which tells you these amyloid mAbs are weak drugs. Watch out, $BIIB",2016-11-23 07:23:00-05:00,LLY,negative
767025.0,Lilly -15% Premarket @$64.75 Following Report that Solanezumab Did Not Meet Primary Endpoint,2016-11-23 07:08:00-05:00,LLY,neutral
767026.0,"Adam Feuerstein @adamfeuerstein Tweet: $LLY Alzheimer's drug fails key clinical trial thestreet.com/story/13903616… Very quick news hit, back with more perspective later.",2016-11-23 07:02:00-05:00,LLY,negative
767027.0,UPDATE: Lilly EXPEDITION 3 Study Outcome Expected To Result In Q4 Charge Of ~$150M or ~$0.09,2016-11-23 06:47:00-05:00,LLY,neutral
767028.0,"Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial, Did Not Meet Primary Endpoint",2016-11-23 06:46:00-05:00,LLY,neutral
767029.0,"QuintilesIMS Forms New Collaboration with Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt, Germany, and Pfizer to Generate Real World Insights On Usage of Anti-Cancer Therapies Across Europe",2016-11-22 08:04:00-05:00,LLY,neutral
767030.0,Intelgenx Technologies Reports Signing Of Term Sheet For Eli Lilly To License Tadalafil Dosing Patent '6943,2016-11-21 08:15:00-05:00,LLY,neutral
767031.0,"Eli Lilly, Incyte Corp Report RA-BEAM and Ra-BUILD Patients Early Response To Baricitinib Show Significant Improvement Compared To Adalimummab In Patient-Reported Outcomes",2016-11-14 09:05:00-05:00,LLY,positive
767032.0,Lilly Announces Jardiance Consistently Reduced the Risk of Cardiovascular Death in Adults With Type 2 Diabetes Regardless of Type of Cardiovascular Disease at Baseline,2016-11-13 17:33:00-05:00,LLY,negative
767033.0,"Traders Attributing Drop In Eli Lilly To Humana Dropping Humalog Insulin From 2017 Formulary, Senator Bernie Sanders Attacked Company In Prior Week For 700% Increase In Drug Price",2016-11-11 10:48:00-05:00,LLY,negative
767034.0,"10 Notable Stocks Trading Ex-Dividend Friday, November 11",2016-11-10 12:47:00-05:00,LLY,neutral
767035.0,"Pharma Stocks Up Post Election: Ariad 16%, Infinity Up 13%, Allergan, Progenics, Endo 10%, Pfizer, Regeneron 8%, AbbVie 7%, Mylan, Medicines Co. 6%, Perrigo, Merck 5%, Bristol-Myers, Eli Lilly, Sanofi, Novartis 3.5%",2016-11-09 09:41:00-05:00,LLY,neutral
767036.0,Biotech Is Getting A Big Boost Following Clinton's Loss,2016-11-09 08:38:00-05:00,LLY,positive
767037.0,"Palatin's Female Arousal Drug Data Impresses, Investors React Positively",2016-11-03 09:06:00-04:00,LLY,positive
767038.0,"Eli Lilly, Incyte Reports New Data from Pivotal RA-BEACON Study Showing Significant Improvement in Patient-Reported Outcomes in RA Patients Treated with Baricitinib vs Placebo",2016-11-02 12:24:00-04:00,LLY,positive
767039.0,"Senator Bernie Sanders Tweets: People are dying or getting sicker because they can't afford their insulin, just so Eli Lilly and Novo Nordisk can make outrageous profits.",2016-11-01 12:31:00-04:00,LLY,neutral
767040.0,"Following Q3 Results, Here's Where Eli Lilly Investors' Focus Is Turning",2016-10-26 13:16:00-04:00,LLY,neutral
767041.0,6 Big Pharma Companies Left To Report September Quarterly Figures,2016-10-25 13:45:00-04:00,LLY,neutral
767042.0,Epic Earnings: Many US Companies Beating Expectations As Season Continues,2016-10-25 11:52:00-04:00,LLY,negative
767043.0,"The Market In 5 Minutes: UA, GM, P&G Earnings On The Street's Mind",2016-10-25 09:19:00-04:00,LLY,neutral
767044.0,"A Peek Into The Markets: U.S. Stock Futures Rise; GM, Apple Earnings In Focus",2016-10-25 07:39:00-04:00,LLY,neutral
767045.0,"Eli Lilly Maintains FY 2016 EPS Guidance, Raises Revenue Outlook from $20.6B - $21.1B to $20.8B - $21.2B vs $21.2B est",2016-10-25 06:27:00-04:00,LLY,neutral
767046.0,"Eli Lilly Q3 EPS $0.88 vs $0.96 Est, Revenue $5.19B vs $5.28B Est",2016-10-25 06:25:00-04:00,LLY,neutral
767047.0,12 Stocks You Should Be Watching Today,2016-10-25 04:58:00-04:00,LLY,neutral
767048.0,"Earnings Scheduled For October 25, 2016",2016-10-25 04:15:00-04:00,LLY,neutral
767049.0,Are The Drugs Working? Pharma Giants Eli Lilly And Merck To Update Investors On Cancer Treatments,2016-10-21 11:36:00-04:00,LLY,negative
767050.0,FDA Has Granted Accelerated Approval for Eli Lilly's Lartruvo with Doxorubicin for Treatment of Advanced Soft Tissue Sarcoma,2016-10-19 13:57:00-04:00,LLY,positive
767051.0,AC Immune Is An Alzheimer's Pure Play With A Lot On The Line,2016-10-18 11:15:00-04:00,LLY,positive
767052.0,Lilly Partners with the National Cancer Institute to Accelerate Cancer Research through New Program under Cancer Moonshot Initiative,2016-10-17 11:16:00-04:00,LLY,negative
767053.0,New Data on the Combination of Lilly's ALIMTA and Merck's KEYTRUDA Show a Near-Doubling of Objective Response Rate Compared to Standard of Care Alone in First-Line Metastatic NSCLC Presented at ESMO 2016,2016-10-09 08:42:00-04:00,LLY,positive
767054.0,Anavex Life Sciences Joins The Club Of Stocks Moving Higher On News Of Alzheimer's Research,2016-10-05 12:38:00-04:00,LLY,neutral
767055.0,"Eli Lilly Announces Elanco US Subsidiary Has Entered Deal to Buy Boehringer Ingelheim Vetmedica's US Feline, Canine, Rabies Vaccines Portfolio for $885M",2016-10-05 06:47:00-04:00,LLY,neutral
767056.0,"In One Expert's View, Eli Lilly's Alzheimer Drug Trial Has A Greater Than 60% Chance Of Success",2016-10-03 14:12:00-04:00,LLY,positive
767057.0,A Possible Trading Opportunity Presents Itself In Biogen's Approaching Phase 3 Results,2016-10-03 13:53:00-04:00,LLY,positive
767058.0,The Drug Price Increase Debate: Separating The Winners From The Losers,2016-09-27 11:23:00-04:00,LLY,positive
767059.0,7 Biggest Price Target Changes For Tuesday,2016-09-27 10:09:00-04:00,LLY,neutral
767060.0,Benzinga's Top Upgrades,2016-09-27 09:08:00-04:00,LLY,positive
767061.0,"The Market In 5 Minutes: Debates, Oil Keep Stocks Mixed",2016-09-27 09:06:00-04:00,LLY,neutral
767062.0,Eli Lilly Is Entering A Period Of Accelerated Growth; Goldman Upgrades Stock To Buy,2016-09-27 08:08:00-04:00,LLY,positive
767063.0,A Peek Into The Markets: U.S. Stock Futures Gain Ahead Of Economic Data,2016-09-27 07:55:00-04:00,LLY,positive
767064.0,"Goldman Sachs Upgrades Eli Lilly to Buy, Raises PT to $95.00",2016-09-27 07:00:00-04:00,LLY,neutral
767065.0,"vTv Therapeutics Shares Initiated With Buy Rating, $13 Target",2016-09-26 11:46:00-04:00,LLY,positive
767066.0,Cerecor Reports Acquisition of TARP-γ8-AMPA Receptor Antagonist from Eli Lilly,2016-09-26 09:12:00-04:00,LLY,negative
767067.0,First Trust Gets Smart With New Sector ETFs,2016-09-26 08:24:00-04:00,LLY,positive
767068.0,Chasing Takeover Rumors Can Be Hazardous To Your Portfolio,2016-09-21 12:34:00-04:00,LLY,neutral
767069.0,"The Market In 5 Minutes: We're Waiting For You, Mrs. Yellen",2016-09-21 08:59:00-04:00,LLY,neutral
767070.0,Clovis Upgraded At Credit Suisse Following Acquisition Rumor,2016-09-21 07:38:00-04:00,LLY,positive
767071.0,"Some Traders Attributing After-Hours Upside in Clovis to Janney Capital Analyst Comment During Bloomberg Interview There Are 'Many Suitors' for Co, Including Lilly, Roche, Merck",2016-09-20 17:03:00-04:00,LLY,neutral
767072.0,"Clovis Spokesperson Responds to Rumor Of Potential Acquisition By Eli Lilly, Tells Benzinga Co. Policy Is to Not Comment On Rumors",2016-09-20 15:28:00-04:00,LLY,neutral
767073.0,Traders Attributing Spike Higher in Clovis Oncology to Unconfirmed Chatter of Lilly Interest,2016-09-20 14:58:00-04:00,LLY,positive
767074.0,3 Pharma Companies Receive Positive EU Opinions,2016-09-16 10:07:00-04:00,LLY,positive
767075.0,Eli Lilly Reports CHMP Recommended Approval of Co.'s Olaratumab in Combo with Doxorubicin for Advanced Soft Tissue Sarcoma,2016-09-16 07:25:00-04:00,LLY,positive
767076.0,New Upside Potential Drives JPMorgan's Eli Lilly Upgrade,2016-09-08 13:14:00-04:00,LLY,neutral
767077.0,Benzinga's Top Upgrades,2016-09-08 09:09:00-04:00,LLY,positive
767078.0,The Market In 5 Minutes: iPhone 7 Arrives,2016-09-08 09:08:00-04:00,LLY,neutral
767079.0,JP Morgan Upgrades Eli Lilly to Overweight,2016-09-08 04:51:00-04:00,LLY,neutral
767080.0,"Apple, Eli Lilly, U.S. Steel: Fast Money Picks For September 7",2016-09-07 06:27:00-04:00,LLY,neutral
767081.0,"Adam Feuerstein @adamfeuerstein Tweet:  $LLY - Cowen analyst Steve Scala goes all in on sola, predicting 99% likelihood of hitting ph3 ADAS-Cog14 primary endpoint.   99%! Yowza.",2016-09-06 11:03:00-04:00,LLY,neutral
767082.0,"Janney Initiates Galapagos At Buy, Sees Fair Value Of Shares At $64",2016-08-30 12:16:00-04:00,LLY,positive
767083.0,Novogen Names Gordon Hirsch as Chief Medical Officer,2016-08-29 07:05:00-04:00,LLY,neutral
767084.0,Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293,2016-08-22 06:01:00-04:00,LLY,neutral
767085.0,"Lilly Announces Health Canada Approves New Indication for Jardiance Tablets for Adults With Type 2 Diabetes, Established Cardiovascular Disease",2016-08-11 07:02:00-04:00,LLY,positive
767086.0,Lilly Volume Spike,2016-08-10 11:03:00-04:00,LLY,neutral
767087.0,Eli Lilly Update on MONARCH 2 Phase 3 Trial Recommended to Continue As Planned By Independent Committee as Interim Efficacy Criteria Not Met,2016-08-10 06:47:00-04:00,LLY,positive
767088.0,UPDATE: Lilly in 10Q Says Received Civil Investigative Demand from U.S. Attorney's Office for the Southern District of New York,2016-07-28 13:29:00-04:00,LLY,positive
767089.0,"Eli Lilly Says DOJ Requested Documents, Information Relating to Relationships With Pharmacy-Benefit Managers - DJ",2016-07-28 13:25:00-04:00,LLY,neutral
767090.0,New Studies Suggest Relationship between Tau Pathology and Progression of Alzheimer's Disease,2016-07-27 16:54:00-04:00,LLY,neutral
767091.0,"John Lechleiter To Step Down From Lilly CEO, David Ricks To Take Position",2016-07-27 06:55:00-04:00,LLY,neutral
767092.0,Technical Alert: Eli Lilly Unchanged After Wild Ride Following Q2 Report,2016-07-26 13:43:00-04:00,LLY,positive
767093.0,"Lilly Sees FY 2016 EPS $3.50 to $3.60 vs $3.56 est, Revenue $20.6B to $21.1B vs $20.9B est",2016-07-26 06:27:00-04:00,LLY,neutral
767094.0,"Lilly Q2 EPS $0.86 vs $0.86 est, Revenue $5.4B vs $5.2B est",2016-07-26 06:26:00-04:00,LLY,neutral
767095.0,"Earnings Scheduled For July 26, 2016",2016-07-26 05:03:00-04:00,LLY,neutral
767096.0,Can MCD Feed Higher Sales with More than Breakfast?,2016-07-25 11:41:00-04:00,LLY,neutral
767097.0,"Week Ahead: It's Not Just Earnings This Time, as GDP, Fed Also on Tap",2016-07-25 10:06:00-04:00,LLY,neutral
767098.0,Eli Lilly Gets FDA Expanded Indication For Type 2 Diabetes Treatment Synjardy To Add Treatment-Naïve Adults,2016-07-19 09:11:00-04:00,LLY,neutral
767099.0,Eli Lilly Reports U.S. FDA expands indication for type 2 diabetes treatment Synjardy to include treatment-naïve adults,2016-07-19 08:01:00-04:00,LLY,positive
767100.0,BMO Analysts Say Merck's Fundamentals Don't Justify Its Valuations,2016-07-18 12:02:00-04:00,LLY,neutral
767101.0,Eli Lilly Reports Clinical Trial Collaboration Deal with Ingelheim for Metastatic Breast Cancer,2016-07-13 08:03:00-04:00,LLY,negative
767102.0,"Watch for Near-Term Profit Taking in Lilly Shares Following Spike Higher as Traders Passing Around Vague, Unconfirmed Chatter on Co.",2016-07-06 13:33:00-04:00,LLY,positive
767103.0,Eli Lilly Shares Spiking Higher,2016-07-06 13:31:00-04:00,LLY,positive
767104.0,"Regen BioPharma, Inc. Enters Into Open Innovation Drug Discovery Program Agreement with Eli Lilly and Company",2016-06-30 08:01:00-04:00,LLY,positive
767105.0,Eli Lilly Canada Granted Approval For Taltz In Treatment Of Moderate-To-Severe Plaque Psoriasis,2016-06-21 12:45:00-04:00,LLY,positive
767106.0,German Supreme Court Grants Lilly Appeal in Alimta Vitamin Regimen Patent Lawsuit,2016-06-14 18:17:00-04:00,LLY,positive
767107.0,Jefferies Shares Pharma Stock Catalyst Outlook,2016-06-14 16:33:00-04:00,LLY,positive
767108.0,Eli Lilly Says JARDIANCE Significantly Reduced Risk of Progressive Kidney Disease in Adults with Type-2 Diabetes with Established CV Disease,2016-06-14 11:01:00-04:00,LLY,negative
767109.0,"SunTrust Highlights Upcoming Pharma Calendar, Favorite Names",2016-06-13 15:20:00-04:00,LLY,positive
767110.0,Lilly Announces New Jardiance Data Show Reduced Risk for Cardiovascular Death Was Consistent Across Age Groups in Adults With Type 2 Diabetes,2016-06-12 17:28:00-04:00,LLY,negative
767111.0,Lilly Presents New Data Showing Once-Weekly Trulicity in Combination with Insulin Glargine Improves Glycemic Control in People with Type 2 Diabetes at 6th American Diabetes Association Scientific Sessions,2016-06-12 17:20:00-04:00,LLY,positive
767112.0,Lilly Announces New Study Results Show Tradjenta Reduces Blood Sugar in Adults With Type 2 Diabetes at Risk for Kidney Impairment,2016-06-12 08:34:00-04:00,LLY,negative
767113.0,Eli Lilly and Incyte Say Two Phase 3 Trials For Arthritis Have Positive Results,2016-06-09 06:48:00-04:00,LLY,positive
767114.0,Studies Demonstrate Lilly's Taltz® (ixekizumab) Maintained or Achieved High Levels of Skin Clearance for Patients with Moderate-to-Severe Plaque Psoriasis through 60 Weeks,2016-06-08 17:00:00-04:00,LLY,neutral
767115.0,Option Alert: LLY Fri 6/10 76.5 Calls (Wkly) Sweep: 801 @  ASK  $0.13: 900 traded vs 320 OI:  Earnings 7/26 Before Open  $74.80 Ref,2016-06-08 13:24:00-04:00,LLY,positive
767116.0,"Eli Lilly Reports Results of Clinical, Patient-Reported Outcomes Data for Baricitinib in Patients with RA",2016-06-07 07:04:00-04:00,LLY,neutral
767117.0,4 Key Takeaways From ASCO,2016-06-06 17:32:00-04:00,LLY,neutral
767118.0,Lilly Announces Encouraging Data of Early-Phase Immuno-Oncology Studies of ALIMTA and CYRAMZA with Merck's KEYTRUDA in NSCLC Presented at #ASCO16,2016-06-05 09:15:00-04:00,LLY,positive
767119.0,Negative Alimta News Disappointing For Eli Lilly,2016-06-03 15:48:00-04:00,LLY,negative
767120.0,"Ouch! Jobs Report Miss Sends Rate Hike Odds Down, Raises Questions",2016-06-03 13:49:00-04:00,LLY,negative
767121.0,"Eli Lilly Shares Selling Off, Hearing Co's Patent On Alimta To be Reviewed At US Patent Office",2016-06-03 12:20:00-04:00,LLY,positive
767122.0,"Morgan Stanley Negative On Eli Lilly, Says 'Negative AlimtaIPR news disappointing since patent was upheld in District Court last year'",2016-06-03 12:03:00-04:00,LLY,negative
767123.0,"Adocia, Lilly Reports Positive Topline Results From Phase 1 Study Of BioChaperone Lispro U100 In Healthy Japanese Subjects, No New Or Unexpected Safety Findings Were Observed",2016-05-31 12:01:00-04:00,LLY,positive
767124.0,Eli Lilly Gets FDA Approval For Its Jentadueto XR For Adults With Type 2 Diabetes,2016-05-31 11:37:00-04:00,LLY,positive
767125.0,U.S. FDA Approves Once-daily Jentadueto XR Tablets for Adults with Type 2 Diabetes,2016-05-31 10:03:00-04:00,LLY,positive
767126.0,Eli Lilly Says It Will Launch 20 New Products Through 2023,2016-05-24 09:41:00-04:00,LLY,neutral
767127.0,Eli Lilly Offers Outline of Potential to Launch 20 New Products in 10 Years,2016-05-24 06:34:00-04:00,LLY,neutral
767128.0,"H.C. Wainwright Initiates Radius Health At Buy, $55 Target",2016-05-23 10:11:00-04:00,LLY,neutral
767129.0,JPMorgan's Take On Big Pharma's New ASCO Abstracts,2016-05-19 11:07:00-04:00,LLY,neutral
767130.0,"Lilly Highlights ASCO Data Underscores Co.'s Diverse Oncology Pipeline, Portfolio",2016-05-18 11:01:00-04:00,LLY,neutral
767131.0,Fitch Says Drug Approvals Are Driving Targeted Acquisitions In U.S. Pharma,2016-05-17 17:26:00-04:00,LLY,neutral
767132.0,"Eli Lilly Now A Strong Buy, Run-Up To Continue, Vetr Top Raters Say",2016-05-17 14:24:00-04:00,LLY,positive
767133.0,"Jefferies Updates Price Targets In Global Pharma, Sees 'Rich Catalyst Environment' Ahead",2016-05-11 13:05:00-04:00,LLY,positive
767134.0,The Market In 5 Minutes: Don't Stop Me Now,2016-05-11 09:34:00-04:00,LLY,positive
767135.0,FDA Says Will Add New Warning to Labels for All Olanzapine-Containing Products; Watch Eli Lilly Shares,2016-05-10 13:00:00-04:00,LLY,negative
767136.0,"FDA Grants Priority Review for Lilly's Olaratumab, an Investigational Medicine for Advanced Soft Tissue Sarcoma",2016-05-04 08:04:00-04:00,LLY,positive
767137.0,Eli Lilly's Taltz Now Available in the U.S. for the Treatment of Moderate-to-Severe Plaque Psoriasis,2016-05-02 14:00:00-04:00,LLY,neutral
767138.0,GeoInvesting Says Anavex Life Sciences' Stock Has A Book Value Of Just $0.36,2016-05-02 12:25:00-04:00,LLY,positive
767139.0,"Adocia, Lilly ReportPositive Topline Results from a Phase 1b Study of Repeated Administration of Ultra-Rapid BioChaperone Lispro U100 in People with Type 2 Diabetes",2016-04-27 12:01:00-04:00,LLY,neutral
767140.0,10 Stocks Moving In Tuesday's Pre-Market Session,2016-04-26 08:29:00-04:00,LLY,neutral
767141.0,Eli Lilly's Q1 EPS Disappoints,2016-04-26 07:27:00-04:00,LLY,negative
767142.0,"Eli Lilly Raises FY 2016 Guidance; Sees EPS $3.50 to $3.60 vs $3.54 est, Revenue $20.6B to $21.1B vs $20.7B est",2016-04-26 06:27:00-04:00,LLY,neutral
767143.0,"Eli Lilly Q1 EPS $0.83 vs $0.85 est, Revenue $4.87B vs $4.82B est",2016-04-26 06:26:00-04:00,LLY,neutral
767144.0,"Keep an Eye on These 12 Stocks for April 26, 2016",2016-04-26 05:29:00-04:00,LLY,neutral
767145.0,"Earnings Scheduled For April 26, 2016",2016-04-26 04:26:00-04:00,LLY,neutral
767146.0,"Aratana, Eli Lilly Team Create 'Watershed Contract' For Pet Biotech Sector",2016-04-25 17:45:00-04:00,LLY,positive
767147.0,"Aratana, Elanco Announce Global Strategic Collaboration, $45 Up Front Payment To Aratana, & Up To $83M",2016-04-25 16:06:00-04:00,LLY,neutral
767148.0,"Transition Therapeutics Reports Dosing of First Patient in Phase 2 Study of Drug Candidate TT701 , Will Trigger $500K Milestone Payment To Eli Lilly",2016-04-25 16:04:00-04:00,LLY,neutral
767149.0,"The Heart Of Major Pharma Q1 Earnings Season: Eli Lilly, AbbVie, Bristol-Myers",2016-04-25 13:57:00-04:00,LLY,neutral
767150.0,"The Market In 5 Minutes: Monday, April 25, 2016",2016-04-25 09:55:00-04:00,LLY,neutral
767151.0,Eli Lilly And Boehringer Reveals Study On Jardiance For Treatment Heart Failure,2016-04-19 07:04:00-04:00,LLY,negative
767153.0,Mid-Afternoon Market Update: Chiasma Tumbles Following FDA Review; Cvent Shares Spike Higher,2016-04-18 14:41:00-04:00,LLY,positive
767154.0,Mid-Day Market Update: US Stocks Turn Positive; Hasbro Shares Gain Following Earnings Beat,2016-04-18 12:03:00-04:00,LLY,positive
767155.0,Mid-Morning Market Update: Markets Open Lower; Morgan Stanley Q1 Profit Beats Expectations,2016-04-18 09:48:00-04:00,LLY,positive
767156.0,Transition Therapeutics Says Partner Eli Lily Will Not Advance TT401 into Phase 3 Development,2016-04-18 06:02:00-04:00,LLY,neutral
767157.0,"Eli Lilly, AstraZeneca Report Continuation of Pivotal Trial for People with Early Alzheimer's Disease; Will Continue to Phase 3 After Positive Interim Safety Data",2016-04-08 07:03:00-04:00,LLY,positive
767158.0,SocGen Picks New Favorites In Big Pharma,2016-04-06 13:44:00-04:00,LLY,positive
767159.0,Societe Generale Initiates Coverage on Eli Lilly at Hold,2016-04-06 11:47:00-04:00,LLY,neutral
767160.0,"Incyte Acquires Rights To Devlop and Commercialize Ruxolitinib From Lilly, Will Make $35M Upfront Payment As Well As Additional Potential Payments Contingent On Certain Regulatory Milestones; Novartis Granted Right To Develop & Commercialize Ruxolitinib",2016-04-06 07:31:00-04:00,LLY,positive
767161.0,WHO Says Number of Adults with Diabetes has Quadrupled Since 1980 -AFP,2016-04-06 04:52:00-04:00,LLY,positive
767162.0,This Data Signals The End For Merck's Anacetrapib,2016-04-04 11:33:00-04:00,LLY,neutral
767163.0,Eli Lilly's Says ACC/AHA U.S. Guideline Says It's Reasonable To Chosose Effient Over Clopidogrel For Certain ACS-PCI Patients,2016-03-31 14:45:00-04:00,LLY,positive
767164.0,"Eli Lilly Phase 3 Show Baricitinib Treatment With Patients In Rheumatoid Arthritis Show Significant Improvements, Met Primary Endpoint",2016-03-31 07:01:00-04:00,LLY,positive
767165.0,Citi Downgrades Novartis Following SAG Investigation,2016-03-29 10:10:00-04:00,LLY,neutral
767166.0,"Biopharma Names LLY, PFE, MRK, And More Popping Higher Following Reports China FDA To Investigate Improper Vaccine Trading",2016-03-28 11:29:00-04:00,LLY,neutral
767167.0,Adam Feuerstein Tweets: '$LLY FDA approves ixekizumab to treat adults with moderate-to-severe plaque psoriasis. Brand name Taltz.',2016-03-22 16:11:00-04:00,LLY,positive
767168.0,Option Alert: LLY May16 70.0 Calls Sweep: 1500 @  ASK  $2.76: 1500 traded vs 55 OI:  Earnings 4/26 Before Open  $69.58 Ref,2016-03-17 10:57:00-04:00,LLY,positive
767169.0,"Lilly Announces Change to Primary Endpoint of EXPEDITION3 Study, Instead Of Co-Primary Endpoints Of Cognition & Function, The Amended Trial Will Include Single Primary Endpoint Of Cognition",2016-03-15 08:16:00-04:00,LLY,neutral
767170.0,Adocia & Lilly Announce Topline Results:  'BioChaperone Lispro U100 demonstrated a statistically significant 31 percent reduction in blood glucose',2016-03-14 13:01:00-04:00,LLY,positive
767171.0,Adocia And Lilly Announce Positive Topline Results From A Phase 1B Study Of Repeated Admin Of Ultra-Rapid BioChaperone Lispro In Patients With Type 1 Diabetes,2016-03-14 13:01:00-04:00,LLY,positive
767172.0,Eli Lilly Studies Show Ixekizumab Improved Work Productivity for Patients W/ Moderate-to-Severe Plaque Psoriasis,2016-03-07 13:16:00-05:00,LLY,positive
767173.0,PeptiDream to License PDPS Technology to Lilly,2016-03-07 04:11:00-05:00,LLY,neutral
767174.0,"Bernstein Cuts LLY FY 2017 EPS From $4.23 To $4.07, Cuts NVS FY 2017 EPS From $5.21 To %5.17",2016-03-03 07:35:00-05:00,LLY,negative
767175.0,Option Alert: LLY Fri 4/8 70.0 Puts (Wkly) Sweep: 1050 @  ASK  $1.15: 1050 traded vs 0 OI: $73.54 Ref,2016-03-02 14:27:00-05:00,LLY,positive
767176.0,Lilly To Present Phase 3 Ixekizumab Data At 74th AAD Conference Taking Place Mar. 4-8th,2016-03-01 08:19:00-05:00,LLY,neutral
767177.0,EMA Recommends Against Approval of Eli Lilly's Psoriasis Treatment Lxekizumab ‍​,2016-02-26 07:07:00-05:00,LLY,positive
767178.0,"Eli Lilly Files Auto Shelf For Mixed Offering, Size Not Disclosed",2016-02-22 14:58:00-05:00,LLY,neutral
767179.0,"Radius Health Shares Up 29% Following Data from Amgen, UCB's Romosozumab Showing Failed Achievement on One of Two Secondary Endpoints",2016-02-22 09:52:00-05:00,LLY,negative
767180.0,Biotech Conference Suggests Tempering Expectations For Eli Lilly Drug,2016-02-16 13:47:00-05:00,LLY,neutral
767181.0,"13G Filing Shows Eli Lilly Holder Primecap Mgmt Co Holds Amended 5.20% Stake As Of Dec 31, Held 5.17% Stake on Sept 30 2015",2016-02-12 07:05:00-05:00,LLY,neutral
767182.0,Eli Lilly Announces Alimta Not Infringed By Actavis Marketing Pemetrexed Trometamol,2016-02-12 07:03:00-05:00,LLY,neutral
767183.0,Most Of Credit Suisse's Top Investment Ideas For 2016...In One Place,2016-02-08 15:56:00-05:00,LLY,positive
767184.0,"Credit Suisse Global Focus List Update: Toyota Out, Agnico Eagle In",2016-02-05 14:21:00-05:00,LLY,positive
767185.0,Earnings Recap For January 28,2016-01-28 16:34:00-05:00,LLY,neutral
767186.0,Eli Lilly Punished For Inline Report,2016-01-28 11:34:00-05:00,LLY,negative
767187.0,"Eli Lilly Sees FY EPS $2.83 to $2.93 est vs $3.43 est, Revenue $20.2B to $20.7B vs $20.8B est",2016-01-28 06:28:00-05:00,LLY,neutral
767188.0,"Eli Lilly Q4 EPS $0.78 vs $0.78 est, Revenue $5.38B vs $5.32B est",2016-01-28 06:26:00-05:00,LLY,neutral
767189.0,"Earnings Scheduled For January 28, 2016",2016-01-28 04:04:00-05:00,LLY,neutral
767190.0,"Lilly, Roche Diagnostics to Partner on Alzheimer's Disease Adjunct Diagnostic Tool",2016-01-27 09:02:00-05:00,LLY,neutral
767191.0,"JNJ Kicks Off Health Care Earnings—What About Deals, Buybacks?",2016-01-25 11:43:00-05:00,LLY,positive
767192.0,US Big Pharma: What To Watch For In Q4 Results,2016-01-25 11:16:00-05:00,LLY,neutral
767193.0,"Stock Marquee Crowded With Oil, Apple, And The Fed",2016-01-25 10:25:00-05:00,LLY,neutral
767194.0,Eli Lilly Reports FDA Acceptance of Filing of CV Outcomes Data for Jardiance,2016-01-25 08:32:00-05:00,LLY,positive
767195.0,U.S. Food and Drug Administration Approves Humulin R U-500 KwikPen,2016-01-21 10:01:00-05:00,LLY,positive
767196.0,Eli Lilly Reiterates FY15 Guidance Of $3.45-$3.55 vs. Est. $3.43-DJ,2016-01-19 08:08:00-05:00,LLY,neutral
767197.0,"Eli Lilly, Incyte Report Submission of NDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe RA",2016-01-19 08:05:00-05:00,LLY,neutral
767198.0,"Argus Reiterates $93 Target On Eli Lilly, Highlights 'Strong Late-Stage Pipeline'",2016-01-15 10:41:00-05:00,LLY,positive
767199.0,"Insulet Enters Agreement With Eli Lilly For OmniPod Delivery Of U200 Concentrated Insulin, Terms Not Dislcosed",2016-01-11 17:01:00-05:00,LLY,positive
767200.0,Eli Lilly Shares Lower Following Weaker-Than-Expected 2016 Guidance,2016-01-05 08:13:00-05:00,LLY,neutral
767201.0,Eli Lilly Shares Trading Down 2+% to $81 Following Weaker-Than-Expected FY16 Outlook,2016-01-05 07:20:00-05:00,LLY,positive
767202.0,"UPDATE: Eli Lilly Sees FY16 Adj. EPS $3.45-$3.55 vs $3.65 Est., Sales $20.2B-$20.7B vs $21.5B Est.",2016-01-05 06:46:00-05:00,LLY,neutral
767203.0,UPDATE: Eli Lilly Reaffirms FY15 Adj. EPS Outlook $3.40-$3.45 vs $3.44 Est.,2016-01-05 06:46:00-05:00,LLY,neutral
767204.0,Eli Lilly Issues Update to FY15 Outlook; Offers FY16 Guidance,2016-01-05 06:45:00-05:00,LLY,neutral
767205.0,"Eli Lilly's 2016 Guidance Released Next Week Could Disappoint, Leerink Warns",2015-12-28 09:59:00-05:00,LLY,negative
767206.0,Leerink's Fernandez on Eli Lilly Ahead of Expected FY16 Guidance on Jan. 5: 'Much Lower Fx Benefit Makes 2016 Guidance Tough; All Eyes on Sola',2015-12-28 09:10:00-05:00,LLY,positive
767207.0,Not All Of Clinton's Policies Are Bad For Pharmaceuticals,2015-12-23 14:13:00-05:00,LLY,negative
767208.0,"UPDATE: Halozyme Says Will Receive Initial $25M Payment, Followed by Milestone Payments of Up to $160M for Each of Up to Five Collab Targets",2015-12-21 08:32:00-05:00,LLY,neutral
767209.0,"Halozyme Reports Entering of Global Collab, Licensing Deal with Lilly",2015-12-21 08:31:00-05:00,LLY,neutral
767210.0,Credit Suisse Offers 2016 U.S. Large-Cap Pharma Outlook,2015-12-19 17:08:00-05:00,LLY,positive
767211.0,3 Biotechs Atlantic Equities Loves And 1 It's Avoiding,2015-12-18 14:10:00-05:00,LLY,positive
767212.0,"Atlantic Equities Initiates Coverage on Eli Lilly at Overweight, Announces $100.00 PT",2015-12-18 08:41:00-05:00,LLY,negative
767213.0,Lilly's Lung Cancer Drug Necitumumab Receives Positive Opinion from EMA,2015-12-18 07:20:00-05:00,LLY,negative
767214.0,Shares of Eli Lilly Up ~0.6% After Credit Suisse Adds to 'Focus List'; Shares of Bristol-Myers Down ~0.7% as Stock Removed from Same List,2015-12-17 09:51:00-05:00,LLY,positive
767215.0,Major Pharma Group Outlook In 2016: Fundamentals To Outweigh Political Headwinds,2015-12-12 14:05:00-05:00,LLY,neutral
767216.0,Eli Lilly and Merk Announces Expansion of Immuno Oncology Collaboration,2015-12-10 06:31:00-05:00,LLY,neutral
767217.0,Eli Lilly Increases Dividend From $0.50 To $0.51/Share,2015-12-08 07:15:00-05:00,LLY,neutral
767218.0,Eli Lilly Could Make A Lot More From Alzheimer's Drug Than Originally Thought,2015-12-07 09:32:00-05:00,LLY,neutral
767219.0,Benzinga's Top Upgrades,2015-12-07 08:59:00-05:00,LLY,positive
767220.0,"Deutsche Bank Upgrades Eli Lilly to Buy, Raises to $99.00",2015-12-07 06:20:00-05:00,LLY,neutral
767221.0,Cautious Stock Rebound as Jobs Data Delivers But Wages Still in Question,2015-12-04 10:46:00-05:00,LLY,negative
767222.0,Lilly Ends Basal Insulin Peglispro Development Program,2015-12-04 08:00:00-05:00,LLY,neutral
767223.0,"New Data Show Lilly's Once-Weekly Trulicity is Effective as Add-on Treatment to Sulfonylurea, Trulicity Primary Endpoint Provided Superior A1C Rduction; Secondary Endpoint Did Not Reach Statistical Significance",2015-12-01 13:02:00-05:00,LLY,positive
767224.0,Barclays' Biopharmaceuticals Blueprint For 2016,2015-12-01 11:54:00-05:00,LLY,neutral
767225.0,Benzinga's Top Upgrades,2015-12-01 08:55:00-05:00,LLY,positive
767226.0,"Barclays Upgrades Eli Lilly to Overweight, Raises PT to $95.00",2015-12-01 05:00:00-05:00,LLY,negative
767227.0,Health Canada Approves JARDIANCE (Empagliflozin) Tablets For Adults With Type 2 Diabetes,2015-11-30 07:06:00-05:00,LLY,positive
767228.0,Eli Lilly Release Confirms FDA Approval If Portrazza,2015-11-24 14:44:00-05:00,LLY,positive
767229.0,FDA Approves Eli Lilly's Portrazza to Treat Advanced Squamous Non-Small Cell Lung Cancer-DJ,2015-11-24 11:42:00-05:00,LLY,positive
767230.0,US Stock Futures Edge Higher Ahead Of Jobless Claims Report,2015-11-19 08:06:00-05:00,LLY,neutral
767231.0,Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial,2015-11-19 06:33:00-05:00,LLY,negative
767232.0,Benzinga's Top Upgrades,2015-11-16 08:54:00-05:00,LLY,positive
767233.0,"BMO Capital Upgrades Eli Lilly to Outperform, Raises PT to $100.00",2015-11-16 06:37:00-05:00,LLY,neutral
767234.0,"WuXi, Lilly Report Strategic Collaboration to Develop Novel Therapeutic in China",2015-11-10 16:32:00-05:00,LLY,positive
767235.0,"UPDATE: Eli Lilly Release Shows New Data on JARDIANCE Showed Reduction to Risk of Rates Endpoint of Hospitalization for Heart Failure, Death from Heart Failure by 39% vs Placebo",2015-11-09 10:47:00-05:00,LLY,negative
767236.0,New Jardiance data show improved CV outcomes regardless of heart failure status at baseline,2015-11-09 10:45:00-05:00,LLY,negative
767237.0,"Ignyta Acquires Exclusive Rights to Taladegib Oncology Program from Lilly for $2M, ~1.2M Ignyta Shares",2015-11-08 16:48:00-05:00,LLY,positive
767238.0,"Lilly, Incyte Announce Data Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of RA",2015-11-07 20:04:00-05:00,LLY,positive
767239.0,"Eli Lilly Spokesperson Confirms Disclosure of DoJ Inquiry Was In Filing A Week Ago, Notes News 'did not generate much media interest until today.'",2015-11-06 12:04:00-05:00,LLY,positive
767240.0,"Eli Lilly Moving Off DoJ Inquiry, But News Is Old",2015-11-06 11:57:00-05:00,LLY,neutral
767241.0,Eli Lilly Spokesperson Says Will Soon Be Providing Statement Related to DoJ Inquiry/Disclosure Related to Wholesalers,2015-11-06 11:46:00-05:00,LLY,neutral
767242.0,BZ NOTE: Eli Lilly Comments on DoJ Inquiry on Wholesalers Came from 10-Q FIled on Oct. 30; News Should Have Been Priced Into the Stock Several Days Ago,2015-11-06 11:19:00-05:00,LLY,positive
767243.0,"UPDATE: Eli Lilly Shares Plunge $1 Over Last Few Mins, Stock Now Down ~2.5% for Session",2015-11-06 10:55:00-05:00,LLY,positive
767244.0,Lilly Says DoJ Conducting Inquiry Of Agreements With Wholesalers -DJ,2015-11-06 10:54:00-05:00,LLY,positive
767245.0,Eli Lilly Shares Falling,2015-11-06 10:53:00-05:00,LLY,positive
767246.0,Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase 3 Data,2015-10-27 13:20:00-04:00,LLY,neutral
767247.0,"US Stock Futures Gain Ahead Of Earnings, Economic Data",2015-10-22 07:01:00-04:00,LLY,positive
767248.0,"Eli Lilly Posts Upbeat Q3 Earnings, Raises Forecast",2015-10-22 06:55:00-04:00,LLY,neutral
767249.0,"Eli Lilly Raises FY 2015 EPS $3.40-$3.45 Vs Est $3.28, Had Seen $3.20-$3.30 & Revs $19.7B-$20B Vs Est $19.93B",2015-10-22 06:27:00-04:00,LLY,neutral
767250.0,"Eli Lilly Q3 EPS $0.89 vs $0.75 est, Revenue $4.96B vs $4.99B est",2015-10-22 06:26:00-04:00,LLY,neutral
767251.0,"Earnings Scheduled For October 22, 2015",2015-10-22 05:00:00-04:00,LLY,neutral
767252.0,"Global Growth Temperature Likely Captured In Caterpillar, McDonald's And Under Armour Earnings",2015-10-21 12:48:00-04:00,LLY,positive
767253.0,Lilly supports global Dementia Discovery Fund,2015-10-21 06:34:00-04:00,LLY,positive
767254.0,Yabao Pharmaceuticals Enters 2nd Innovative Collaboration With Eli Lilly and Company to Develop Diabetes Treatment,2015-10-20 10:00:00-04:00,LLY,positive
767255.0,Google Stands Out Amid Low Earnings Expectations,2015-10-18 18:02:00-04:00,LLY,negative
767256.0,New Type 2 Diabetes Treatment Synjardy Tablets Now Available in U.S. Pharmacies,2015-10-14 08:30:00-04:00,LLY,neutral
767257.0,Incyte and Eli Lilly Announce Baricitnib Results,2015-10-14 06:47:00-04:00,LLY,neutral
767258.0,"JMP Analyst Says Eli Lilly's CETP Failure Positive For Esperion Therapeutics ETC-1002 Oral Candidate, States Strategic Value Of Asset Has Increased",2015-10-13 07:50:00-04:00,LLY,positive
767259.0,US Stock Futures Down; JPMorgan Earnings In Focus,2015-10-13 07:31:00-04:00,LLY,neutral
767260.0,"Lilly and ImaginAb Announce Preclinical Immuno-Oncology Collaboration, no terms",2015-10-13 07:01:00-04:00,LLY,negative
767261.0,Fast Money Traders Share Their Thoughts On Eli Lilly and And The Restaurant Sector,2015-10-13 06:43:00-04:00,LLY,positive
767262.0,Fast Money Picks For October 13,2015-10-13 06:42:00-04:00,LLY,neutral
767263.0,"UPDATE: Chardan's Amusa Highlights Bull vs Bear Case for Esperion, Sees the Latter as 'More Important'",2015-10-12 13:17:00-04:00,LLY,positive
767264.0,"Chardan Capital's Amusa on Esperion Following Evacetrapib Discontinuation: '...by increasing the likelihood of  regulatory scrutiny on ETC-1002, the evacetrapib failure reduces the chance ETC-1002 gets there...'",2015-10-12 13:13:00-04:00,LLY,negative
767265.0,Eli Lilly Discontinues Evacetrapib; Investors Move Bets To Alternatives,2015-10-12 09:56:00-04:00,LLY,neutral
767266.0,"Regeneron Trading Up To $517/Share Up 2.6% Premarket On Eli Lilly Evacetraqib Development Discontinuation, Watch Regenron Partner Sanofi",2015-10-12 08:26:00-04:00,LLY,neutral
767267.0,UPDATE: Shares of Esperion Therapeutics Trading Up ~14% Following Discontinuation of Lilly's Evacetrapib,2015-10-12 08:14:00-04:00,LLY,positive
767268.0,"UPDATE: Shares of Eli Lilly Trading Down ~8%, Now Under $80 at $79.49",2015-10-12 08:13:00-04:00,LLY,positive
767269.0,TheStreet's Adam Feuerstein Recently Tweets: 'Watch $ESPR' on the Heels of Eli Lilly Discontinuation of Evacetrapib,2015-10-12 08:11:00-04:00,LLY,neutral
767270.0,"Esperion Shares Trading Higher To $28.50/Share, Up 14.9% Premarket Following Eli Lilly Development Discontinuation For Evacetraqib",2015-10-12 08:11:00-04:00,LLY,positive
767271.0,Shares of Eli Lilly Resume; Now Trading Down ~$83,2015-10-12 08:09:00-04:00,LLY,positive
767272.0,UPDATE: Eli Lilly Evacetraqib Devlopment Discontinuation Expected To Result In Q4 Charge Of $90M or $0.05 After-Tax,2015-10-12 08:05:00-04:00,LLY,neutral
767273.0,"UPDATE: Eli Discontinuing Evacetraqib Development Due To Low Probability Of Study TO Achieve Primary Endpoint Based On Results To Date, Not Being Stopped Due To Safety Findings",2015-10-12 08:04:00-04:00,LLY,positive
767274.0,"UPDATE: Lilly Will Terminate Phase 3 Trial of Evacetrapib, Cites Insufficient Efficacy",2015-10-12 08:03:00-04:00,LLY,neutral
767275.0,Lilly Announces Will Discontinue Development of Evacetrapib,2015-10-12 08:00:00-04:00,LLY,neutral
767276.0,Watching Volatility In Other Big Pharma Names Amid Eli Lilly Halt,2015-10-12 07:48:00-04:00,LLY,neutral
767277.0,Eli Lilly Shares Halted News Pending,2015-10-12 07:42:00-04:00,LLY,positive
767278.0,US Stock Futures Flat Ahead Of Fed Speakers,2015-10-12 06:47:00-04:00,LLY,neutral
767279.0,"Lilly, Innovent Biologics Expand Their Strategic Alliance",2015-10-11 22:04:00-04:00,LLY,positive
767280.0,Lilly Acquires Phase III Intranasal Glucagon from Locemia Solutions; Terms Not Disclosed,2015-10-09 16:00:00-04:00,LLY,positive
767281.0,Benzinga's Top Upgrades,2015-10-09 09:02:00-04:00,LLY,positive
767282.0,Credit Suisse Upgrades Eli Lilly; Likes Jardiance For Short-Term And Pipeline For Long-Term,2015-10-09 08:37:00-04:00,LLY,positive
767283.0,"Credit Suisse Upgrades Eli Lilly to Outperform, Raises PT to $105.00",2015-10-09 05:57:00-04:00,LLY,positive
767284.0,Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib - a CDK 4 and 6 Inhibitor - in Advanced Breast Cancer,2015-10-08 07:00:00-04:00,LLY,negative
767285.0,US Insurers Cautious on Lilly's Diabetes Drug Jardiance -Reuters,2015-10-02 11:21:00-04:00,LLY,negative
767286.0,10 Defensive Stock Ideas From Bank Of America,2015-10-01 15:37:00-04:00,LLY,neutral
767287.0,Stocks Hitting 52-Week Lows,2015-09-29 10:21:00-04:00,LLY,negative
767288.0,Morning Market Losers,2015-09-29 10:02:00-04:00,LLY,negative
767289.0,Eli Lilly and Incyte Announce Positive Top Line Phase 3 Baricitnib Results,2015-09-29 06:48:00-04:00,LLY,positive
767290.0,"Lilly, Sanofi Reach Settlement Agreement On Insulin Glargine Litigation In U.S.; Lilly To Have Ability To Launch Basaglar In 2016, Further Details Confidential",2015-09-28 09:35:00-04:00,LLY,positive
767291.0,Lilly's CYRAMZA® (ramucirumab) Significantly Improves Progression-Free Survival in Phase II Bladder Cancer Trial,2015-09-28 08:02:00-04:00,LLY,negative
767292.0,"Forget The 2016 Election Candidates, CEOs Are Driving Change",2015-09-21 14:03:00-04:00,LLY,negative
767293.0,Bank Of America: New Eli Lilly Data Is 'Game-Changing',2015-09-18 13:36:00-04:00,LLY,neutral
767294.0,"Eli Lilly's 'Home Run' Is Jardiance, Says Morgan Stanley",2015-09-18 11:00:00-04:00,LLY,neutral
767295.0,"Boehringer Ingelheim Pharma, Eli Lilly Announce Jardiance Significantly Reduced Risk of Combined Endpoint of CV Death, Non-Fatal Heart Attack, Stroke",2015-09-17 11:48:00-04:00,LLY,negative
767296.0,Eli Lilly Says Abasaglar Showed Similar Safety to Lantus - Reuters,2015-09-15 06:34:00-04:00,LLY,positive
767297.0,U.S. FDA approves Synjardy tablets for adults with type 2 diabetes,2015-08-27 10:32:00-04:00,LLY,positive
767298.0,Benzinga's Top Initiations,2015-08-27 09:42:00-04:00,LLY,positive
767299.0,"Berenberg Initiates Coverage on Eli Lilly at Buy, Announces $100.00 PT",2015-08-27 07:44:00-04:00,LLY,neutral
767300.0,U.S. District Court Rules in Lilly's Favor on Alimta Vitamin Regimen Patent,2015-08-25 17:10:00-04:00,LLY,positive
767301.0,Benzinga's Volume Movers,2015-08-20 10:35:00-04:00,LLY,neutral
767302.0,Lily +3% on Positive Jardiance Results,2015-08-20 08:55:00-04:00,LLY,positive
767303.0,Jardiance demonstrated cardiovascular risk reduction in people with type 2 diabetes at high risk for CV events,2015-08-20 07:33:00-04:00,LLY,negative
767304.0,Eli Lilly CEO: Recent Events In China Don't Change Much,2015-08-16 13:32:00-04:00,LLY,neutral
767305.0,Here's A Look At Eli Lilly's Future Pipeline,2015-08-15 10:39:00-04:00,LLY,neutral
767306.0,Lilly Issues Update on Evacetrapib Phase 3 Trial: Last Patient Visit in ACCELERATE Expecting Jul. '16,2015-07-27 08:01:00-04:00,LLY,neutral
767307.0,"Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest Conference Calls",2015-07-23 16:01:00-04:00,LLY,neutral
767308.0,Eli Lilly CEO Explains The Reasons Behind The $0.16 EPS Beat,2015-07-23 13:39:00-04:00,LLY,neutral
767309.0,Lilly CEO Says Bubble in Prices of Smaller Biotech Cos -Reuters,2015-07-23 09:56:00-04:00,LLY,neutral
767310.0,Eli Lilly Sees FY15 Adj. EPS $3.20-$3.30 vs $3.18 Est.,2015-07-23 06:27:00-04:00,LLY,neutral
767311.0,"Eli Lilly Reports Q1 Adj. EPS $0.90 Vs Est $0.74, Sales $4.98B Vs Est $4.91B",2015-07-23 06:25:00-04:00,LLY,neutral
767312.0,"Earnings Scheduled For July 23, 2015",2015-07-23 04:46:00-04:00,LLY,neutral
767313.0,What's Coming For Large-Cap Pharma Stocks This Earnings Season?,2015-07-22 16:13:00-04:00,LLY,neutral
767314.0,"Did McDonald's, Caterpillar & Amazon Lose Sizzle To Strong Dollar?",2015-07-22 13:59:00-04:00,LLY,positive
767315.0,Evercore ISI's Mark Schoenebaum: New Eli Lilly Data 'Incrementally Positive',2015-07-22 10:49:00-04:00,LLY,positive
767316.0,Data Using New Delayed-Start Methodology Suggested Benefit of Early Treatment with Solanezumab in Patients with Mild Alzheimer's Disease,2015-07-22 07:04:00-04:00,LLY,positive
767317.0,Data Utilizing New Delayed-Start Methodology Suggested Benefit of Early Treatment with Solanezumab in Patients with Mild Alzheimer's Disease,2015-07-22 07:02:00-04:00,LLY,positive
767318.0,New Alzheimer's Trials Could Produce The Most Important Drugs In History,2015-07-21 15:14:00-04:00,LLY,positive
767319.0,Fast Money Picks For July 21,2015-07-21 06:26:00-04:00,LLY,neutral
767320.0,Has Eli Lilly Found A Cure For Alzheimer's?,2015-07-20 11:57:00-04:00,LLY,neutral
767321.0,"Stifel, JMP Securities Discuss What To Expect From AAIC Conference",2015-07-20 08:30:00-04:00,LLY,positive
767322.0,Benzinga's Top Downgrades,2015-07-15 09:28:00-04:00,LLY,positive
767323.0,"Morgan Stanley Cuts Eli Lilly: Says Downgraded Not Related to Negative Call on Alzheimer's Data, Sees Current Share Price Factoring 'in pipelineenthusiasm for two blockbuster candidates:' Solanezumab, Evacetrapib",2015-07-15 08:48:00-04:00,LLY,positive
767324.0,Morgan Stanley Downgrades Eli Lilly to Equalweight,2015-07-15 06:49:00-04:00,LLY,neutral
767325.0,Stocks Hitting 52-Week Highs,2015-07-13 10:05:00-04:00,LLY,neutral
767326.0,"Eli Lilly Issues Statement Regarding FDA Panel Review of Necitumumab: 'Encouraged' by Committee's Constructuive Discussion, Working Closely with FDA to Continue Review",2015-07-09 13:56:00-04:00,LLY,neutral
767327.0,Fast Money Picks For July 9,2015-07-09 07:20:00-04:00,LLY,neutral
767328.0,Fast Money Picks For July 7,2015-07-07 06:47:00-04:00,LLY,neutral
767329.0,"AAIC Is Coming: Here's What To Expect, Biogen And Eli Lilly Investors",2015-07-03 10:21:00-04:00,LLY,neutral
767330.0,"Lilly, Immunocore Report Immunotherapy-based Clinical Trial Collaboration in Melanoma",2015-06-29 08:02:00-04:00,LLY,neutral
767331.0,Eli Lilly Shares Go Parabolic,2015-06-25 11:08:00-04:00,LLY,positive
767332.0,Bank of America Upgrades Eli Lilly to Buy,2015-06-25 06:50:00-04:00,LLY,neutral
767333.0,\Eli Lilly Announces UK Court Has Ruled in Favor of Co. in Alimta Vitamin Regimen Patent Suit,2015-06-25 06:00:00-04:00,LLY,positive
767334.0,"Sales Of This Eli Lilly Drug Could Nearly Double Wall St. Consensus In 2020, SunTrust Predicts",2015-06-24 11:09:00-04:00,LLY,neutral
767335.0,"Ken Langone's Top Stock Picks: Schlumberger, Eli Lilly And Facebook",2015-06-22 13:31:00-04:00,LLY,positive
767336.0,CYRAMZA Hepatocellular Carcinoma Data Published by The Lancet Oncology,2015-06-19 08:01:00-04:00,LLY,neutral
767337.0,Eli Lilly Price Target Hiked To $92 At Argus; Here's Why,2015-06-18 11:10:00-04:00,LLY,neutral
767338.0,The Note Moving Pharma Giants Today,2015-06-17 16:06:00-04:00,LLY,neutral
767339.0,Lilly's investigational migraine prevention medicine met primary endpoint in a Phase 2b study,2015-06-17 12:02:00-04:00,LLY,neutral
767340.0,Benzinga's Top Initiations,2015-06-17 09:29:00-04:00,LLY,positive
767341.0,"Eli Lilly, Dana-Farber Announce Research Collaboration For New Medicines To Fight Cancer",2015-06-17 08:06:00-04:00,LLY,negative
767342.0,"Eli Lilly, Sara Cannon Research Institute Enter Collaboration To Develop Investigational Oncology Therapy",2015-06-17 08:02:00-04:00,LLY,neutral
767343.0,"Piper Jaffray Initiates Coverage on Eli Lilly at Overweight, Announces $97.00 PT",2015-06-17 06:10:00-04:00,LLY,negative
767344.0,New Report: Abbvie Is Jefferies' Top Global Pharma Stock,2015-06-16 12:15:00-04:00,LLY,positive
767345.0,UPDATE: Alzheimers Association Says Release of Data Under Embargo to Conference Participants Might have Influenced Lily Share Price,2015-06-12 14:36:00-04:00,LLY,positive
767346.0,Alzheimer's Group Says May Not Offer Early Look At Highly Sought Data On Lilly Drug -Reuters,2015-06-12 14:34:00-04:00,LLY,neutral
767347.0,"Studies Report Psoriasis Patients Achieved Significant Levels of Skin Clearance, Improved Quality of Life after 12 Weeks of Ixekizumab Treatment",2015-06-10 12:04:00-04:00,LLY,positive
767348.0,Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis,2015-06-10 08:02:00-04:00,LLY,neutral
767349.0,Fast Money Picks For June 10,2015-06-10 07:27:00-04:00,LLY,neutral
767350.0,Lily Shares Spike to All-Time High,2015-06-09 15:41:00-04:00,LLY,positive
767351.0,Lily Shares Spike to High; Weekly Jun 12 $79.5 Call Active,2015-06-09 14:09:00-04:00,LLY,positive
767352.0,"This Technology Could Disrupt U.S. Pharma Stocks, Credit Suisse Says",2015-06-08 14:03:00-04:00,LLY,positive
767353.0,New Data Show Enhanced Effects of Lilly's Once-Weekly Trulicity (dulaglutide) to Lantus (insulin glargine) in Patients with Type 2 Diabetes,2015-06-08 09:15:00-04:00,LLY,neutral
767354.0,Lily Presents Study Indicating Once-Weekly Trulicity More Effective than Once-Daily Victoza in Japanese Patients after 52 Weeks,2015-06-07 08:31:00-04:00,LLY,positive
767355.0,Lilly's Basal Insulin Peglispro Shows Superiority to Glargine in Reducing HbA1c in People with Type 2 Diabetes,2015-06-07 08:15:00-04:00,LLY,positive
767356.0,Lilly's Basal Insulin Peglispro Studies Demonstrate Superiority to Glargine in People with Type 1 Diabetes,2015-06-07 08:13:00-04:00,LLY,positive
767357.0,Lilly to Report Pivotal Phase 3 Study Results for Investigational Psoriasis Treatment at 23rd World Congress of Dermatology,2015-06-04 09:04:00-04:00,LLY,neutral
767358.0,16 Biotech Stocks Moving Off The ASCO Conference,2015-06-01 15:51:00-04:00,LLY,neutral
767359.0,"Lilly, AstraZeneca to Partner on Immuno-Oncology Combination Clinical Trial in Solid Tumors",2015-05-29 08:04:00-04:00,LLY,positive
767360.0,Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data,2015-05-28 13:00:00-04:00,LLY,neutral
767361.0,Eli Lilly Reports Results Of Cash Tender Offer,2015-05-28 08:07:00-04:00,LLY,neutral
767362.0,Eli Lilly Reports Will Present CYRAMZA Data at ASCO Meeting: Will Submit to Japanese Regulatory Authorities,2015-05-28 08:06:00-04:00,LLY,neutral
767363.0,Eli Lilly Announces FDA Approves Humalog,2015-05-27 08:33:00-04:00,LLY,positive
767364.0,Lilly to Present New Clinical Data at 75th American Diabetes Association Scientific Sessions,2015-05-27 07:32:00-04:00,LLY,neutral
767365.0,"Lilly, Sanford-Burnham Collaborate to Investigate Immunological Therapies",2015-05-14 06:03:00-04:00,LLY,neutral
767366.0,Lilly Announces Cash Tender Offer for Up to $1.6Aggregate Principal Amount of Its Outstanding Debt Securities and the Redemption of Its 6.57% Notes due 2016,2015-05-12 08:33:00-04:00,LLY,positive
767367.0,"Lilly, BioNTech Announce Research Collaboration on Novel Cancer Immunotherapies",2015-05-11 15:16:00-04:00,LLY,negative
767368.0,"Credit Suisse: We Prefer Pfizer, Bristol Over Pharma Peers",2015-05-05 08:51:00-04:00,LLY,positive
767369.0,Shares Of Lilly Spike Lower Momentarily To $71.25 Before Rebounding To $73,2015-05-01 15:57:00-04:00,LLY,neutral
767370.0,Hearing Unconfirmed Market Chatter of Potential Merck Bid for Lilly,2015-05-01 10:14:00-04:00,LLY,negative
767371.0,Benzinga's Top Upgrades,2015-04-29 09:48:00-04:00,LLY,positive
767372.0,Citigroup Upgrades Eli Lilly To  Buy,2015-04-29 08:57:00-04:00,LLY,neutral
767373.0,IPO Outlook: CoLucid Offers Hope For Migraine Sufferers,2015-04-29 08:20:00-04:00,LLY,negative
767374.0,Citigroup Upgrades Eli Lilly to Buy,2015-04-29 07:00:00-04:00,LLY,neutral
767375.0,BofA Sees Many Catalysts On Eli Lilly's Horizon,2015-04-28 16:57:00-04:00,LLY,neutral
767376.0,Lilly's CYRAMZA Receives Approval For Use With FOLFIRI In Second-Line Treatment Of Metastatic Colorectal Cancer,2015-04-24 16:30:00-04:00,LLY,negative
767377.0,Eli Lilly CFO: Solid Underlying Performance Despite FX Headwind,2015-04-24 13:19:00-04:00,LLY,positive
767378.0,BMO's Updated Eli Lilly Model Following Earnings,2015-04-24 11:50:00-04:00,LLY,neutral
767379.0,"US Stock Futures Down Ahead Of Earnings, Economic Data",2015-04-23 08:14:00-04:00,LLY,neutral
767380.0,Eli Lilly Tops Q1 Views,2015-04-23 07:18:00-04:00,LLY,positive
767381.0,Lilly Q1 EPS $4.65B vs $4.62B est,2015-04-23 06:26:00-04:00,LLY,neutral
767382.0,Lilly Confirms FY Guidance,2015-04-23 06:26:00-04:00,LLY,neutral
767383.0,Lilly Q1 EPS $0.87 vs $0.77 est,2015-04-23 06:25:00-04:00,LLY,neutral
767384.0,"Earnings Scheduled For April 23, 2015",2015-04-23 04:03:00-04:00,LLY,neutral
767385.0,Eli Lilly Partner Deciphera Pharma Announces Data Highlighting Kinase Inhibitor Pipeline at AACR Meeting,2015-04-22 08:05:00-04:00,LLY,negative
767386.0,Lilly's Ixekizumab Meets Primary Endpoint in a Phase 3 Study Investigating Treatment of Psoriatic Arthritis,2015-04-20 08:05:00-04:00,LLY,neutral
767387.0,"Lilly, Bristol-Myers Squibb Restructure Erbitux Pact In North America; Lilly Gets Full Commercialization Rights While Bristol-Myers Gets Tiered Royalties On Product Sales",2015-04-16 12:18:00-04:00,LLY,neutral
767388.0,SunTrust's Latest Comments On Merck,2015-04-15 15:32:00-04:00,LLY,neutral
767389.0,Morgan Stanley's Major Pharma Q1 Preview,2015-04-14 16:47:00-04:00,LLY,neutral
767390.0,7 Trends Drug Investors Should Know,2015-04-13 16:32:00-04:00,LLY,neutral
767391.0,8 Companies That Are Fighting Indiana's 'Religious Freedom' Law,2015-04-01 12:28:00-04:00,LLY,positive
767392.0,"EMA Recommends Approval of Eli Lilly, Boehringer Ingelheim's Empagliflozin Plus Metformin",2015-03-27 08:11:00-04:00,LLY,positive
767393.0,Analyst: Here's Why Eli Lilly Is Worth More Than It Used To Be,2015-03-23 17:28:00-04:00,LLY,positive
767394.0,"FDA Concludes 2 Year Zyprexa Relprevv Review Of Two Deaths Related To Schizophrenia Drug, FDA Says No New Warnings Needed",2015-03-23 14:08:00-04:00,LLY,negative
767395.0,"Pfizer, Lilly To Resume Phase 3 Chronic Pain Program For Tanezumab",2015-03-23 12:42:00-04:00,LLY,negative
767396.0,"SunTrust Names Eli Lilly, Merck, Bristol-Myers as 'Favorite' Pharma Firms",2015-03-23 12:21:00-04:00,LLY,neutral
767397.0,"Pfizer, Eli Lilly Announce Preparing of Resumption for Phase 3 Chronic Pain Program for Tanezumab",2015-03-23 08:00:00-04:00,LLY,negative
767398.0,Eli Lilly Just Unveiled A Major Biotech Collaboration In China,2015-03-20 11:50:00-04:00,LLY,neutral
767399.0,"UPDATE: Lilly Says Innovent Will Get Upfront Payment of $56M, Could Get Future Payments $400M+",2015-03-20 08:03:00-04:00,LLY,neutral
767400.0,Lilly and Innovent Biologics Announce a Strategic Alliance to Bring Potential Oncology Therapies to Patients in China and Around the World,2015-03-20 08:02:00-04:00,LLY,neutral
767401.0,"Eli Lilly, Hanmi Report Exclusive License Deal for Development, Commercialization of Immunological Therapy",2015-03-19 08:03:00-04:00,LLY,positive
767402.0,8 Healthcare Names Cowen & Co Are Talking About,2015-03-10 18:02:00-04:00,LLY,neutral
767403.0,German Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit,2015-03-06 08:33:00-05:00,LLY,positive
767404.0,Denovo Biopharma Announces It Has Exclusively Licensed Pomaglumetad Methionil From Eli Lily & Co.,2015-03-03 08:06:00-05:00,LLY,neutral
767405.0,5 'Key Pipeline Catalysts' To Watch At Eli Lilly,2015-02-23 17:42:00-05:00,LLY,neutral
767406.0,Lilly Announces Delay In Submission For Basal Insulin Peglispro To Regulatory Agencies,2015-02-23 08:33:00-05:00,LLY,negative
767407.0,Eli Lilly Reports Delay on Regulatory Submission Timing for Basal Insulin Peglispro,2015-02-23 08:30:00-05:00,LLY,negative
767408.0,Eli Lilly Reports Baricitinib Found Superior to Placebo for Reducing RA Disease Activity,2015-02-23 07:07:00-05:00,LLY,positive
767409.0,"Lilly, Incyte Report Baricitinib Superior to Placebo in Reducing RA Disease Activity in Second Phase 3 Study",2015-02-23 07:02:00-05:00,LLY,positive
767410.0,Lilly Provides Phase 3 Trial Update On Evacetrapib,2015-02-19 08:02:00-05:00,LLY,neutral
767411.0,"UPDATE: Lilly Says China, Parts of Asia Most Profitable of Emerging Markets, Parts of India Subcontinent Least Profitable",2015-02-11 08:46:00-05:00,LLY,positive
767412.0,Lilly Says Still Room to Grow Business in China,2015-02-11 08:41:00-05:00,LLY,neutral
767413.0,Lilly Currently Presenting at Leerink Global Healthcare Conference,2015-02-11 08:38:00-05:00,LLY,neutral
767414.0,"After A Blockbuster 2014, What Will 2015 Hold For Pharmaceutical M&A?",2015-02-06 15:28:00-05:00,LLY,positive
767415.0,IPO Alert: Biotech Investors Should Watch Advanced Accelerator's New Drug Lineup,2015-02-05 10:32:00-05:00,LLY,positive
767416.0,UBS: Eli Lilly's 'Outlook Continuing To Improve',2015-02-02 10:25:00-05:00,LLY,positive
767417.0,Lilly Announces FDA Approves First-in-class Glyxambi Tablets for Adults With Type 2 Diabetes,2015-02-02 08:37:00-05:00,LLY,positive
767418.0,Eli Lilly CEO Explains The Reasons Behind Not Changing 2015 Guidance On Back Of Strengthening Dollar,2015-02-02 07:43:00-05:00,LLY,positive
767419.0,"UPDATE: Eli Lilly Posts Upbeat Q4 Profit, Sales Decline",2015-01-30 07:26:00-05:00,LLY,positive
767420.0,"Eli Lilly Guides FY 2015 Lower, Expects $19.5B to $20B",2015-01-30 06:27:00-05:00,LLY,negative
767421.0,"Eli Lilly Q4 EPS $0.75, $0.73 Est",2015-01-30 06:25:00-05:00,LLY,neutral
767422.0,"Earnings Scheduled For January 30, 2015",2015-01-30 04:57:00-05:00,LLY,neutral
767423.0,10 Must Watch Stocks for Today,2015-01-30 04:13:00-05:00,LLY,neutral
767424.0,A Pair Trade With Eli Lilly And Johnson & Johnson? Goldman Just Explained Why It's A Solid Idea,2015-01-15 17:40:00-05:00,LLY,positive
767425.0,10 Biotech Stories You Might've Missed This Week,2015-01-15 13:18:00-05:00,LLY,negative
767426.0,Goldman Sachs Upgrades Eli Lilly to Neutral,2015-01-15 06:55:00-05:00,LLY,neutral
767427.0,Notes From The Street: 'FLASHBACK....Oil Going To $200/Barrel',2015-01-13 08:20:00-05:00,LLY,neutral
767428.0,Merck and Eli Lilly Announce Agreement For Collaboration on Cancer Clinical Trial,2015-01-13 08:01:00-05:00,LLY,negative
767429.0,'FDA stops import of Lilly's Cialis from Australia',2015-01-12 18:02:00-05:00,LLY,negative
767430.0,"Eil Lilly CEO Talks New Product Launches, Pricing Pressure From Other Companies",2015-01-12 16:04:00-05:00,LLY,negative
767431.0,FDA Issues Import Block On Eli Lilly's Cialis,2015-01-12 12:31:00-05:00,LLY,negative
767432.0,FDA issues Import Block Alert On Lilly's Cialis,2015-01-12 11:34:00-05:00,LLY,negative
767433.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2,2015-01-12 11:03:00-05:00,LLY,neutral
767434.0,From CNBC: Eli Lilly CEO 'Anticipates 2015 Drug Price Increases; Remains Interested In Smaller M&A  Deals',2015-01-12 10:25:00-05:00,LLY,positive
767435.0,"Fast Money Picks For January 12: Twitter, Eli Lilly, Lions Gate",2015-01-12 07:10:00-05:00,LLY,neutral
767436.0,Bank of America Downgrades Eli Lilly to Neutral,2015-01-09 07:31:00-05:00,LLY,neutral
767437.0,#Premarket Prep Technical Update - Eli Lilly Higher,2015-01-08 14:01:00-05:00,LLY,neutral
767438.0,"Deutsche Bank, Stifel Differ On Outlook For Eli Lilly",2015-01-08 12:46:00-05:00,LLY,neutral
767439.0,Benzinga's Top Upgrades,2015-01-08 09:09:00-05:00,LLY,positive
767440.0,Jefferies Upgrades Eli Lilly To Buy,2015-01-08 08:25:00-05:00,LLY,neutral
767441.0,"UPDATE: Deutsche Bank Downgrades Eli Lilly On Positive Outlook, Modest Upside",2015-01-08 07:32:00-05:00,LLY,positive
767442.0,"Jefferies Upgrades Eli Lilly to Buy, Raises PT to $80.00",2015-01-08 05:18:00-05:00,LLY,neutral
767443.0,Deutsche Bank Downgrades Eli Lilly to Hold,2015-01-08 05:09:00-05:00,LLY,neutral
767444.0,4 Stocks Trending On Social Media This Wednesday,2015-01-07 12:27:00-05:00,LLY,neutral
767445.0,Eli Lilly Moves Higher Following FY 2014 & 2015 Outlook,2015-01-07 09:25:00-05:00,LLY,neutral
767446.0,"From Eli Lilly Guidance Conference Call: Mgmt Still Expecting FY14 Sales in $19.4-$19.8B Range, vs $19.7B Analyst Est.",2015-01-07 09:16:00-05:00,LLY,neutral
767447.0,Benzinga's Top #PreMarket Losers,2015-01-07 08:19:00-05:00,LLY,negative
767448.0,Eli Lilly Sees FY2014 EPS $2.72-2.80,2015-01-07 07:31:00-05:00,LLY,neutral
767449.0,Eli Lilly Sees FY2015 EPS $3.10-3.20; Sees Sales $20.30B-20.80B,2015-01-07 07:31:00-05:00,LLY,neutral
767450.0,Fast Money Halftime Report Final Trade From January 6,2015-01-06 15:34:00-05:00,LLY,neutral
767451.0,#Premarket Prep Technical Update - Eli Lilly Trading Higher,2015-01-02 15:06:00-05:00,LLY,neutral
767452.0,US Stock Futures Surge Ahead Of Manufacturing Data,2015-01-02 07:00:00-05:00,LLY,neutral
767453.0,Lilly Completes Acquisition of Novartis Animal Health,2015-01-01 08:22:00-05:00,LLY,neutral
767454.0,FTC Places Conditions on Lilly's Proposed Deal to Divest Sentinel to Virbac SA,2014-12-22 11:04:00-05:00,LLY,neutral
767455.0,"Lilly, Adocia Announce Alliance to Co-Develop BioChaperone Lispro",2014-12-19 05:07:00-05:00,LLY,neutral
767456.0,7 Stocks You Should Be Watching Today,2014-12-16 04:14:00-05:00,LLY,neutral
767457.0,Lilly Announces Dividend Increase From $0.49 To $0.50/share,2014-12-15 16:31:00-05:00,LLY,positive
767458.0,UPDATE: FDA Expands Approval For Cyramza,2014-12-12 12:50:00-05:00,LLY,positive
767459.0,Eli Lilly's Cyramza Receives Expanded FDA Approval,2014-12-12 12:49:00-05:00,LLY,positive
767460.0,"Morgan Stanley Upgrades Eli Lilly and Company to Overweight, Raises PT to $85.00",2014-12-11 09:40:00-05:00,LLY,negative
767461.0,"Lilly, Incyte Announce Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis Met Primary Endpoint",2014-12-09 07:17:00-05:00,LLY,negative
767462.0,"Eli Lilly, Anthem, Inc. and HealthCore Create Research Collaboration",2014-12-08 08:04:00-05:00,LLY,positive
767463.0,"Jefferies Maintains Hold on Eli Lilly and Company, Raises PT to $5.00",2014-12-04 08:00:00-05:00,LLY,neutral
767464.0,Zosano Pharma and Eli Lilly and Company Enter Into Exclusive Licensing Agreement for Zosano's ZP-PTH Product Candidate,2014-12-02 08:32:00-05:00,LLY,positive
767465.0,Lilly Announces Co. AstraZeneca Report Enrollment of First Patient Into AMARANTH,2014-12-01 07:01:00-05:00,LLY,neutral
767466.0,From 13G: Eli Lilly Company Reports 9.1% Stake In Coherus BioSciences Inc.,2014-11-24 15:39:00-05:00,LLY,neutral
767467.0,#Premarket Prep Technical Update - Eli Lilly Higher,2014-11-21 15:17:00-05:00,LLY,neutral
767468.0,"Eli Lilly Reports New Retrospective Data Showed Empagliflozin Reduced A1C, Body Weight, Markers of Abdominal Fat in Adults with Type 2 Diabetes",2014-11-17 16:04:00-05:00,LLY,neutral
767469.0,#Premarket Prep Technical Update - Eli Lilly Makes Multi-Year High And Retreats,2014-11-11 14:44:00-05:00,LLY,neutral
767470.0,FDA Approves Ramcirumab In Combination With Paclitaxel For Gastric Cancer,2014-11-05 14:31:00-05:00,LLY,negative
767471.0,Credit Suisse Raises Eli Lilly Price Target,2014-11-03 12:05:00-05:00,LLY,positive
767472.0,"Eli Lilly Recently Filed 10-Q; Seeing FY14 EPS Expected in $2.36-$2.44 Range Amid Revisions on Boehringer Deal, Facility Closing",2014-10-29 14:42:00-04:00,LLY,neutral
767473.0,"Lilly, Boehringer Ingelheim Changing Structure of Diabetes Alliance In Certain Countries ",2014-10-29 08:06:00-04:00,LLY,positive
767474.0,"Lilly Responds to Decision in Case of Terrence Allen, et al. v. Takeda ",2014-10-27 19:53:00-04:00,LLY,neutral
767475.0,UPDATE:  Judge Cut $9B Award To Eli Lilly & Takeda Pharma To $36.8M,2014-10-27 15:57:00-04:00,LLY,positive
767476.0,"Takeda, Lilly Receive $9B Actos Award To $36.8M",2014-10-27 15:56:00-04:00,LLY,positive
767477.0,Virbac to Acquire US Veterinary Assets from Eli Lilly ,2014-10-27 05:07:00-04:00,LLY,positive
767478.0,#Premarket Prep Technical Update - Eli Lilly Trading Higher,2014-10-24 14:20:00-04:00,LLY,neutral
767479.0,"US Stock Futures Rise Ahead Of Earnings, Economic Data",2014-10-23 07:41:00-04:00,LLY,neutral
767480.0,UPDATE: Eli Lilly Posts Lower Q3 Profit,2014-10-23 07:23:00-04:00,LLY,positive
767481.0,Eli Lilly and Company Sees FY2014 EPS $2.34-2.42,2014-10-23 06:33:00-04:00,LLY,neutral
767482.0,Eli Lilly and Company Reports Q3 EPS of $0.66 vs $0.69 Est; Revenue of $4.88B vs $4.83B Est,2014-10-23 06:30:00-04:00,LLY,neutral
767483.0,"Earnings Scheduled For October 23, 2014",2014-10-23 05:11:00-04:00,LLY,neutral
767484.0,CANDA NK-2 Files Motion To Dismiss Patent Infringement Suit,2014-10-22 17:48:00-04:00,LLY,negative
767485.0,"Lilly, Zymeworks Announce Expansion Of Strategic Licensing And Collaboration Agreement",2014-10-22 16:18:00-04:00,LLY,positive
767486.0,FDA Accepts Filing Of A NDA For Empagliflozin ,2014-10-21 09:03:00-04:00,LLY,positive
767487.0,Benzinga Weekly Preview: Earnings Season Is In Full Swing,2014-10-19 10:19:00-04:00,LLY,neutral
767488.0,UPDATE: Lilly To Initiate Efforts To Sell Guayama Site,2014-10-16 14:33:00-04:00,LLY,neutral
767489.0,Lilly Announces Plan to Realign Puerto Rico Manufacturing Operations,2014-10-16 14:32:00-04:00,LLY,neutral
767490.0,"Jefferies Maintains Hold on Eli Lilly and Company, Raises PT to $70.00",2014-10-13 08:30:00-04:00,LLY,neutral
767491.0,Eli Lilly's Olaratumab Wins FDA Orphan Drug Designation,2014-10-10 10:02:00-04:00,LLY,positive
767492.0,#Premarket Prep Technical Update - Eli Lilly Trading HIgher,2014-10-03 14:23:00-04:00,LLY,neutral
767493.0,Markets Little Changed Ahead Of Friday's Jobs Report,2014-10-02 17:10:00-04:00,LLY,neutral
767494.0,Eli Lilly Will Discontinue Tabalumab Development of Efficacy Data,2014-10-02 08:35:00-04:00,LLY,neutral
767495.0,"Guggenheim Securities Initiates Coverage on Eli Lilly and Company at Buy, Announces $80.00 PT",2014-10-02 06:09:00-04:00,LLY,positive
767496.0,"Dyax Offers Highlights of Recent Progress in Licensing, Funded-Research Portfolio",2014-09-22 07:17:00-04:00,LLY,positive
767497.0,Lilly Wins Approval From FDA For Diabetes Treatment Trulicity - Bloomberg,2014-09-18 15:58:00-04:00,LLY,positive
767498.0,Eli Lilly Reports CYRAMZA in Combo with Paclitaxel Showed Significant Improvement in Overall Survival in Second-Line Gastric Cancer Patients,2014-09-18 08:06:00-04:00,LLY,negative
767499.0,"Lipocine Inc Halted: Feds Eye Safety, Efficacy Of Testosterone",2014-09-17 11:45:00-04:00,LLY,positive
767500.0,"Denovo Biopharma Reports Purchase of Enzastaurin from Eli Lilly, Includes Rights to Develop, Manufacture, Commercialize, No Terms Disclosed",2014-09-16 12:35:00-04:00,LLY,negative
767501.0,"Eli Lilly, AstraZeneca Report Alliance to Co-Develop Potential Treatment for Alzheimer's, Lilly to Pay Up to $500M in Milestones",2014-09-16 07:01:00-04:00,LLY,negative
767502.0,Lilly Announces CYRAMZA Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint Of Overall Survival,2014-09-12 08:00:00-04:00,LLY,negative
767503.0,What Is A High Risk Market?,2014-09-08 09:39:00-04:00,LLY,negative
767504.0,"Lilly's Basal Insulin Peglispro Demonstrated Hba1c Superiority Against Lantus in Phase Iii Trials In Patients With Type 1 Diabetes; Expects US, EC Submissions By End of Q1 2015",2014-09-04 08:06:00-04:00,LLY,positive
767505.0,Markets Little Changed In Low Volume And Slow News Ahead Of Long Weekend,2014-08-27 17:17:00-04:00,LLY,negative
767506.0,Deutsche Bank: Eli Lilly At 'Critical Stage' In Its Journey,2014-08-27 12:55:00-04:00,LLY,negative
767507.0,"Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers at Hold",2014-08-27 12:32:00-04:00,LLY,neutral
767508.0,"Deutsche Bank Initiates Coverage on Eli Lilly and Company at Buy, Announces $71.00 PT",2014-08-27 06:41:00-04:00,LLY,neutral
767509.0,New Type 2 Diabetes Treatment Jardiance Tablets For Adults Now Available In U.S. Pharmacies,2014-08-26 09:04:00-04:00,LLY,neutral
767510.0,Eli Lilly Reports New Type 2 Diabetes Treatment Jardiance Tabs Now Available in US Pharmacies,2014-08-26 09:03:00-04:00,LLY,neutral
767511.0,Lilly's Ixekizumab Met all Primary and Key Secondary Objectives,2014-08-21 07:05:00-04:00,LLY,neutral
767512.0,"Lilly's Ixekizumab Found Superior to Etanercept, Placebo in Phase 3 Trial, Met All Primary, Key Secondary Endpoints",2014-08-21 07:04:00-04:00,LLY,positive
767513.0,Eli Lilly reports FDA Granting of Tentative Approval for Basaglar,2014-08-18 17:37:00-04:00,LLY,positive
767514.0,Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments,2014-08-11 16:46:00-04:00,LLY,positive
767515.0,#Premarket Prep Technical Update - Eli Lilly Trading Lower,2014-08-05 15:02:00-04:00,LLY,negative
767516.0,FDA Approves Jardiance Rempagliflozin Tablets for Adults withType 2 Diabetes ,2014-08-02 04:02:00-04:00,LLY,positive
767517.0,UPDATE: Tigress Initiates Coverage On Eli Lilly ,2014-08-01 15:48:00-04:00,LLY,neutral
767518.0,Tigress Financial Initiates Coverage on Eli Lilly and Company at Buy,2014-08-01 14:11:00-04:00,LLY,neutral
767519.0,Dow Suffers 300 Point Drop; S&P 500 And NASDAQ Also Tumble,2014-07-31 16:49:00-04:00,LLY,negative
767520.0,#Premarket Prep Technical Update - Eli Lilly Trading Lower,2014-07-31 14:25:00-04:00,LLY,negative
767521.0,Stocks Lower As Earnings Season Takes Back Seat To Geopolitical Uncertainties,2014-07-29 16:37:00-04:00,LLY,negative
767522.0,Thursday Morning Earnings Reports,2014-07-24 12:14:00-04:00,LLY,neutral
767523.0,Eli Lilly and Company Reports Q2 Adjusted EPS of $0.68 vs $0.65 Est; Revenue of $4.94B vs $4.88B Est,2014-07-24 06:36:00-04:00,LLY,neutral
767524.0,"Earnings Scheduled For July 24, 2014",2014-07-24 05:31:00-04:00,LLY,neutral
767525.0,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Higher,2014-07-18 14:18:00-04:00,LLY,neutral
767526.0,"Alzheimer's Rates Falling, But Pharma's Search For A Cure Yields No Results",2014-07-17 11:12:00-04:00,LLY,negative
767527.0,New Study Shows Beta-Amyloid Imaging Is Associated With Altered Diagnosis And Management Of Alzheimer's Disease,2014-07-16 08:18:00-04:00,LLY,neutral
767528.0,Lilly And Immunocore Enter Immunotherapy Agreement To Co-Discover And Co-Develop Novel Cancer Therapies,2014-07-16 07:05:00-04:00,LLY,neutral
767529.0,Benzinga's Top #PreMarket Gainers,2014-07-15 08:14:00-04:00,LLY,positive
767530.0,US Stock Futures Mostly Higher Ahead Of Goldman Sachs Earnings,2014-07-15 07:34:00-04:00,LLY,neutral
767531.0,New Data Shows Cognitive Impairment Precedes and Predicts Subsequent Functional Impairment in Patients with Mild Alzheimer's Disease ,2014-07-15 05:31:00-04:00,LLY,neutral
767532.0,Dow Sets New Intraday High; Citigroup Impresses With Earnings,2014-07-14 16:44:00-04:00,LLY,positive
767533.0,#Premarket Prep Technical Update - Eli Lilly Trading Lower,2014-07-07 12:02:00-04:00,LLY,negative
767534.0,Barclays Downgrades Pharmaceutical Sector,2014-07-02 15:31:00-04:00,LLY,neutral
767535.0,UPDATE: Barclays Upgrades Eli Lilly Despite Sector Downgrade,2014-07-02 09:40:00-04:00,LLY,neutral
767536.0,Benzinga's Top Upgrades,2014-07-02 08:24:00-04:00,LLY,positive
767537.0,"Barclays Upgrades Eli Lilly and Company to Equal-weight, Raises PT to $63.00",2014-07-02 06:30:00-04:00,LLY,neutral
767538.0,CHMP Issues Positive Report For Lilly's Insulin Glargine Product,2014-06-27 08:03:00-04:00,LLY,positive
767539.0,Bernstein Analysts Say A Hostile Deal with Eli Lilly Is Unlikely Because of Indiana Law,2014-06-25 06:27:00-04:00,LLY,negative
767540.0,#Premarket Prep Technical Update - Eli Lilly Trading HIgher,2014-06-20 14:31:00-04:00,LLY,neutral
767541.0,Lilly Reports Empagliflozin/Linagliptin Combination Tablet Showed Reduction in Blood Glucose in Two Phase III Trials ,2014-06-15 16:38:00-04:00,LLY,neutral
767542.0,Lilly Announces New Data on Basal Insulin Peglispro Shows Novel Mechanism of Action ,2014-06-14 17:09:00-04:00,LLY,positive
767543.0,Studies Show LY2963016 from Lilly and Boehringer Ingelheim has Similar Safety and Efficacy Profile to Lantus® ,2014-06-14 17:08:00-04:00,LLY,positive
767544.0,"Market Wrap For June 11: Momentum Hit, Dow Suffers Triple Digit Loss",2014-06-11 16:36:00-04:00,LLY,negative
767545.0,"Eli Lilly Announces Top-Line Results oh Phase III Hepatocellular Carcinoma Trial, Says Did Not Meet Primary Endpoint",2014-06-11 08:02:00-04:00,LLY,neutral
767546.0,ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?,2014-06-04 13:58:00-04:00,LLY,neutral
767547.0,ASCO Meeting Day 2: 'Promising' Results From JNJ's Imbruvica & Targeted Therapy,2014-06-04 10:32:00-04:00,LLY,neutral
767548.0,#Premarket Prep Technical Update - Eli Lilly Finding Resistance At $60.00,2014-06-02 13:29:00-04:00,LLY,neutral
767549.0,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Lower,2014-06-02 13:29:00-04:00,LLY,negative
767550.0,#Premarket Prep Technical Update - Eli Lilly Trading Lower,2014-06-02 13:29:00-04:00,LLY,negative
767551.0,UPDATE: Morgan Stanley Reiterates On Eli Lilly & Co. On Lackluster Survival Benefit,2014-06-02 09:17:00-04:00,LLY,positive
767552.0,Lilly Reports Increased Access to Clinical Trials Data for Qualified Researchers,2014-06-02 08:00:00-04:00,LLY,positive
767553.0,US Stock Futures Edge Lower Ahead Of Consumer Spending Report,2014-05-30 07:21:00-04:00,LLY,negative
767554.0,QIAGEN Announces Collaboration with Lilly,2014-05-30 05:31:00-04:00,LLY,neutral
767555.0,"Sanofi, Lilly Announce Licensing Agreement for Nonprescription Cialis ",2014-05-28 05:31:00-04:00,LLY,positive
767556.0,Eli Lilly Announces Will Hold Investor Web Call on Jun. 16th to Discuss Phase III Data for Dulaglutide,2014-05-27 14:02:00-04:00,LLY,neutral
767557.0,#Premarket Prep Technical Update - Eli Lilly Trading HIgher,2014-05-22 13:03:00-04:00,LLY,neutral
767558.0,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Lower,2014-05-15 12:51:00-04:00,LLY,negative
767559.0,Eli Lilly Announces Linagliptin Positive Results,2014-05-15 12:51:00-04:00,LLY,positive
767560.0,Lilly Says Abemaciclib in Phase 1 Study Demonstrated Single-Agent Activity,2014-05-14 17:05:00-04:00,LLY,neutral
767561.0,"Stocks To Watch For May 14, 2014",2014-05-14 07:43:00-04:00,LLY,neutral
767562.0,Google Celebrates Dorothy Hodgkin & Her Contributions To Chemistry,2014-05-12 16:27:00-04:00,LLY,positive
767563.0,UPDATE: Eli Lilly Announces Peglispro Shows Superiority Compared to Insulin Glargine in HBA1C,2014-05-12 09:05:00-04:00,LLY,positive
767564.0,Eli Lilly Announces Peglispro Shows Superiority Compared to Insulin Glargine in HBA1C,2014-05-12 09:03:00-04:00,LLY,positive
767565.0,Lilly Strongly Disagrees with Court's Ruling in Brazil Labor Case ,2014-05-09 18:41:00-04:00,LLY,negative
767566.0,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Lower,2014-05-09 11:39:00-04:00,LLY,negative
767567.0,Market Wrap For April 29: Dow Approaches Record Highs Despite Ongoing Ukraine Tension and Upcoming Fed Meeting ,2014-04-29 16:43:00-04:00,LLY,positive
767568.0,Market Wrap For April 24: Apple's Smashing Earnings Overshadowed By Ukraine Concerns,2014-04-24 16:41:00-04:00,LLY,neutral
767569.0,"Eli Lilly Reports Q1 Adjusted EPS of $0.70, Inline; Revenue of $4.68B vs $4.79B Est",2014-04-24 06:32:00-04:00,LLY,neutral
767570.0,"Earnings Scheduled For April 24, 2014",2014-04-24 05:33:00-04:00,LLY,neutral
767571.0,"Market Wrap For April 23: S&P 500 Ends Winning Streak, Apple Announces 7-for-1 Stock Split",2014-04-23 16:46:00-04:00,LLY,positive
767572.0,MKM Partners Downgrades Eli Lilly and Company to Neutral,2014-04-23 07:47:00-04:00,LLY,neutral
767573.0,"Benzinga's M&A Chatter for Tuesday April 22, 2014",2014-04-22 18:19:00-04:00,LLY,neutral
767574.0,US Stock Futures Edge Higher Ahead Of McDonald's Earnings,2014-04-22 07:31:00-04:00,LLY,neutral
767575.0,Lilly to Acquire Novartis Animal Health for Approximately $5.4B in Cash,2014-04-22 05:40:00-04:00,LLY,neutral
767576.0,UPDATE: Lilly's CYRAMZA is First FDA-Approved Treatment for Advanced Gastric Cancer After Prior Chemotherapy ,2014-04-21 21:29:00-04:00,LLY,negative
767577.0,FDA Approves Cyramza for Stomach Cancer,2014-04-21 16:17:00-04:00,LLY,negative
767578.0,"No Legwork Mondays – Takeda, Eli Lilly And Actos",2014-04-21 10:33:00-04:00,LLY,negative
767579.0,#Premarket Prep Technical Update - Eli Lilly Trading Higher,2014-04-17 15:05:00-04:00,LLY,neutral
767580.0,"Market Wrap For April 14: Markets Surge on Positive Retail Data, Citi Earnings",2014-04-14 16:36:00-04:00,LLY,positive
767581.0,#Premarket Prep Technical Update - Eli Lilly Trading Higher,2014-04-14 14:16:00-04:00,LLY,neutral
767582.0,"Jefferies Upgrades Eli Lilly and Company to Hold, Raises PT to $54.00",2014-04-14 08:50:00-04:00,LLY,neutral
767583.0,Eli Lilly to Report First Quarter Results April 24th Before Market Open,2014-04-10 16:25:00-04:00,LLY,neutral
767584.0,Anne Marie Baiynd tweets: 'Careful with $LLY - looks like it is on its way to fill the gap',2014-04-09 07:31:00-04:00,LLY,positive
767585.0,Market Wrap For April 8: Markets Bounce Higher As Earnings Season Begins,2014-04-08 16:54:00-04:00,LLY,neutral
767586.0,Fitch Says Lilly's Ratings Intact Following $9B Actos Jury Verdict,2014-04-08 12:36:00-04:00,LLY,positive
767587.0,UPDATE: BMO Capital Upgrades Eli Lilly,2014-04-08 12:18:00-04:00,LLY,neutral
767588.0,Mark Schoenebaum Tweet: '$LLY will owe nothing in this lost court case. THEY ARE INDEMNIFIED. yet stock down. weird',2014-04-08 09:46:00-04:00,LLY,negative
767589.0,"Lilly Issues Response to Verdict in Case of Terrence Allen, et al. v. Takeda, Says Lilly Will Be Indemnified for Expenses",2014-04-08 09:18:00-04:00,LLY,positive
767590.0,Benzinga's Top Upgrades,2014-04-08 08:45:00-04:00,LLY,positive
767591.0,"BMO Capital Upgrades Eli Lilly and Company to Market Perform, Raises PT to $62.00",2014-04-08 07:54:00-04:00,LLY,neutral
767592.0,Takeda Responds to $6B Verdict in Diabetes Drug Case,2014-04-08 06:57:00-04:00,LLY,positive
767593.0,Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield ,2014-04-08 04:50:00-04:00,LLY,positive
767594.0,Lilly to Present Early-Stage Data Targeting Key Cancer Pathways at AACR 2014 ,2014-04-06 19:40:00-04:00,LLY,negative
767595.0,Market Wrap For April 3: Markets Winning Streak Fails To Extend To Five Days,2014-04-03 17:50:00-04:00,LLY,positive
767596.0,#Premarket Prep Technical Update - Eli Lilly Makes Multi-Year High And Retreats,2014-04-03 14:31:00-04:00,LLY,neutral
767597.0,UPDATE: Cowen & Company Upgrades Eli Lilly,2014-04-03 13:37:00-04:00,LLY,neutral
767598.0,Benzinga's Top Upgrades,2014-04-03 07:40:00-04:00,LLY,positive
767599.0,"Cowen & Company Upgrades Eli Lilly and Company to Outperform, Raises PT to $68.00",2014-04-03 07:28:00-04:00,LLY,neutral
767600.0,Market Wrap For April 1: S&P 500 Hitting New All-Time High Not An April Fools' Joke,2014-04-01 16:47:00-04:00,LLY,positive
767601.0,Moody's Says Alimta Patent Ruling Credit Positive for Lilly,2014-04-01 12:43:00-04:00,LLY,positive
767602.0,"Eli Lilly Expands Authorized Generic Deals with Prasco, Will Market Authorized Generic of Evista in US",2014-04-01 09:10:00-04:00,LLY,positive
767603.0,UPDATE: Bank of America Reiterates on Eli Lilly and Co. Following Alimta Case Ruling,2014-04-01 08:04:00-04:00,LLY,neutral
767604.0,"Bank of America Maintains Buy on Eli Lilly and Company, Raises PO to $69.00",2014-04-01 06:46:00-04:00,LLY,negative
767605.0,UPDATE: Court Upholds Validity of Lilly's Alimta Patent Through 2022 ,2014-03-31 19:48:00-04:00,LLY,neutral
767606.0,Federal Judge Upholds Eli Lilly's Alimta Cancer Drug Patent; Had been Challenged by Generic Makers,2014-03-31 19:18:00-04:00,LLY,negative
767607.0,Eli Lilly Range Bound,2014-03-12 14:48:00-04:00,LLY,neutral
767608.0,Lilly Announces FDA Complete Response Letter for Empagliflozin ,2014-03-05 09:33:00-05:00,LLY,neutral
767609.0,Biotechs vs. Pharmaceuticals: What's the Difference?,2014-03-04 10:30:00-05:00,LLY,neutral
767610.0,"Lilly's Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide, Hits Primary Endpoint",2014-02-25 08:05:00-05:00,LLY,neutral
767611.0,Elanco Announces Agreement to Acquire Lohmann Animal Health; Lowers FY 2014 Earnings Guidance to $2.72-2.80 on a Non-GAAP Basis,2014-02-24 08:03:00-05:00,LLY,positive
767612.0,"Market Wrap For February 19: Stocks Close Lower, Nasdaq Ends Winning Streak",2014-02-19 17:01:00-05:00,LLY,positive
767613.0,Eli Lilly Reports Ramucirumab Phase III Met Primary Endpoint of Overall Survival,2014-02-19 08:06:00-05:00,LLY,neutral
767614.0,Market Wrap For January 31: Markets End January On Sour Note,2014-01-31 16:38:00-05:00,LLY,neutral
767615.0,Pfizer vs. Eli Lilly - Which Is The Better Investment?,2014-01-31 13:09:00-05:00,LLY,positive
767616.0,"#PreMarket Primer: Friday, January 31: Emerging Market Turmoil Spills Over Into Europe",2014-01-31 07:03:00-05:00,LLY,negative
767617.0,"Sanofi Files Suit in US to Defend Lantus, Lantus SoloStar Patent Rights ",2014-01-30 17:13:00-05:00,LLY,neutral
767618.0,Market Wrap For January 30: Markets Focus on Good News,2014-01-30 17:06:00-05:00,LLY,positive
767619.0,Eli Lilly Declines,2014-01-30 14:50:00-05:00,LLY,neutral
767620.0,UPDATE: Eli Lilly Posts Drop In Q4 Profit,2014-01-30 07:46:00-05:00,LLY,positive
767621.0,"#PreMarket Primer: Thursday, January 30: Fed Cut Stimulus By Further $10 Billion",2014-01-30 07:03:00-05:00,LLY,negative
767622.0,"Eli Lilly Reports Q4 Adjusted EPS of $0.74, Inline; Revenue of $5.81B vs $5.45B Est",2014-01-30 06:33:00-05:00,LLY,neutral
767623.0,"Earnings Scheduled For January 30, 2014",2014-01-30 04:54:00-05:00,LLY,neutral
767624.0,Tug Of War In Ariad Pharmaceuticals,2014-01-28 14:36:00-05:00,LLY,negative
767625.0,"Benzinga's M&A Chatter for Monday January 27, 2014",2014-01-27 17:21:00-05:00,LLY,neutral
767626.0,Benzinga Weekly Preview: Tech Sector To Steal The Spotlight,2014-01-24 16:08:00-05:00,LLY,negative
767627.0,Ariad Shares Continue to Surge Amidst Buyout Rumors,2014-01-24 16:06:00-05:00,LLY,positive
767628.0,Top Trending Tickers On StockTwits For January 23,2014-01-23 11:15:00-05:00,LLY,positive
767629.0,"UK Daily Mail Reports Aria Approached by Big Pharma, Including Lilly",2014-01-22 17:15:00-05:00,LLY,neutral
767630.0,Is The Market On Drugs?,2014-01-16 14:30:00-05:00,LLY,neutral
767631.0,Lilly Acquires CGRP Antibody for Migraine Prevention from Arteaus Therapeutics ,2014-01-13 07:15:00-05:00,LLY,neutral
767632.0,"Barclays Downgrades Eli Lilly and Company to Underweight, Lowers PT to $51.00",2014-01-10 08:54:00-05:00,LLY,negative
767633.0,"BMO Capital Downgrades Eli Lilly and Company to Underperform, Maintains $50.00 PT",2014-01-08 08:11:00-05:00,LLY,neutral
767634.0,Market Wrap For January 7: Markets Reverse 3-Day Slump,2014-01-07 16:39:00-05:00,LLY,neutral
767635.0,Lilly Commited To Maintaining Dividend at Least at Current Level,2014-01-07 07:04:00-05:00,LLY,neutral
767636.0,Eli Lilly Reconfirms 2013 Expectations; Sees 2014 EPS $2.77-$2.85 ,2014-01-07 07:02:00-05:00,LLY,neutral
767637.0,US Stock Futures Gain Ahead Of GDP Data,2013-12-20 07:11:00-05:00,LLY,positive
767638.0,"PeptiDream Announces Collaboration, License Agreement with Lilly ",2013-12-20 05:55:00-05:00,LLY,positive
767639.0,ImmunoGen Reporting that Lilly May Extend its Pact With Added Payment,2013-12-13 07:40:00-05:00,LLY,positive
767640.0,Citron Pharma Launches Generic Cymbalta Delayed Release Capsules ,2013-12-11 16:15:00-05:00,LLY,negative
767641.0,FDA Approves First Generic Versions of Antidepressant Drug Cymbalta ,2013-12-11 15:37:00-05:00,LLY,positive
767642.0,"Lilly Reports Edivoxetine Did Not Meet Primary Endpoint, Expecting Q4 Charge $0.01/Share",2013-12-05 08:01:00-05:00,LLY,neutral
767643.0,"Bloomberg Reporting Merck, Eli Lilly Rumored to Be Interested in Novartis' Veterinary Unit",2013-12-03 12:20:00-05:00,LLY,positive
767644.0,QIAGEN Announces Agreement to Develop Molecular Companion Diagnostic Paired with Lilly Investigational Cancer Compounds ,2013-11-18 08:09:00-05:00,LLY,negative
767645.0,"Actavis Confirms Patent Challenge of Generic Axiron, Says Lilly Filed Suit",2013-11-14 08:19:00-05:00,LLY,positive
767646.0,US Stock Futures Mixed Ahead of Economic Data,2013-11-14 07:10:00-05:00,LLY,neutral
767647.0,Lilly to Invest $700M to Enhance Global Insulin Manufacturing Capacity,2013-11-14 06:09:00-05:00,LLY,neutral
767648.0,UPDATE: Goldman Sachs Downgrades Eli Lilly & Company on Relative Lack of Differentiation in Pipeline,2013-11-11 10:17:00-05:00,LLY,negative
767649.0,Benzinga's Top Downgrades,2013-11-11 08:02:00-05:00,LLY,positive
767650.0,US Stock Futures Mixed After Friday Rally,2013-11-11 07:12:00-05:00,LLY,neutral
767651.0,"Goldman Sachs Downgrades Eli Lilly and Company to Sell, Lowers PT to $48.00",2013-11-11 06:50:00-05:00,LLY,negative
767652.0,UPDATE: FDA Approves Addition to Cialis Product Label,2013-10-25 08:02:00-04:00,LLY,positive
767653.0,Elli Lilly Says FDA Approves Addition to Cialis Product Label,2013-10-25 08:00:00-04:00,LLY,positive
767654.0,"MKM Partners Upgrades Eli Lilly and Company to Buy, Maintains $59.00 PT",2013-10-24 10:57:00-04:00,LLY,neutral
767655.0,Benzinga's Top Pre-Market Gainers,2013-10-23 08:11:00-04:00,LLY,positive
767656.0,US Stock Futures Down Ahead Of Earnings,2013-10-23 07:23:00-04:00,LLY,neutral
767657.0,UPDATE: Eli Lilly Q3 Profit Drops 9.3%,2013-10-23 07:18:00-04:00,LLY,positive
767658.0,Eli Lilly and Company Reports Q3 EPS of $1.11 vs $1.04 Est; Revenue of $5.77B vs $5.76B Est,2013-10-23 06:37:00-04:00,LLY,neutral
767659.0,FDA Grants Priority Review to Lilly's Ramucirumab ,2013-10-23 06:36:00-04:00,LLY,positive
767660.0,"Earnings Scheduled For October 23, 2013",2013-10-23 04:54:00-04:00,LLY,neutral
767661.0,"Stocks To Watch For October 23, 2013",2013-10-23 04:40:00-04:00,LLY,neutral
767662.0,Earnings Expectations For The Week Of October 21: The Crunch Is On,2013-10-20 12:33:00-04:00,LLY,neutral
767663.0,Fitch Affirms Eli Lilly Rating; Raises Outlook from Negative to Stable,2013-10-11 09:41:00-04:00,LLY,negative
767664.0,"Jefferies Downgrades Eli Lilly and Company to Underperform, Lowers PT to $40.00",2013-10-11 07:35:00-04:00,LLY,negative
767665.0,"Market Primer: Friday, October 11: Budget Showdown Could Be Nearing Its End",2013-10-11 06:55:00-04:00,LLY,neutral
767666.0,Edward Jones Upgrades Eli Lilly and Company to Sell,2013-10-10 07:14:00-04:00,LLY,neutral
767667.0,"Credit Suisse Starts Pfizer, Bristol-Myers, AbbVie, Allergan at Outperform, Merck, Eli Lilly, Forest Labs at Neutral",2013-10-08 16:57:00-04:00,LLY,positive
767668.0,"PreMarket Info Recap for October 3, 2013: Quiet Markets, Range Bound",2013-10-03 09:24:00-04:00,LLY,neutral
767669.0,"Lilly Reaffirms Outlook, Will Buyback Up to $5B in Shares, Maintaining Dividend",2013-10-03 07:24:00-04:00,LLY,positive
767670.0,Pharmaceutical Industry Expected To Collect Billions From Obamacare,2013-10-02 12:51:00-04:00,LLY,neutral
767671.0,Eli Lilly Says Disappointed in Medicare's Decision to Deny Patient Access to Beta-Amyloid Imaging Agents,2013-09-30 08:05:00-04:00,LLY,negative
767672.0,"Lilly Disappointed in Medicare Decision to Deny Appropriate Patient Access to Beta-Amyloid Imaging Agents, Including Amyvid",2013-09-28 09:15:00-04:00,LLY,negative
767673.0,Lilly Shows Investigational Dulaglutide Resulted in Improved Indicators,2013-09-26 07:46:00-04:00,LLY,positive
767674.0,Lilly Says RAINBOW Trial Met Primary Endpoint; Separate Phase III Trial of Ramucirumab in Women with ROSE Did Not Meet Endpoint,2013-09-26 07:35:00-04:00,LLY,neutral
767675.0,Eli Lilly Says RAINBOW Trial Met Primary Endpoint; Separate Phase III Trial of Ramucirumab in Women with ROSE Did Not Meet Endpoint,2013-09-26 07:31:00-04:00,LLY,neutral
767676.0,Lilly to Present Data Across Diabetes Portfolio at 49th European Association for Study of Diabetes Annual Meeting,2013-09-17 08:07:00-04:00,LLY,neutral
767677.0,Benzinga Market Primer for September 12: Kerry and Lavrov Discuss The Terms Of Syria Resolution At Two Day Meeting,2013-09-12 06:34:00-04:00,LLY,neutral
767678.0,"Humana, Lilly Collaborate on Research to Improve Health Care Outcomes ",2013-08-29 10:22:00-04:00,LLY,positive
767679.0,Immunogen Shares Charge Higher Following News of Deal with Lilly for TAP Technology,2013-08-28 13:26:00-04:00,LLY,positive
767680.0,UPDATE: Immuogen May Get Up to $200.5M Under Deal with Eli Lilly,2013-08-28 13:20:00-04:00,LLY,neutral
767681.0,Form 8-K Shows Immunogen Entered into License Deal with Eli Lilly for Targeted Antibody Payload Technology,2013-08-28 13:17:00-04:00,LLY,neutral
767682.0,Eli Lilly Accused of Bribing Doctors in China -WantChinaTimes,2013-08-22 06:20:00-04:00,LLY,negative
767683.0,Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control ,2013-08-15 11:10:00-04:00,LLY,negative
767684.0,Eli Lilly Soaring After Positive Cancer Drug Data (LLY),2013-08-13 09:42:00-04:00,LLY,negative
767685.0,"Notable Stocks Trading Ex-Dividend Today: DuPont, Kroger, Eli Lilly, Microsoft, TJX",2013-08-13 08:19:00-04:00,LLY,neutral
767686.0,Lilly Reports Phase III Necitumumab Study Met Primary Endpoint,2013-08-13 08:01:00-04:00,LLY,neutral
767687.0,"Barclays Maintains Equal-weight on Eli Lilly and Company, Raises PT to $58.00",2013-07-25 08:41:00-04:00,LLY,neutral
767688.0,"Benzinga Market Primer: Thursday, July 25: Futures Lower After Technical Breakdown",2013-07-25 06:31:00-04:00,LLY,negative
767689.0,"Benzinga's PreMarket Info Recap for July 24, 2013: Ford and General Motors Trading at 2-Year Highs!",2013-07-24 09:17:00-04:00,LLY,neutral
767690.0,Benzinga's Top Pre-Market Gainers,2013-07-24 08:22:00-04:00,LLY,positive
767691.0,A Peek Into The Market Before The Trading Starts,2013-07-24 07:25:00-04:00,LLY,neutral
767692.0,Eli Lilly and Company Raises FY2013 EPS Guidance from $3.82-3.97 to $4.05-4.15 vs $3.93 Est,2013-07-24 07:20:00-04:00,LLY,neutral
767693.0,"UPDATE: Eli Lilly Posts 31% Rise In Q2 Profit, Lifts Full-Year Outlook",2013-07-24 07:15:00-04:00,LLY,positive
767694.0,Eli Lilly and Company Reports Q2 EPS of $1.16 vs $1.01 Est; Revenue of $5.92B vs $5.82B Est,2013-07-24 06:33:00-04:00,LLY,neutral
767695.0,Eli Lilly and Company Reports Q2 EPS of $1.16 vs $1.01 Est,2013-07-24 06:32:00-04:00,LLY,neutral
767696.0,"Benzinga Market Primer: Wednesday, July 24: Apple Earnings Beat",2013-07-24 06:28:00-04:00,LLY,neutral
767697.0,US Stock Futures Rise After Upbeat Apple Results,2013-07-24 06:05:00-04:00,LLY,neutral
767698.0," Earnings Scheduled For July 24, 2013",2013-07-24 04:18:00-04:00,LLY,neutral
767699.0,Transition Therapeutics Enters Osteoarthritis License and Collaboration Agreement with Lilly ,2013-07-23 16:47:00-04:00,LLY,positive
767700.0,"Earnings Expectations for the Week of July 22 (AAPL, GM, MCD, NFLX)",2013-07-22 07:29:00-04:00,LLY,neutral
767701.0,Weekly Preview: Earnings Season Kicks Into Hyperdrive ,2013-07-19 15:45:00-04:00,LLY,neutral
767702.0,"Bloomberg Reporting Eli Lilly Spokesperson Says to Freeze Worker, Exec Pay This Year",2013-07-17 15:54:00-04:00,LLY,negative
767703.0,Eli Lilly Tries Again with Alzheimer's Drug as the Race for a Cure Continues (LLY),2013-07-16 11:30:00-04:00,LLY,neutral
767704.0,New Study Shows Men Taking Cialis® (tadalafil) Tablets Once Daily Returned to Normal Erectile Function after Incomplete Response to As-Needed PDE5 Inhibitor Therapy ,2013-07-16 08:02:00-04:00,LLY,negative
767705.0,Lilly to Host Call Discussing Trial Design of New Solanezumab Phase 3 Study,2013-07-03 09:04:00-04:00,LLY,neutral
767706.0,"Boehringer, Lilly Offer Results of CV Post-Hoc Meta-Analysis Examining CV Events in Adults with Type 2 Diabetes Treated with Linagliptin",2013-06-25 09:08:00-04:00,LLY,neutral
767707.0,"Phase 3 Study Shows Empagliflozin Significantly Reduced Blood Glucose in Adults with Type 2 Diabetes, Impaired Kidney Function ",2013-06-22 13:13:00-04:00,LLY,neutral
767708.0,Lilly Announces Phase 3 Data Show Empagliflozin Plus Insulin Significantly Reduced HbA1c in Adults with Type 2 Diabetes ,2013-06-22 13:00:00-04:00,LLY,neutral
767709.0,"Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Announce Updates to Prescribing Information for TRADJENTA® (linagliptin) Tablets and JENTADUETO® (linagliptin and metformin hydrochloride) Tablets ",2013-06-20 11:05:00-04:00,LLY,neutral
767710.0,Eli Lilly Issues Alert for Two Illegal Scans Involving Co. Name,2013-06-19 15:17:00-04:00,LLY,negative
767711.0,UPDATE: Lilly Doesn't See Charge as Material,2013-06-13 16:41:00-04:00,LLY,neutral
767712.0,"Lilly Issues Release: Voluntarily Terminates Phase II Study of LY2886721, Says Decision Doesn't Affect Other Alzheimer's Compounds, Sees Charge",2013-06-13 16:40:00-04:00,LLY,neutral
767713.0,A Peek Into The Market Before The Trading Starts,2013-06-13 07:18:00-04:00,LLY,neutral
767714.0,"Lilly, Incyte Announce Baricitinib Efficacy and Safety Data from Phase 2b JADA Study in Patients with Rheumatoid Arthritis ",2013-06-13 06:05:00-04:00,LLY,positive
767715.0,"Drug Company Profits Set to Increase from Additions to DSM-5 (LLY, NVS, PFE)",2013-06-06 08:59:00-04:00,LLY,positive
767716.0,Lilly Announces PRONOUNCE Trial Did Not Meet Primary Superiority Endpoint,2013-06-03 08:07:00-04:00,LLY,negative
767717.0,"CVR Energy, Warner Chilcott and Other Top Performers in May",2013-06-02 09:35:00-04:00,LLY,positive
767718.0,"SunTrust Robinson Humphrey Initiates Coverage on Eli Lilly and Company at Buy, Announces $63.00 PT",2013-05-29 16:37:00-04:00,LLY,neutral
767719.0,New Data on FORTEO® (teriparatide [rDNA origin] injection) Show Increased Bone Mineral Density in Men with Glucocorticoid-Induced Osteoporosis,2013-05-29 08:08:00-04:00,LLY,positive
767720.0,"UPDATE: Jefferies Upgrades Eli Lilly to Hold, Raises PT Following SOTP Analysis",2013-05-28 10:46:00-04:00,LLY,neutral
767721.0,"PreMarket Info Recap for May 28, 2013",2013-05-28 09:25:00-04:00,LLY,neutral
767722.0,"Jefferies Upgrades Eli Lilly and Company to Hold, Raises PT to $49.00",2013-05-28 07:55:00-04:00,LLY,neutral
767723.0,"U.S. Steel, Genomic Health and Other Stocks Insiders Are Buying",2013-05-18 15:54:00-04:00,LLY,neutral
767724.0,"PreMarket Info Recap for May 14, 2013",2013-05-14 09:16:00-04:00,LLY,neutral
767725.0,Eli Lillly Says CEO John Lechleiter's Surgery Went as Expected,2013-05-14 09:05:00-04:00,LLY,neutral
767726.0,Benzinga's Top Pre-Market Losers ,2013-05-10 08:33:00-04:00,LLY,negative
767727.0,Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma,2013-05-10 08:04:00-04:00,LLY,neutral
767728.0,Lilly Says Enzastaurin Phase III Did Not Meet Primary Endpoint; Reaffirms Outlook,2013-05-10 08:01:00-04:00,LLY,neutral
767729.0,Benzinga's Top Pre-Market Losers,2013-05-06 08:15:00-04:00,LLY,negative
767730.0,"Benzinga Market Primer: Thursday, April 25",2013-04-25 06:42:00-04:00,LLY,neutral
767731.0,Eli Lilly Approaching the April 19th low of $56.37; Currently Seen as Intra-Day Support,2013-04-24 10:30:00-04:00,LLY,positive
767732.0,Eli Lilly and Company Reports Q1 EPS of $1.14 vs $1.05 Est; Revenue of $5.60B vs $5.66B Est,2013-04-24 06:34:00-04:00,LLY,neutral
767733.0,US Stock Futures Up Ahead Of Earnings,2013-04-24 06:06:00-04:00,LLY,neutral
767734.0,"Stocks To Watch For April 24, 2013",2013-04-24 04:30:00-04:00,LLY,neutral
767735.0,"Earnings Scheduled For April 24, 2013",2013-04-24 04:22:00-04:00,LLY,neutral
767736.0,"Eli Lilly Earnings Preview: EPS, Sales Growth Expected",2013-04-23 12:43:00-04:00,LLY,positive
767737.0,Earnings Expectations for the Week of April 22,2013-04-21 18:20:00-04:00,LLY,neutral
767738.0,"Weekly Preview: Earnings Season Continues, Apple In Focus",2013-04-19 16:38:00-04:00,LLY,neutral
767739.0,Lilly Buys Novel Tau Tangle Diagnostic Progra,2013-04-17 08:03:00-04:00,LLY,positive
767740.0,Lilly Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes,2013-04-16 08:07:00-04:00,LLY,positive
767741.0,ETF Showdown: A Pharma Fight,2013-04-11 16:21:00-04:00,LLY,negative
767742.0,AP Reporting Eli Lilly Planning to Cut Hundreds from US Sales Force by July 1st,2013-04-11 16:09:00-04:00,LLY,negative
767743.0,UPDATE: Jefferies Raises PT on Eli Lilly & Co. as Least-Preferred Name,2013-04-10 12:11:00-04:00,LLY,neutral
767744.0,"Jefferies Maintains Underperform on Eli Lilly and Company, Raises PT to $44.00",2013-04-10 08:03:00-04:00,LLY,neutral
767745.0,"Eli Lilly Rejects $57.25 Resistance, 20 EMA Support Lower At $56.04, Breakout In Play ",2013-04-09 13:31:00-04:00,LLY,negative
767746.0,"Eli Lilly Attempting To Breakout Over $57 Resistance, RSI Overbought ",2013-04-03 11:23:00-04:00,LLY,neutral
767747.0,Eli Lilly Working with Indianapolis Officials for Proposal to Invest Added $180M in Insulin Manufacturing Ops,2013-04-02 08:04:00-04:00,LLY,neutral
767748.0,Eli Lilly Isues Statement Re Intention to Cancel Listing of Shares,2013-03-26 12:02:00-04:00,LLY,positive
767749.0,"EMA Accepts Marketing Authorization App for Boehringer, Lilly Empagliflozin",2013-03-26 11:34:00-04:00,LLY,positive
767750.0,This Dead Money Sector is Leading the S&P This Year,2013-03-25 08:21:00-04:00,LLY,negative
767751.0,"Eli Lilly Fails At $55.75 Resistance, 20 EMA Support Lower At $54.83, Breakout Still In Play",2013-03-22 12:55:00-04:00,LLY,neutral
767752.0,Lilly Says New Study of Cialis Met Primary Endpoint in Men with Lower Urinary Tract Symptoms of Benign Hyperlasia,2013-03-18 11:17:00-04:00,LLY,neutral
767753.0,Magnet Trades: The Case of Eli Lilly,2013-03-14 15:41:00-04:00,LLY,neutral
767754.0,Are Scientists Edging Closer to a Cure for Alzheimer's?,2013-03-11 08:58:00-04:00,LLY,neutral
767755.0,"Eli Lilly Breaks Out Over $55 Resistance To Continue Uptrend, MACD Attempting Bullish Crossover",2013-03-05 14:01:00-05:00,LLY,neutral
767756.0,Eli Lilly Sets Date for '13 Diabetes Pipeline Update,2013-03-05 08:01:00-05:00,LLY,neutral
767757.0,Eli Lilly Files Automatic Mixed Securities Shelf,2013-03-01 08:59:00-05:00,LLY,positive
767758.0,"If The Market Falls, Try These Low Beta ETFs",2013-02-28 18:27:00-05:00,LLY,negative
767759.0,Eli Lilly Issues Statement Related to Intention to Cancel Listing of London Stock Exchange Shares,2013-02-27 12:08:00-05:00,LLY,positive
767760.0,UPDATE: Credit Suisse Raises PT to $68 on Eli Lilly on Patent Ruling Confidence,2013-02-27 10:48:00-05:00,LLY,positive
767761.0,Eli Lilly Continues Advance After Breakout Over $54 Resistance ,2013-02-20 11:32:00-05:00,LLY,neutral
767762.0,Eli Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab,2013-02-07 08:06:00-05:00,LLY,neutral
767763.0,Eli Lilly Re-testing Breakout Over $53.50 ,2013-02-06 17:10:00-05:00,LLY,neutral
767764.0,"UPDATE: Goldman Sachs Reiterates Neutral Rating, Raises PT on Eli Lilly & Company",2013-01-30 14:01:00-05:00,LLY,neutral
767765.0,UPDATE: Citigroup Raises Eli Lilly PT to $60 on Eli Lilly on Potential Upside,2013-01-30 13:17:00-05:00,LLY,neutral
767766.0,"Goldman Sachs Maintains Neutral on Eli Lilly and Company, Raises PT to $56.00",2013-01-30 09:51:00-05:00,LLY,neutral
767767.0,"Citigroup Maintains Buy on Eli Lilly and Company, Raises PT to $60.00",2013-01-30 09:46:00-05:00,LLY,neutral
767768.0,Novo Spokesperson Says Will Introduce Tresiba in Some EU Countries in First Half - Bloomberg,2013-01-29 11:07:00-05:00,LLY,neutral
767769.0,Lilly Planning Five New Drug Regulatory Filings in 2013,2013-01-29 09:27:00-05:00,LLY,neutral
767770.0,"UPDATE: Eli Lilly Posts Upbeat Q4 Profit, Lifts FY13 Forecast",2013-01-29 07:58:00-05:00,LLY,positive
767771.0,Eli Lilly & Co Reports Q4 EPS of $0.85 vs $0.82 Est; Revenue $5.96B vs $5.78B Est,2013-01-29 06:35:00-05:00,LLY,neutral
767772.0,"US Stock Futures Slightly Lower Ahead Of Ford Earnings, Consumer Confidence Data",2013-01-29 05:59:00-05:00,LLY,positive
767773.0,"Earnings Scheduled For January 29, 2013",2013-01-29 03:39:00-05:00,LLY,neutral
767774.0,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)",2013-01-26 12:17:00-05:00,LLY,positive
767775.0,"The Week Ahead: Earnings from Facebook, Ford, Caterpillar; US Jobs Report",2013-01-25 18:15:00-05:00,LLY,neutral
767776.0,"CLSA Initiates Coverage on Eli Lilly and Company at Sell, Announces $47.00 PT",2013-01-17 07:55:00-05:00,LLY,neutral
767777.0,"UPDATE: Jefferies & Company Reiterates Underperform Rating, Raises PT on Eli Lilly & Co.",2013-01-16 09:31:00-05:00,LLY,neutral
767778.0,"Jefferies Maintains Underperform on Eli Lilly and Company, Raises PT to $43.00",2013-01-16 08:52:00-05:00,LLY,neutral
767779.0,Lily's Amyvid Approved in EU for Patients with Cognitive Impairment Being Evaluated for Alzheimer's,2013-01-15 15:48:00-05:00,LLY,positive
767780.0,"UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Eli Lilly & Co.",2013-01-09 12:36:00-05:00,LLY,neutral
767781.0,"Bank of America Maintains Buy on Eli Lilly and Company, Raises PO to $60.00",2013-01-09 10:36:00-05:00,LLY,negative
767782.0,Goldman Sachs and Others That May Beat Earnings,2013-01-08 13:42:00-05:00,LLY,neutral
767783.0,"UBS Maintains Neutral on Eli Lilly and Company, Raises PT to $51.00",2013-01-07 13:20:00-05:00,LLY,neutral
767784.0,"UPDATE: BMO Capital Markets Reiterates Market Perform Rating, Raises PT on Eli Lilly & Co.",2013-01-07 12:07:00-05:00,LLY,neutral
767785.0,"Eli Lilly Reassumes Sole Worldwide Development, Commercialization Role for Novel Basal Insulin Analog",2013-01-07 08:05:00-05:00,LLY,positive
767786.0,"Stocks To Watch For January 7, 2013",2013-01-07 02:50:00-05:00,LLY,neutral
767787.0,Eli Lilly Offers Solid FY13 EPS Outlook; Shares Slightly Higher,2013-01-04 08:12:00-05:00,LLY,positive
767788.0,Eli Lilly to Pay $29.4M to Settle SEC Foreign Bribery Case,2012-12-20 12:16:00-05:00,LLY,negative
767789.0,"Benzinga Market Primer, Tuesday, December 18 ",2012-12-18 06:53:00-05:00,LLY,neutral
767790.0,"Eli Lilly Authorizes $1.5B Buyback Plan, Declares $0.49/Share Qtr. Dividend",2012-12-17 16:46:00-05:00,LLY,neutral
767791.0,"Eli Lilly Reaffirms FY12 Outlook; Sees Q4 Charge of $20-35M Pretax, or ~$0.02/Share",2012-12-13 08:05:00-05:00,LLY,neutral
767792.0,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)",2012-12-12 12:57:00-05:00,LLY,positive
767793.0,Benzinga's Top Pre-Market Losers,2012-12-12 08:19:00-05:00,LLY,negative
767794.0,Eli Lilly Discusses Next Steps for Solanezumab,2012-12-12 08:15:00-05:00,LLY,neutral
767795.0,Lilly Provides Update on Solanezumab Phase 3 Study,2012-12-12 06:58:00-05:00,LLY,neutral
767796.0,"Three More Defensive Stock Picks for 2013 (LLY, PFE, VTR)",2012-12-10 15:12:00-05:00,LLY,positive
767797.0,"Citigroup Initiates Coverage on Eli Lilly and Company at Buy, Annoucnes $55.00 PT",2012-11-30 14:30:00-05:00,LLY,neutral
767798.0,"Citi Reiterates Buy on Eli Lilly and Company, Maintains $55.00 PT",2012-11-29 16:30:00-05:00,LLY,neutral
767799.0,Eli Lilly's Tabalumab Receives Orphan Drug Designation for Multiple Myeloma Treatment,2012-11-21 14:03:00-05:00,LLY,neutral
767800.0,"Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Advance into Phase III Trials",2012-11-13 16:05:00-05:00,LLY,neutral
767801.0,Lilly to Present Phase II Rheumatoid Arthritis and Biomarker Data at ACR For Two Investigational Medicines to Treat Autoimmune Diseases,2012-11-09 09:03:00-05:00,LLY,positive
767802.0,Lilly to Announce Expansion of Indianapolis Insulin Manufacturing Operations,2012-10-30 12:04:00-04:00,LLY,neutral
767803.0,European Commission Approves Lilly's Cialis for Benign Prostatic Hyperplasia ,2012-10-30 07:47:00-04:00,LLY,positive
767804.0,"BMO Capital Markets Maintains Eli Lilly & at Market Perform, Lowers PT from $50 to $47",2012-10-26 08:24:00-04:00,LLY,negative
767805.0,"Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)",2012-10-25 14:09:00-04:00,LLY,positive
767806.0,UPDATE: Eli Lilly Posts Downbeat Q3 Profit,2012-10-24 07:57:00-04:00,LLY,positive
767807.0,Eli Lilly & Reports Q3 EPS $0.79 vs $0.83 Est; Revenues $5.62B vs $5.62B Est,2012-10-24 07:33:00-04:00,LLY,neutral
767808.0,"Earnings Scheduled For October 24, 2012",2012-10-24 04:12:00-04:00,LLY,neutral
767809.0,Eli Lilly Releases Data From Two Retrospective Studies,2012-10-23 13:24:00-04:00,LLY,neutral
767810.0,New Retrospective Studies of Hospital Readmission Rates for Subsequent Heart   Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient or Plavix Presented at TCT,2012-10-23 13:17:00-04:00,LLY,negative
767811.0,Eli Lilly Says Got Positive Data for Phase III on Type 2 Diabetes Drug,2012-10-22 08:57:00-04:00,LLY,positive
767812.0,Lilly Diabetes Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes,2012-10-22 08:15:00-04:00,LLY,positive
767813.0,Earnings Expectations for the Week of October 22,2012-10-22 08:15:00-04:00,LLY,neutral
767814.0,Amyvid Recommended for Approval in Europe,2012-10-19 10:56:00-04:00,LLY,positive
767815.0,EU Recommends Approval of Lilly's Brain Plaque Test,2012-10-19 09:07:00-04:00,LLY,positive
767816.0,ALIMTA Extends Survival in Continuation Maintenance Setting for Specific Lung Cancer Patients,2012-10-17 16:47:00-04:00,LLY,negative
767817.0,Lilly Announces New Data Further Exploring Mechanistic Differences Between FORTEO and Zoledronic Acid,2012-10-15 12:32:00-04:00,LLY,neutral
767818.0,Leerink Swan Upgrades Eli Lilly & from Market Perform to Outperform,2012-10-15 10:00:00-04:00,LLY,neutral
767819.0,Lilly Announces Ramucirumab Showed Prolonged Progression-Free Survival in Gastric Cancer Treatment,2012-10-15 08:08:00-04:00,LLY,negative
767820.0,Cowen Downgrades Eli Lilly & from Neutral to Underperform,2012-10-12 08:43:00-04:00,LLY,neutral
767821.0,"Jefferies & Company Maintains Eli Lilly & at Underperform, Raises PT from $35 to $36",2012-10-12 06:56:00-04:00,LLY,neutral
767822.0,"Bank of America Maintains Eli Lilly & at Buy, Raises PO from $52 to $57",2012-10-11 06:37:00-04:00,LLY,negative
767823.0,Part I: Must Know ETFs For Q3 Earnings ,2012-10-09 14:37:00-04:00,LLY,neutral
767824.0,UPDATE: Goldman Sachs Upgrades Eli Lilly & Co. to Neutral on Sola Data  ,2012-10-09 13:56:00-04:00,LLY,neutral
767825.0,"UBS Maintains Eli Lilly & at Neutral, Raises PT from $45 to $49",2012-10-09 11:13:00-04:00,LLY,neutral
767826.0,Lilly Crosses $52 on Heavy Volume,2012-10-09 09:58:00-04:00,LLY,neutral
767827.0,"Lilly Hits 52-Week High Following Monday's Positive Phase 3 Results, $51.80",2012-10-09 09:44:00-04:00,LLY,positive
767828.0,A Peek Into The Market Before The Trading Starts,2012-10-09 07:22:00-04:00,LLY,neutral
767829.0,Benzinga's Top Upgrades,2012-10-09 07:18:00-04:00,LLY,positive
767830.0,"Goldman Sachs Upgrades Eli Lilly & from Sell to Neutral, Raises PT from $42 to $54",2012-10-09 05:57:00-04:00,LLY,neutral
767831.0,Hearing BMO Making Cautious Comments on Lilly,2012-10-08 15:31:00-04:00,LLY,negative
767832.0,Lilly Hits $50 Following Positive Phase 3 Results,2012-10-08 14:20:00-04:00,LLY,positive
767833.0,"Lilly Hits 52-Week High on Phase 3 Results, $49.38",2012-10-08 13:22:00-04:00,LLY,neutral
767834.0,Eli Lilly Reports Phase 3 Results of Solanezumab; Decline in Expedition1 Study Not Significant,2012-10-08 13:16:00-04:00,LLY,negative
767835.0,Lilly Spiking Higher,2012-10-08 13:15:00-04:00,LLY,neutral
767836.0,Eli Lilly Says Ending Partnership with Amylin Wasn't Easy; Broad Diabetes Pipeline is Advantage; End of Amylin Deal Was Bet on Dulaglutide,2012-10-08 09:54:00-04:00,LLY,negative
767837.0,From Earlier: Lilly and Boehringer Say Linagliptin Treatment Shows Significance,2012-10-02 08:28:00-04:00,LLY,positive
767838.0,A Peek Into The Market Before The Trading Starts,2012-10-02 07:15:00-04:00,LLY,neutral
767839.0,Eli Lilly Reports on SGLT-2 Trials,2012-10-02 06:25:00-04:00,LLY,neutral
767840.0,Deutsche Bank Suspends Coverage on Eli Lilly &,2012-10-01 16:26:00-04:00,LLY,neutral
767841.0,"Eli Lilly Releases Data from Phase 2 Ramucirumab Trials, Says Indicate May be Beneficial to Patients with Non-Small Cell Lung Cancer",2012-10-01 11:15:00-04:00,LLY,negative
767842.0,Lilly Presents Phase II Results for Monoclonal Antibody Ramucirumab in Lung Cancer ,2012-09-29 07:31:00-04:00,LLY,negative
767843.0,McCormick Appoints Jacques Tapiero to Board of Directors,2012-09-26 08:04:00-04:00,LLY,neutral
767844.0,"UBS Maintains Eli Lilly & at Neutral, Raises PT from $42 to $45",2012-09-21 10:03:00-04:00,LLY,neutral
767845.0,Cialis Tablets Recommended for Approval for the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia in the European Union,2012-09-21 08:45:00-04:00,LLY,positive
767846.0,"UPDATE: Goldman Sachs Reiterates Sell Rating, Raises PT on Eli Lilly & Co.",2012-09-14 13:13:00-04:00,LLY,neutral
767847.0,"Goldman Sachs Maintains Eli Lilly & at Sell, Raises PT from $39 to $42",2012-09-14 06:34:00-04:00,LLY,neutral
767848.0,Seven Cheap Large-Caps Yielding Over 4% ,2012-09-06 14:07:00-04:00,LLY,neutral
767849.0,Eli Lilly Says Phase III Study on Pointbreak Did Not Meet Primary Endpoint of Improved Overall Survival,2012-09-06 09:05:00-04:00,LLY,positive
767850.0,"Sanford C. Bernstein Upgraded Eli Lilly & from Market Perform to Outperform, Announced PT to $52",2012-09-05 10:00:00-04:00,LLY,neutral
767851.0,"UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Eli Lilly",2012-08-29 13:19:00-04:00,LLY,neutral
767852.0,"Lilly Stops Phase 3 Development on Schizophrenia Treatment, Sees $0.02 Charge, Forecast for FY12 Unchanged",2012-08-29 08:03:00-04:00,LLY,negative
767853.0,"Bank of America Maintains Eli Lilly & at Buy, Raises PO from $46 to $52",2012-08-29 06:30:00-04:00,LLY,negative
767854.0,"Atlantic Equities Upgrades Eli Lilly & from Underweight to Overweight, Announces PT of $49",2012-08-28 07:41:00-04:00,LLY,negative
767855.0,Benzinga's Top Upgrades,2012-08-28 07:32:00-04:00,LLY,positive
767856.0,A Peek Into The Market Before The Trading Starts,2012-08-28 07:15:00-04:00,LLY,neutral
767857.0,Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient® (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure ,2012-08-27 06:08:00-04:00,LLY,neutral
767858.0,Eli Lilly Alzheimer's Drug Misses Goals,2012-08-24 14:11:00-04:00,LLY,negative
767859.0,U.S. Court of Appeals Upholds Validity of Lilly's Alimta Compound Patent,2012-08-24 12:08:00-04:00,LLY,neutral
767860.0,Credit Suisse Upgrades Eli Lilly & Co. from Neutral to Outperform,2012-08-24 11:20:00-04:00,LLY,positive
767861.0,Teva Loses Bid to Invalidate Patent on Lily's Alimata Drug -Bloomberg,2012-08-24 11:17:00-04:00,LLY,negative
767862.0,UPDATE: Eli Lilly's Conference Call on Solanezumab Ends,2012-08-24 10:08:00-04:00,LLY,neutral
767863.0,UPDATE: Eli Lilly Says Doesn't See Solanezumab Results Affecting Financial  View,2012-08-24 09:40:00-04:00,LLY,neutral
767864.0,Jefferies Maintains Underperform on Eli Lilly,2012-08-24 09:11:00-04:00,LLY,neutral
767865.0,"Lilly Rises 9.5% Pre-Market as Alzheimer's Drug Fails to Meet Primary Endpoints, But Slows Progression of Disease",2012-08-24 08:13:00-04:00,LLY,negative
767866.0,Benzinga's Top Pre-Market Gainers,2012-08-24 08:09:00-04:00,LLY,positive
767867.0,Eli Lilly Announces Negative Results of Solanezumab Phase 3 Trial,2012-08-24 07:39:00-04:00,LLY,negative
767868.0,A Peek Into The Market Before The Trading Starts,2012-08-24 07:27:00-04:00,LLY,neutral
767869.0,Eli Lilly and Company Announces Top-Line Results on Solanezumab Phase 3 Clinical Trials in Patients with Alzheimer's Disease ,2012-08-24 07:07:00-04:00,LLY,neutral
767870.0,FDA Approves Prescribing Eli Lilly's Tradjenta Tablets,2012-08-17 14:58:00-04:00,LLY,positive
767871.0,Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield,2012-08-13 00:25:00-04:00,LLY,positive
767872.0,"UPDATE: Lilly Says Fewer Forteo Patients Had Worsening Back Pain; Says had 9 Deaths in Study, 4 in Forteo Group and 5 in Risedronate Group",2012-08-07 09:05:00-04:00,LLY,negative
767873.0,Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures,2012-08-07 09:02:00-04:00,LLY,negative
767874.0,Benzinga's Top Pre-Market Losers,2012-08-07 08:14:00-04:00,LLY,negative
767875.0,"Financial Breakfast: Morning News Summary for July 30, 2012",2012-07-30 07:29:00-04:00,LLY,neutral
767876.0,Benzinga's Top Downgrades,2012-07-30 07:19:00-04:00,LLY,positive
767877.0,"Jefferies & Company Downgrades Eli Lilly & from Hold to Underperform, Lowers PT  from $37 to $35",2012-07-30 06:15:00-04:00,LLY,negative
767878.0,UPDATE: Morgan Stanley Raises PT on Eli Lily & Co. from $39 to $41,2012-07-27 10:57:00-04:00,LLY,neutral
767879.0,"Morgan Stanley Maintains Eli Lilly & at Underweight, Raises PT from $39 to $41",2012-07-27 07:14:00-04:00,LLY,neutral
767880.0,Boehringer Ingelheim and Eli Lilly and Company Announced Jentadueto tablets Receive Approval for the Treatment of Adults with Type 2 Diabetes in Europe  ,2012-07-25 09:28:00-04:00,LLY,positive
767881.0,UPDATE: Eli Lilly Sees $250M Generics Effect on Emerging Market Sales,2012-07-25 09:15:00-04:00,LLY,neutral
767882.0,Eli Lilly Says Will Buy Back 420M Shares By the End of the Year,2012-07-25 09:08:00-04:00,LLY,positive
767883.0,"Financial Breakfast: Morning News Summary for July 25, 2012",2012-07-25 07:35:00-04:00,LLY,neutral
767884.0,"Benzinga Market Primer, Wednesday July 25",2012-07-25 06:49:00-04:00,LLY,neutral
767885.0,Eli Lilly & Reports Q2 EPS $0.83 vs $0.77 Est; Revenues $5.6B vs $5.59B Est,2012-07-25 06:30:00-04:00,LLY,neutral
767886.0,US Stock Futures Mixed; Apple Shares Drop In Pre-Market Trading,2012-07-25 06:29:00-04:00,LLY,neutral
767887.0,Earnings Scheduled For July 25,2012-07-25 04:26:00-04:00,LLY,neutral
767888.0,What You Need in Order to Retire Before Age 60,2012-07-24 16:09:00-04:00,LLY,neutral
767889.0,From Earlier: Pharmacokinetic Study Results Released Evaluating Interactions Between LIVALO and Protease Inhibitor Combination in Healthy Volunteers  ,2012-07-23 07:12:00-04:00,LLY,positive
767890.0,Earnings Expectations for the Week of July 23,2012-07-23 07:07:00-04:00,LLY,neutral
767891.0,Pharmacokinetic Study Results Released Evaluating Interactions Between LIVALO and Protease Inhibitor Combination in Healthy Volunteers,2012-07-22 20:10:00-04:00,LLY,positive
767892.0,"Morgan Stanley Maintains Eli Lilly & at Underweight, Raises PT from $35 to $39",2012-07-18 06:09:00-04:00,LLY,neutral
767893.0,3 New Bets by a Biotech Hedge Fund,2012-07-13 17:32:00-04:00,LLY,neutral
767894.0,"Jefferies & Company Maintains Eli Lilly & at Hold, Raises PT from $36 to $37",2012-07-13 07:00:00-04:00,LLY,neutral
767895.0,Lilly's Schizophrenia Drug as Effective as Placebo -IBD,2012-07-11 11:19:00-04:00,LLY,positive
767896.0,Eli Lilly Announces Negative Clinical Trial Results From Schizophrenia Study,2012-07-11 09:01:00-04:00,LLY,negative
767897.0,Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study ,2012-07-11 08:03:00-04:00,LLY,neutral
767898.0,"Immigrants: Restless Dreamers, Economic Pillars",2012-07-10 12:38:00-04:00,LLY,negative
767899.0,Lilly Obtains Six Months U.S. Pediatric Exclusivity for Cymbalta (duloxetine HCl) ,2012-07-06 08:00:00-04:00,LLY,neutral
767900.0,Lilly Obtains Six Months U.S. Pediatric Exclusivity for Cymbalta (duloxetine HCl) ,2012-07-06 08:00:00-04:00,LLY,neutral
767901.0,Bristol-Myers to Acquire Amylin,2012-07-02 13:45:00-04:00,LLY,neutral
767902.0,Lilly Statement on Affordable Care Act Ruling by Supreme Court,2012-06-28 11:21:00-04:00,LLY,positive
767903.0,UPDATE: Goldman Sachs Raises PT on Eli Lily & Company to $38 ,2012-06-27 09:21:00-04:00,LLY,neutral
767904.0,"Goldman Sachs Maintains Eli Lilly & Company at Sell, Raises PT from $35 to $38",2012-06-27 06:41:00-04:00,LLY,neutral
767905.0,Lilly Puts Statement Out on Pdufa Vote,2012-06-26 17:30:00-04:00,LLY,neutral
767906.0,"Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program ",2012-06-19 08:01:00-04:00,LLY,positive
767907.0,"Lilly Releases Data on Diabetes Drug, Patients Lost Weight on Lilly's Drug, Gained on Sanofi's",2012-06-11 16:31:00-04:00,LLY,positive
767908.0,"UPDATE: Lilly Says 1 Serious Adverse Event in 8 MG Group, 4 Serious Adverse Events in 2 MG Group, No Deaths or Opportunistic Infection in Active Treatment Group",2012-06-08 10:50:00-04:00,LLY,negative
767909.0,"Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis ",2012-06-08 10:47:00-04:00,LLY,positive
767910.0,Eli Lilly's CEO Says No Large Pharma Deals Coming -WSJ,2012-06-06 15:48:00-04:00,LLY,negative
767911.0,Eli Lilly Announces Lung Cancer Study Showed Encouraging Results For ALIMTA-based Regimens And Full-dose Radiation ,2012-06-04 09:05:00-04:00,LLY,negative
767912.0,Eli Lilly Announces Patients With Most Common Type Of Lung Cancer Lived Longer With ALIMTA-Based Continuation Maintenance Therapy ,2012-06-04 09:01:00-04:00,LLY,negative
767913.0,Eli Lilly Says Amyvid Now Available in Select US Markets,2012-06-01 09:41:00-04:00,LLY,neutral
767914.0,"Cardinal Health to Manufacture, Distribute Eli Lilly and Company's Brain Imaging Agent Amyvid",2012-06-01 08:30:00-04:00,LLY,neutral
767915.0,15 Great Stocks with Great Yield,2012-05-31 15:40:00-04:00,LLY,positive
767916.0,Vivus' Qnexa Is Not Guaranteed Approval. Remember Provenge?,2012-05-31 12:52:00-04:00,LLY,negative
767917.0,Lily: New Data Showed LIVALO Met Primary Endpoint of LDL-C Reduction When Compared with Pravastatin ,2012-05-31 06:36:00-04:00,LLY,neutral
767918.0,Eli Lilly Announces Jentadueto Tablets Recommended for Approval in Treatment of Adults with Type 2 Diabetes in Europe ,2012-05-29 16:15:00-04:00,LLY,positive
767919.0,FDA Fee Bill Gets Enough Support for Passage as Vote Continues -Bloomberg,2012-05-24 15:28:00-04:00,LLY,positive
767920.0,New Phase 3 data for Tradjenta,2012-05-24 09:01:00-04:00,LLY,neutral
767921.0,"BMO Capital Markets Initiates Coverage on Eli Lilly & at Market Perform, Announces PT of $38",2012-05-18 07:57:00-04:00,LLY,neutral
767922.0,Eli Lilly Receives Positive Mad Money/Jim Cramer Mention -CNBC,2012-05-17 18:50:00-04:00,LLY,positive
767923.0,Option Alert: Heavy Volume in Lilly Calls,2012-05-10 15:49:00-04:00,LLY,positive
767924.0,UPDATE: Bank of America Increases PO on Eli Lilly & Co to $46,2012-05-07 07:31:00-04:00,LLY,negative
767925.0,"Bank of America Maintains Eli Lilly at Buy, Raises PO from $43 to $46",2012-05-07 06:46:00-04:00,LLY,negative
767926.0,"Option Alert: Eli Lilly July 42 Call; Block Trade: 6,000 Contracts; Currently $41.20",2012-05-04 12:16:00-04:00,LLY,negative
767927.0,FDA Considering Letting Patients Purchase Drugs Without Prescriptions,2012-04-30 12:09:00-04:00,LLY,neutral
767928.0,"Financial Breakfast: Morning News Summary for April 25, 2012",2012-04-25 07:35:00-04:00,LLY,neutral
767929.0,Eli Lilly & Reports Q1 EPS $0.92 vs $0.79 Est; Revenues $5.6B vs $5.35B Est,2012-04-25 06:31:00-04:00,LLY,neutral
767930.0,Earnings Scheduled For April 25,2012-04-25 03:48:00-04:00,LLY,neutral
767931.0,"Earnings Expectations for the Week of April 23 (AAPL, XOM, UPS)",2012-04-22 11:23:00-04:00,LLY,neutral
767932.0,Why our portfolio is John Deere green,2012-04-18 05:46:00-04:00,LLY,neutral
767933.0,How I approach biotech investing,2012-04-16 20:33:00-04:00,LLY,neutral
767934.0,Why we added biotech stock Sequenom to the lineup,2012-04-12 21:18:00-04:00,LLY,neutral
767935.0,Lilly's CEO on CNBC Says Hopes to Offset Decline Due to Patent Expiration ,2012-04-12 11:20:00-04:00,LLY,positive
767936.0,Safeguard Scientifics Will Realize Additional Proceeds from Eli Lilly's Acquisition of Avid Radiopharma,2012-04-10 09:05:00-04:00,LLY,positive
767937.0,Safeguard Scientifics to Realize Additional Proceeds from Eli Lilly's Acquisition of Avid Radiopharmaceuticals   ,2012-04-10 09:04:00-04:00,LLY,positive
767938.0,Benzinga's Top Pre-Market Gainers,2012-04-09 08:15:00-04:00,LLY,positive
767939.0,Eli Lilly Announces FDA Approves Amyvid for Use in Patients Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Decline ,2012-04-09 07:01:00-04:00,LLY,positive
767940.0,Where the Rubber Meets the Road for Obamacare,2012-04-03 12:28:00-04:00,LLY,neutral
767941.0,Benzinga's Top Pre-Market Gainers,2012-04-03 08:21:00-04:00,LLY,positive
767942.0,ImmunoCellular's Intellectual Property Steadily Increases,2012-03-28 22:43:00-04:00,LLY,positive
767943.0,"Lilly's Anti-IL-17 Monoclonal Antibody, Ixekizumab, Met Primary Endpoint in Phase II Study in Patients With Chronic Plaque Psoriasis",2012-03-28 17:13:00-04:00,LLY,neutral
767944.0,Amylin Rejected $3.5 Billion Offer; Stock Soars,2012-03-28 13:07:00-04:00,LLY,negative
767945.0,Amylin Pharmaceuticals Announces BYETTA Approved for Use with Basal Insulin in Europe ,2012-03-23 08:00:00-04:00,LLY,positive
767946.0,"Benzinga's M&A Chatter for Wednesday March 21, 2012",2012-03-21 19:21:00-04:00,LLY,neutral
767947.0,"Forest Labs Spiking Higher on Takeover Chatter, Lilly Rumored Buyer",2012-03-21 10:18:00-04:00,LLY,neutral
767948.0,"St. Jude, Novo Nordisk and Other Health Care Stocks Worth a Look Now",2012-03-21 07:20:00-04:00,LLY,positive
767949.0,"A Look At The New Russell High Yield ETF (HDIV, ABT, KFT)",2012-03-15 14:55:00-04:00,LLY,neutral
767950.0,S&P Indices Announces Changes to U.S. Index,2012-03-09 18:51:00-05:00,LLY,neutral
767951.0,"Fresh Del Monte, BlackRock and Other Stocks Insiders Are Buying",2012-03-08 06:41:00-05:00,LLY,positive
767952.0,"Boehringer Ingelheim and Lilly's new oral type 2 diabetes treatment for adults, Jentadueto tablets, now available in U.S. pharmacies  ",2012-03-07 08:02:00-05:00,LLY,neutral
767953.0,UPDATE: JP Morgan Upgrades Eli Lilly to Neutral,2012-03-02 10:18:00-05:00,LLY,positive
767954.0,"Financial Breakfast: Morning News Summary for March 2, 2012",2012-03-02 07:19:00-05:00,LLY,neutral
767955.0,"JP Morgan Upgrades Eli Lilly from Underweight to Neutral, Maintains PT at $40",2012-03-02 06:22:00-05:00,LLY,positive
767956.0,CHMP Recommends Approval of BYETTA for Use With Basal Insulin,2012-02-17 07:55:00-05:00,LLY,positive
767957.0,Stocks Going Ex-Dividend the Third Week of February 2012,2012-02-07 20:37:00-05:00,LLY,neutral
767958.0,New Study Evaluates Cialis in parallel with Tamsulosin in Men with Signs and Symptoms Suggestive of Benign Prostatic Hyperplasia  ,2012-02-07 08:06:00-05:00,LLY,positive
767959.0,Eli Lilly Says Cialis Data Met Primary Endpoint,2012-02-07 08:02:00-05:00,LLY,neutral
767960.0,Amylin Pharmaceuticals Continues to Soar in Wake of Bydureon Approval,2012-02-02 13:49:00-05:00,LLY,positive
767961.0,Earnings Roundup,2012-01-31 08:42:00-05:00,LLY,neutral
767962.0,FDA Approves Lilly & Co's Jentadueto Tablets,2012-01-31 08:25:00-05:00,LLY,positive
767963.0,"Financial Breakfast: Morning News Summary for January 31, 2012",2012-01-31 07:24:00-05:00,LLY,neutral
767964.0,UPDATE: Eli Lilly Reports 27% Decline In Q4 Profit,2012-01-31 06:56:00-05:00,LLY,positive
767965.0,From Earlier: FDA Approves Lilly's Jentadueto Tablets for the Treatment of Adult Patients with Type 2 Diabetes  ,2012-01-31 06:42:00-05:00,LLY,positive
767966.0,Eli Lilly & Reports Q4 EPS $0.87 vs $0.81 Est; Revenues $6.05B vs $5.90B Est	 				,2012-01-31 06:30:00-05:00,LLY,neutral
767967.0,US Stock Futures Signal Higher Start On Wall Street,2012-01-31 06:11:00-05:00,LLY,neutral
767968.0,Earnings Scheduled For January 31,2012-01-31 03:17:00-05:00,LLY,neutral
767969.0,Earnings Expectations for the Week of January 30,2012-01-29 09:53:00-05:00,LLY,neutral
767970.0,Elanco Animal Health Announces Lilly's Agreement to Acquire ChemGen Corp; Terms Not Disclosed ,2012-01-24 13:01:00-05:00,LLY,positive
767971.0,"Benzinga's M&A Chatter for Tuesday January 17, 2012",2012-01-17 20:00:00-05:00,LLY,neutral
767972.0,"UPDATE: Deutsche Bank Raises PT to $40, Maintains Hold on Eli Lilly",2012-01-17 06:34:00-05:00,LLY,neutral
767973.0,ShangPharma Announces Opening of New Facility to Support Lilly's Pipeline ,2012-01-10 08:05:00-05:00,LLY,positive
767974.0,UPDATE: Eli Lilly Says Decline in 2012 Guidance Reflects Zyprexa Patent Expiration,2012-01-05 08:08:00-05:00,LLY,neutral
767975.0,Eli Lilly Guides 2012 EPS $3.10-3.20 vs $3.67 Est,2012-01-05 08:07:00-05:00,LLY,neutral
767976.0,Eli Lilly & Hits 52-Week High of $41.97,2012-01-03 09:31:00-05:00,LLY,neutral
767977.0,ETF Showdown: Fun With Pharma,2011-12-30 16:10:00-05:00,LLY,positive
767978.0,Eli Lilly & Hits 52-Week High of $41.87,2011-12-27 10:47:00-05:00,LLY,neutral
767979.0,Best Biotech Stocks of 2011,2011-12-27 10:39:00-05:00,LLY,positive
767980.0,Eli Lilly & Hits 52-Week High of $41.85,2011-12-22 09:30:00-05:00,LLY,neutral
767981.0,Eli Lilly & Hits 52-Week High of $41.44,2011-12-21 09:40:00-05:00,LLY,neutral
767982.0,Ligand Enters into Platform Captisol License and Supply Agreements with Lilly; Terms Not Disclosed,2011-12-21 08:03:00-05:00,LLY,positive
767983.0,"Financial Breakfast: Morning News Summary for December 20, 2011",2011-12-20 07:27:00-05:00,LLY,neutral
767984.0,"ImmunoGen, Inc. Announces Antibody-Drug Conjugate Collaboration With Lilly ",2011-12-20 07:10:00-05:00,LLY,neutral
767985.0,"Fast Money Picks For December 16th (AET, M, MANT, ETR, COV, LLY, ADBE)",2011-12-15 20:16:00-05:00,LLY,neutral
767986.0,Eli Lilly & Hits 52-Week High of $40.49,2011-12-15 09:42:00-05:00,LLY,neutral
767987.0,Eli Lilly & Hits 52-Week High of $40.25,2011-12-14 11:52:00-05:00,LLY,neutral
767988.0,Eli Lilly & Hits 52-Week High of $40.13,2011-12-13 11:24:00-05:00,LLY,neutral
767989.0,Katherine Baicker Elected to Lilly Board of Directors ,2011-12-12 08:30:00-05:00,LLY,neutral
767990.0,"From Earlier, Lilly Oncology Reveals Findings From Study of JAK2 Inhibitor for Blood Cancers at ASH Meeting ",2011-12-12 08:28:00-05:00,LLY,negative
767991.0,Eli Lilly & Hits 52-Week High of $39.79,2011-12-07 09:34:00-05:00,LLY,neutral
767992.0,"3M, Eli Lily, General Electric Receive Positive Mad Money/Jim Cramer Mention -CNBC ",2011-12-06 18:07:00-05:00,LLY,positive
767993.0,"Lilly Announces First and Only International, Prospective Observational Study Designed to Understand Barriers to Progression of Insulin Treatment  ",2011-12-01 08:02:00-05:00,LLY,neutral
767994.0,Eli Lilly Spokesperson Says the Company does Not Comment on Rumors; Response to Chatter Lilly is Pursuing Acquisition of Forest Laboratories,2011-11-22 10:27:00-05:00,LLY,neutral
767995.0,Forest Laboratories Moving Higher; May be Attributed to Takeover Chatter,2011-11-22 10:09:00-05:00,LLY,neutral
767996.0,New Analysis of Data Presented at AHA Regarding Effect of Effient on Cardiovascular Events in STEMI Patients According to Timing of PCI ,2011-11-16 15:04:00-05:00,LLY,neutral
767997.0,Kenexa Announces Partnership With Eli Lilly and Company ,2011-11-16 07:02:00-05:00,LLY,neutral
767998.0,Lilly CEO Lechleiter Outlines Opportunities for Improved Health and Economic Growth in Asia-Pacific Region ,2011-11-10 13:00:00-05:00,LLY,positive
767999.0,From Earlier: Amylin to End Diabetes Drug Deal with Lilly,2011-11-08 12:09:00-05:00,LLY,neutral
768000.0,A Peek Into The Market Before The Trading Starts,2011-11-08 07:29:00-05:00,LLY,neutral
768001.0,Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin ,2011-11-08 06:30:00-05:00,LLY,positive
768002.0,Siemens PETNET Solutions Signs Nationwide Commercial Agreement to Manufacture and Distribute Lilly's Molecular Imaging Agent ,2011-11-07 10:02:00-05:00,LLY,positive
768003.0,Fitch Downgrades Eli Lilly's Bank Loan Rating To 'A' From 'A+',2011-11-03 10:42:00-04:00,LLY,neutral
768004.0,Watch for YM BioSciences' Upcoming Clinical Data Catalyst,2011-10-31 23:15:00-04:00,LLY,neutral
768005.0,UPDATE: First Global Upgrades Eli Lilly to Moderate Outperform,2011-10-28 09:37:00-04:00,LLY,neutral
768006.0,Lilly's ALIMTA Receives EC Approval,2011-10-28 08:44:00-04:00,LLY,positive
768007.0,"Financial Breakfast: Morning News Summary for October 28, 2011",2011-10-28 07:45:00-04:00,LLY,neutral
768008.0,Eli Lilly Announces ALIMTA First Chemotherapy Approved in Europe as Continuation Maintenance Therapy for Most Common Form of Lung Cancer  ,2011-10-28 07:17:00-04:00,LLY,negative
768009.0,First Global Upgrades Eli Lilly from Market Perform to Market Outperform,2011-10-28 06:29:00-04:00,LLY,neutral
768010.0,Lilly Cuts 2011 Financial Guidance Due to Xigris Withdrawal; Expects $3.84-$3.89 vs $4.33 Est and $4.30-$4.35 Prior,2011-10-25 08:08:00-04:00,LLY,negative
768011.0,UPDATE: Lilly Sees Charge $0.75-0.95 Pretax; Reaffirms Forecast Adj EPS 2011,2011-10-25 08:08:00-04:00,LLY,neutral
768012.0,Lilly Announces Withdrawal of Xigris® Following Recent Clinical Trial Results ,2011-10-25 08:02:00-04:00,LLY,neutral
768013.0,"Eli Lilly: FDA Approves First Generic Olanzapine To Treat Schizophrenia, Bipolar Disorder",2011-10-24 15:14:00-04:00,LLY,positive
768014.0,UPDATE: Jefferies Lowers PT on Eli LIlly to $33,2011-10-24 08:21:00-04:00,LLY,negative
768015.0,Jefferies Lowers PT on Eli Lilly to $33,2011-10-24 06:44:00-04:00,LLY,negative
768016.0,Earnings Roundup,2011-10-20 10:08:00-04:00,LLY,neutral
768017.0,Eli Lilly Sees Zyprexa Expiration to Significantly Hurt Sales,2011-10-20 09:18:00-04:00,LLY,negative
768018.0,UPDATE: Eli Lilly Reports Decline In Q3 Net Profit,2011-10-20 08:54:00-04:00,LLY,positive
768019.0,Eli Lilly Reports Q3 EPS $1.13 vs $1.13 Est; Revenues $6.15B vs $6.06B Est					,2011-10-20 08:54:00-04:00,LLY,neutral
768020.0,Eli Lilly and Company's Profit Falls,2011-10-20 07:36:00-04:00,LLY,positive
768021.0,Earnings Scheduled For October 20,2011-10-20 04:32:00-04:00,LLY,neutral
768022.0,BYETTA Approved for Use with Insulin Glargine in the US,2011-10-19 19:06:00-04:00,LLY,positive
768023.0,"Eli Lilly Earnings Preview: Analysts Expect Rising Revenue, Falling EPS",2011-10-17 08:40:00-04:00,LLY,negative
768024.0,Top 4 Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield,2011-10-14 04:31:00-04:00,LLY,positive
768025.0,New Study Shows Cialis Significantly Improved Study Endpoints in Men,2011-10-12 08:01:00-04:00,LLY,positive
768026.0,Will Earnings Be a Catalyst?,2011-10-07 18:43:00-04:00,LLY,neutral
768027.0,Notable Call Options Activity in Eli Lilly,2011-10-07 15:41:00-04:00,LLY,neutral
768028.0,Resistance  10-07-2011,2011-10-07 15:19:00-04:00,LLY,neutral
768029.0,"Financial Breakfast: Morning News Summary for October 7, 2011",2011-10-07 07:39:00-04:00,LLY,neutral
768030.0,Cialis for Once Daily Use Now FDA-Approved to Treat Men With Signs and Symptoms of Benign Prostatic Hyperplasia and Men With Both Erectile Dysfunction and Signs and Symptoms of BPH  ,2011-10-07 06:55:00-04:00,LLY,positive
768031.0,Lilly's Cialis is Approved for Treatment of Enlarged Prostates,2011-10-06 16:35:00-04:00,LLY,positive
768032.0,Lilly CEO Says Not Interested in Pfizer Nutrition Business,2011-10-05 13:20:00-04:00,LLY,negative
768033.0,Lilly CEO Wants Better Chance to Win Worker Green Cards,2011-10-05 09:44:00-04:00,LLY,positive
768034.0,Eli Lilly Announces ALIMTA Helped Keep Most Common Form of Lung Cancer at Bay In Elderly Patients ,2011-09-26 13:01:00-04:00,LLY,negative
768035.0,ALIMTA Receives Positive Opinion From CHMP as Continuation Maintenance Therapy for Deadly Form of Lung Cancer,2011-09-26 08:01:00-04:00,LLY,negative
768036.0,Lilly Invests $30 Million in Partnership to Address Non-Communicable Diseases,2011-09-13 07:02:00-04:00,LLY,neutral
768037.0,A Peek Into The Market Before The Trading Starts,2011-09-12 07:21:00-04:00,LLY,neutral
768038.0,"Amylin Pharmaceuticals, Eli Lilly, and Alkermes Announce Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors",2011-09-12 07:01:00-04:00,LLY,negative
768039.0,Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations ,2011-09-07 09:03:00-04:00,LLY,neutral
768040.0,"Mustafa Nevzat Could Attract Other Suitors, Ultimately Be Sold For About $1B - WSJ",2011-09-01 15:22:00-04:00,LLY,positive
768041.0,Eli Lilly Announces Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes ,2011-08-25 14:50:00-04:00,LLY,positive
768042.0,Effient Showed Significant 26% Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study ,2011-08-15 09:38:00-04:00,LLY,positive
768043.0,"Bydureon FDA Action Date Set For January 28, 2012",2011-08-10 16:18:00-04:00,LLY,neutral
768044.0,Eli Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion ,2011-08-09 08:03:00-04:00,LLY,neutral
768045.0,Leerink Swann Upgrades Eli Lilly to Market Perform,2011-08-01 07:41:00-04:00,LLY,neutral
768046.0,U.S. Court of Appeals Affirms Validity of Lilly's Strattera Patent ,2011-07-29 12:35:00-04:00,LLY,neutral
768047.0,Bank of America Comments on Eli Lilly,2011-07-29 07:46:00-04:00,LLY,neutral
768048.0,Stocks Going Ex Dividend the Second Week of August,2011-07-28 17:58:00-04:00,LLY,neutral
768049.0,BYDUREON™ Reply Submitted to FDA,2011-07-28 08:02:00-04:00,LLY,neutral
768050.0,Hearing Supreme Court Asked to Overturn Obama's Health Care Reform,2011-07-27 15:19:00-04:00,LLY,positive
768051.0,"EMA Gives Negative Opinion on Ariclaim, Cymbalta, Xeristar Extensions",2011-07-22 09:15:00-04:00,LLY,negative
768052.0,"Deutsche Bank Maintains Eli Lilly Hold, $38.50 PT",2011-07-21 16:42:00-04:00,LLY,neutral
768053.0,Fifteen Health Care ETFs Trading Near 52-Week Highs,2011-07-21 13:57:00-04:00,LLY,positive
768054.0,Earnings Roundup For July 21,2011-07-21 09:40:00-04:00,LLY,neutral
768055.0,"News Summary for July 20, 2011",2011-07-21 07:53:00-04:00,LLY,neutral
768056.0,A Peek Into The Market Before The Trading Starts,2011-07-21 07:41:00-04:00,LLY,neutral
768057.0,"Lilly Sees Year EPS $4.25-4.35, Had Seen $4.15-4.30",2011-07-21 07:34:00-04:00,LLY,neutral
768058.0,UPDATE: Eli Lilly Reports 11% Drop In Q2 Earnings,2011-07-21 07:06:00-04:00,LLY,negative
768059.0,US Stock Futures Down As Investors Await Earnings Reports ,2011-07-21 06:28:00-04:00,LLY,positive
768060.0,Earnings Scheduled For July 21,2011-07-21 03:30:00-04:00,LLY,neutral
768061.0,Eli Lilly & Earnings Preview: Analysts Predict Higher Earnings Over Prior Quarter,2011-07-18 14:55:00-04:00,LLY,neutral
768062.0,Citi Comments on Eli Lilly,2011-07-18 08:12:00-04:00,LLY,neutral
768063.0,Eli Lilly Announces New Data Showed Minimal Potential for Drug Interaction Between Cholesterol Drug LIVALO and a Common Antiretroviral Therapy ,2011-07-18 07:22:00-04:00,LLY,neutral
768064.0,Jefferies Raises PT On Eli Lilly To $34,2011-07-18 07:14:00-04:00,LLY,neutral
768065.0,Jefferies Raises PT On Eli Lilly To $34,2011-07-18 07:14:00-04:00,LLY,neutral
768066.0,Earnings Expectations for the Week of July 18,2011-07-17 09:18:00-04:00,LLY,neutral
768067.0,Twelve Health Care ETFs Trading Near 52-Week Highs,2011-07-13 07:38:00-04:00,LLY,positive
768068.0,Citi Reiterates Hold and PT of $38 on Eli Lilly,2011-07-08 09:26:00-04:00,LLY,neutral
768069.0,Sideline Money Flows In  07-01-2011,2011-07-01 14:55:00-04:00,LLY,neutral
768070.0,Wells Fargo Maintains Market Perform on Eli Lilly,2011-07-01 09:33:00-04:00,LLY,positive
768071.0,J.P. Morgan Comments On Eli Lilly Investor Day,2011-07-01 07:54:00-04:00,LLY,neutral
768072.0,Deutsche Bank Discusses Eli Lilly Investor Meeting,2011-07-01 07:51:00-04:00,LLY,neutral
768073.0,Citi Maintains Hold Rating On Eli Lilly,2011-06-29 07:56:00-04:00,LLY,neutral
768074.0,"Fast Money Picks For June 29th (LULU, XHB, BAC, LLY)",2011-06-28 19:40:00-04:00,LLY,neutral
768075.0,Eli Lilly: Newly Published Study Showed Axiron Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men,2011-06-28 10:45:00-04:00,LLY,positive
768076.0,Eli Lilly Announces New Investment to Boost Its Biotechnology Capabilities ,2011-06-28 07:58:00-04:00,LLY,positive
768077.0,Citi Maintains Hold Rating on Eli Lilly,2011-06-27 07:34:00-04:00,LLY,neutral
768078.0,Jefferies Maintains Buy on Amylin Pharmaceuticals,2011-06-27 07:25:00-04:00,LLY,neutral
768079.0,Eli Lilly: Linagliptin Recommended For Approval In The Treatment Of Type 2 Diabetes In Europe,2011-06-24 08:56:00-04:00,LLY,positive
768080.0,Forest Labs and Watson Pharma to Open Near 52-Week Highs,2011-06-23 08:44:00-04:00,LLY,neutral
768081.0,Deutsche Bank Sees No Catalyst At Eli Lilly Investor Meeting ,2011-06-23 07:56:00-04:00,LLY,negative
768082.0,Goldman Sachs Suggests Buying Put Spreads on Eli Lilly and Company,2011-06-22 10:06:00-04:00,LLY,neutral
768083.0,Colgate and Forest Labs to Open Near 52-Week Highs,2011-06-21 08:22:00-04:00,LLY,neutral
768084.0,"News Summary for June 21, 2011",2011-06-21 08:06:00-04:00,LLY,neutral
768085.0,A Peek Into The Market Before The Trading Starts,2011-06-21 07:25:00-04:00,LLY,neutral
768086.0,Eli Lilly and Amylin Pharmaceuticals Announces BYDUREON Receives Marketing Authorization in Europe   ,2011-06-21 07:00:00-04:00,LLY,neutral
768087.0,Lilly Declares Third-Quarter 2011 Dividend of $0.49/Share,2011-06-20 16:07:00-04:00,LLY,neutral
768088.0,Options Brief: Eli Lilly and Company,2011-06-15 13:54:00-04:00,LLY,neutral
768089.0,Boehringer Ingelheim and Eli Lilly's New Type 2 Diabetes Treatment Tradjenta Tablets for Adults Now Available in U.S. Pharmacies ,2011-06-15 09:01:00-04:00,LLY,neutral
768090.0,CIGNA and Forest Laboratories Open Near 52-Week Highs,2011-06-10 09:48:00-04:00,LLY,neutral
768091.0,Synthes and Eli Lilly Sign Development and Collaboration Agreement ,2011-06-09 11:30:00-04:00,LLY,positive
768092.0,UPDATE: Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order ,2011-06-08 16:57:00-04:00,LLY,neutral
768093.0,U.S. District Court Rules in Favor of Eli Lilly in Amylin Litigation ,2011-06-08 16:18:00-04:00,LLY,positive
768094.0,FDA Approves Updates to Lilly's HumalogLabel ,2011-06-08 08:01:00-04:00,LLY,positive
768095.0,Will Prozac Murder Trial Doom Eli Lilly Stock?,2011-06-06 14:33:00-04:00,LLY,negative
768096.0,Options Brief: Eli Lilly and Company,2011-06-02 10:27:00-04:00,LLY,neutral
768097.0,"Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer",2011-06-01 12:13:00-04:00,LLY,positive
768098.0,Hapoalim Cutting Ocverage On Multitude Of Names,2011-06-01 11:48:00-04:00,LLY,negative
768099.0,Top 4 Large-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest ROE,2011-06-01 01:12:00-04:00,LLY,positive
768100.0,Diabetes Device Market to Reach $24 Billion by 2017 ,2011-05-24 09:11:00-04:00,LLY,neutral
768101.0,"Eli Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement ",2011-05-23 16:21:00-04:00,LLY,positive
768102.0,"Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement",2011-05-23 10:02:00-04:00,LLY,positive
768103.0,Top Healthcare and Major Drugs stocks to watch- Sector Performance,2011-05-22 14:55:00-04:00,LLY,positive
768104.0,A Mega Cap ETF Joins the First Trust AlphaDEX Lineup,2011-05-19 16:04:00-04:00,LLY,positive
768105.0,Eli Lilly Announces Study Determined Best Dose and Showed 55% Response Rate With Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients,2011-05-19 08:12:00-04:00,LLY,positive
768106.0,ELi Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcoma,2011-05-19 08:11:00-04:00,LLY,neutral
768107.0,GlaxoSmithKline and Isis Pharmaceuticals partnership shouldn't be overlooked as a long-term,2011-05-18 06:29:00-04:00,LLY,neutral
768108.0,Eli Lilly Provides Its Perspective in Response to Amylin Lawsuit,2011-05-16 14:11:00-04:00,LLY,negative
768109.0,"Lilly Says Suit Is Without Merit, Will Vigorously Defend Position",2011-05-16 10:21:00-04:00,LLY,negative
768110.0,Lilly Rejected By U.S. Supreme Court On Gemzar Patent -Bloomberg,2011-05-16 10:02:00-04:00,LLY,positive
768111.0,Lilly Provides Statement in Response to Amylin Lawsuit ,2011-05-16 09:54:00-04:00,LLY,negative
768112.0,Bank Of America Raising PT On LLY To $43,2011-05-16 07:43:00-04:00,LLY,neutral
768113.0,Amylin Pharmaceuticals Files Suit Against Eli Lilly ,2011-05-16 07:11:00-04:00,LLY,neutral
768114.0,Going Large: First Trust Introduces Mega-Cap ETF,2011-05-12 15:04:00-04:00,LLY,positive
768115.0,Using the Euro as a Barometer  05-10-2011,2011-05-10 16:03:00-04:00,LLY,neutral
768116.0,"Defense, Defense  05-03-2011",2011-05-03 15:40:00-04:00,LLY,positive
768117.0,UPDATE: FDA Approves Tradjenta™ Tablets for the Treatment of Type 2 Diabetes (LLY),2011-05-02 17:31:00-04:00,LLY,positive
768118.0,UPDATE: FDA Approves New Treatment for Type 2 Diabetes; Marketed by Eli Lilly  ,2011-05-02 15:20:00-04:00,LLY,positive
768119.0,"Lilly, Boehringer Win FDA Approval For Diabetes Drug, Bloomberg (LLY)",2011-05-02 14:44:00-04:00,LLY,positive
768120.0,Stocks Going Ex Dividend the Second Week of May,2011-04-30 22:23:00-04:00,LLY,neutral
768121.0,Lilly In Advanced Talks To Resolve SEC Foreign Bribery Probe -DJ (LLY),2011-04-29 13:25:00-04:00,LLY,positive
768122.0,New Treatment For Chronic Low Back Pain Approved by Health Canada (LLY),2011-04-29 12:14:00-04:00,LLY,negative
768123.0,U.S. District Court Order Maintains Patent Exclusivity for Lilly's Cymbalta (LLY),2011-04-27 16:23:00-04:00,LLY,neutral
768124.0,"Biotech /Pharma Stocks Snapshot; Technology and Medical Devices on the Rise Within Healthcare; Aethlon Medical, ELI Lilly (LLY), Medtronic (MDT), Pfizer (PFE), Apple (AAPL)",2011-04-27 15:28:00-04:00,LLY,neutral
768125.0,Lilly and Medtronic Announce Drug-Device Collaboration for Parkinson's Disease ,2011-04-26 09:01:00-04:00,LLY,neutral
768126.0,"Five Stocks that May End Up, umm, Higher, if Marijuana is Legalized",2011-04-20 11:02:00-04:00,LLY,neutral
768127.0,"Hapoalim Upgrades LLY From Hold To Buy, Raises PT To $39",2011-04-19 09:34:00-04:00,LLY,neutral
768128.0,Deutsche Bank Maintains Hold on Eli Lilly (LLY),2011-04-19 07:36:00-04:00,LLY,neutral
768129.0,"CEOWORLD Daily Business Roundup- BP, GS, GM, RIMM, YHOO, TXN, IBM, YHOO, C, INTC, WMT, AAPL…",2011-04-19 06:16:00-04:00,LLY,neutral
768130.0,Jefferies Maintains Hold on Eli Lilly (LLY),2011-04-18 09:53:00-04:00,LLY,neutral
768131.0,A Peek Into The Market Before The Trading Starts,2011-04-18 07:28:00-04:00,LLY,neutral
768132.0,Eli Lilly Reports Upbeat Q1 Earnings,2011-04-18 06:36:00-04:00,LLY,neutral
768133.0,US Stock Futures Down As Investors Await Citigroup Earnings,2011-04-18 06:14:00-04:00,LLY,positive
768134.0,"Earnings Scheduled For April 18 (AMTD, TXN, KEY, C, LLY, GCI, HAL, MTB, BRO, AMLN, ZION, CR)",2011-04-18 00:51:00-04:00,LLY,neutral
768135.0,"Stocks To Watch For April 18 (C, TXN, JNJ, HAL, LLY)",2011-04-18 00:46:00-04:00,LLY,neutral
768136.0,Monday's Economic and Earnings Schedule,2011-04-17 21:52:00-04:00,LLY,neutral
768137.0,"CEOWORLD Daily Business Roundup- JNJ, CHK, AMD, T, AXP, AAPL, INTC, JPM, GOOG, LLY, CSCO…",2011-04-16 07:47:00-04:00,LLY,neutral
768138.0,"Top Percentage Gainers and Losers as of 10am 4/15/11 (AGO, OPXA, MBI, AMLN, ABMD, CTCT, CRUS, GGC, OTIV, SFG, BAC, LLY, ALKS)",2011-04-15 10:09:00-04:00,LLY,negative
768139.0,"BYDUREON Recommended For Approval In Europe (LLY, ALKS)                                                ",2011-04-15 08:59:00-04:00,LLY,positive
768140.0,"Eli Lilly, Amylin Pharmaceuticals, and Alkermes Announce BYDUREON Recommended for Approval in Europe ",2011-04-15 07:18:00-04:00,LLY,positive
768141.0,Jefferies: LLY Q1 Earnings Could Be Under Pressure,2011-04-14 08:17:00-04:00,LLY,negative
768142.0,Market Holds Its Ground 04-07-2011,2011-04-07 18:54:00-04:00,LLY,neutral
768143.0,Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer ,2011-04-04 15:01:00-04:00,LLY,negative
768144.0,Axiron Topical Solution CIII Now Available in Pharmacies ,2011-04-01 16:01:00-04:00,LLY,positive
768145.0,"Mad Money Lightning Round: Cramer Likes Gentex, Micron Technology (AES, CHS, ASNA, BTU, WLT, LLY, LYG, GNTX, MSFT, INTC, CSCO, MU)",2011-03-29 01:22:00-04:00,LLY,negative
768146.0,Lilly and Avid Receive Complete Response Letter from FDA for Amyvid,2011-03-18 07:47:00-04:00,LLY,positive
768147.0,Jefferies Comments On Eli Lilly Strattera Appeal,2011-03-18 07:42:00-04:00,LLY,neutral
768148.0,Lilly Announces Important Action Regarding Recall of Alcohol Prep Pads Made by Triad Group,2011-03-17 16:16:00-04:00,LLY,positive
768149.0,Citi Maintains Hold Rating On LLY,2011-03-15 08:38:00-04:00,LLY,neutral
768150.0,A Peek Into The Market Before The Trading Starts,2011-03-14 07:30:00-04:00,LLY,neutral
768151.0,Lilly Makes an Irrevocable Offer to Acquire Janssen Animal Health ,2011-03-14 07:08:00-04:00,LLY,neutral
768152.0,Health Insurers Triple S&P 500 Returns,2011-03-10 12:21:00-05:00,LLY,neutral
768153.0,"Stocks To Watch When Human Genome Sciences Reopens After Benlysta Approval (HGSI, GSK, LJPC, ANTH, CEPH)",2011-03-09 17:49:00-05:00,LLY,positive
768154.0,Citi Comments On LLY 10-K,2011-03-08 09:37:00-05:00,LLY,neutral
768155.0,"Amylin Pharmaceuticals, Eli Lilly and Alkermes Announce Top-line Results from DURATION-6 Study",2011-03-03 08:04:00-05:00,LLY,neutral
768156.0,Two ETFs for the Recovery in Big Pharma,2011-02-11 14:59:00-05:00,LLY,neutral
768157.0,A Peek Into The Market Before The Trading Starts,2011-02-11 07:48:00-05:00,LLY,neutral
768158.0,Eli Lilly Announces Senior Leadership Changes,2011-02-11 07:15:00-05:00,LLY,neutral
768159.0,Jefferies Updates Estimates on Eli Lilly (LLY),2011-02-04 09:00:00-05:00,LLY,neutral
768160.0,Roche Misses on Tamiflu Decline - Analyst Blog,2011-02-03 08:31:00-05:00,LLY,negative
768161.0,Roche Misses on Tamiflu Decline - Analyst Blog,2011-02-03 08:15:00-05:00,LLY,negative
768162.0,Stocks Going Ex Dividend the Second Week of February,2011-02-02 23:49:00-05:00,LLY,neutral
768163.0,Hospira Misses; 2011 View Weak - Analyst Blog,2011-02-02 13:31:00-05:00,LLY,negative
768164.0,Hospira Misses; 2011 View Weak - Analyst Blog,2011-02-02 13:15:00-05:00,LLY,negative
768165.0,"Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab ",2011-02-02 09:43:00-05:00,LLY,negative
768166.0,Earnings Preview: Alkermes - Analyst Blog,2011-01-31 13:03:00-05:00,LLY,neutral
768167.0,Earnings Preview: Alkermes - Analyst Blog,2011-01-31 12:30:00-05:00,LLY,neutral
768168.0,"Company News for January 28, 2011 - Corporate Summary",2011-01-28 10:01:00-05:00,LLY,neutral
768169.0,Hapoalim Reiterates Hold on Eli Lilly (LLY),2011-01-28 09:46:00-05:00,LLY,neutral
768170.0,"Company News for January 28, 2011 - Corporate Summary",2011-01-28 09:29:00-05:00,LLY,neutral
768171.0,Jefferies Comments on Eli Lilly's FY 2010 Earnings (LLY),2011-01-27 11:50:00-05:00,LLY,neutral
768172.0,Eli Lilly Tops Ests; Guides In Line - Analyst Blog,2011-01-27 10:31:00-05:00,LLY,positive
768173.0,Cost Control Helps Amylin Cut Loss - Analyst Blog,2011-01-27 10:31:00-05:00,LLY,negative
768174.0,Cost Control Helps Amylin Cut Loss - Analyst Blog,2011-01-27 10:15:00-05:00,LLY,negative
768175.0,Eli Lilly Tops Ests; Guides In Line - Analyst Blog,2011-01-27 09:45:00-05:00,LLY,positive
768176.0,"Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance ",2011-01-27 07:52:00-05:00,LLY,neutral
768177.0,A Peek Into The Market Before The Trading Starts,2011-01-27 07:47:00-05:00,LLY,neutral
768178.0,Eli Lilly Beats EPS Estimates By 1 Cent (LLY),2011-01-27 07:03:00-05:00,LLY,neutral
768179.0,"Earnings Scheduled For January 27 (CAT, MSFT, PG, T, BMY, LLY, AMZN, AZN, TWC, SNDK, NOK, CB, JBLU, VRSN, PMCS, CL, MSI, KLAC)",2011-01-27 03:44:00-05:00,LLY,neutral
768180.0,Teva and APP Announce Launch of Generic Gemzar,2011-01-26 08:13:00-05:00,LLY,neutral
768181.0,Earnings Preview: Eli Lilly - Analyst Blog,2011-01-25 11:00:00-05:00,LLY,neutral
768182.0,Earnings Preview: Eli Lilly - Analyst Blog,2011-01-25 10:45:00-05:00,LLY,neutral
768183.0,Citi Increases EPS Estimate on Eli Lilly (LLY) ,2011-01-24 09:42:00-05:00,LLY,neutral
768184.0,FDA Panel Reviews Lilly Drug - Analyst Blog,2011-01-21 16:01:00-05:00,LLY,neutral
768185.0,FDA Panel Reviews Lilly Drug - Analyst Blog,2011-01-21 15:39:00-05:00,LLY,neutral
768186.0,Bleeding Risk with MRK's Candidate  - Analyst Blog,2011-01-20 11:01:00-05:00,LLY,negative
768187.0,Bleeding Risk with MRK's Candidate  - Analyst Blog,2011-01-20 10:30:00-05:00,LLY,negative
768188.0,MannKind in Jeopardy - Analyst Blog,2011-01-20 10:01:00-05:00,LLY,negative
768189.0,MannKind in Jeopardy - Analyst Blog,2011-01-20 09:45:00-05:00,LLY,negative
768190.0,FDA To Review Alzheimer's Brain Scan (LLY),2011-01-19 08:08:00-05:00,LLY,neutral
768191.0,Community to put Directors in Tenet - Analyst Blog,2011-01-17 17:01:00-05:00,LLY,neutral
768192.0,Community to put Directors in Tenet - Analyst Blog,2011-01-17 16:45:00-05:00,LLY,neutral
768193.0,Merck's Blood Thinner in Trouble - Analyst Blog,2011-01-14 16:31:00-05:00,LLY,negative
768194.0,Merck's Blood Thinner in Trouble - Analyst Blog,2011-01-14 16:01:00-05:00,LLY,negative
768195.0,FDA Panel Rejects LLY's candidate  - Analyst Blog,2011-01-13 12:01:00-05:00,LLY,negative
768196.0,FDA Panel Rejects LLY's candidate  - Analyst Blog,2011-01-13 11:15:00-05:00,LLY,negative
768197.0,Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application,2011-01-12 17:05:00-05:00,LLY,neutral
768198.0,"Benzinga's Top Upgrades (LLY, CPNO, VZ, SLE)",2011-01-12 09:26:00-05:00,LLY,positive
768199.0,Hapoalim Upgrades Eli Lilly To Hold (LLY),2011-01-12 08:42:00-05:00,LLY,neutral
768200.0,Data on Sanofi Cancer Candidate - Analyst Blog,2011-01-07 11:33:00-05:00,LLY,negative
768201.0,Data on Sanofi Cancer Candidate - Analyst Blog,2011-01-07 11:00:00-05:00,LLY,negative
768202.0,Label Expansion for Roche's Actemra - Analyst Blog,2011-01-06 17:00:00-05:00,LLY,neutral
768203.0,Label Expansion for Roche's Actemra - Analyst Blog,2011-01-06 16:38:00-05:00,LLY,neutral
768204.0,Bristol-Myers Outlook Mixed - Analyst Blog,2011-01-04 15:03:00-05:00,LLY,neutral
768205.0,Bristol-Myers Outlook Mixed - Analyst Blog,2011-01-04 14:32:00-05:00,LLY,neutral
768206.0,Citi Comments On Eli Lilly Product Trends,2011-01-04 08:09:00-05:00,LLY,neutral
768207.0,"Mad Money Lightning Round: Cramer Advises Investors To Buy Baidu (AXL, F, GM, LLY, BIDU, DEO)",2011-01-04 03:58:00-05:00,LLY,negative
768208.0,'Mad Money Lightning Round': Baidu's Terrific,2011-01-03 19:28:00-05:00,LLY,neutral
768209.0,Xoma: Key Diabetes Drug Study Preview,2011-01-03 19:03:00-05:00,LLY,neutral
768210.0,Label Expansion Sought for Byetta - Analyst Blog,2010-12-23 09:03:00-05:00,LLY,neutral
768211.0,Label Expansion Sought for Byetta - Analyst Blog,2010-12-23 08:15:00-05:00,LLY,neutral
768212.0,Amylin and Lilly Seek Expanded Use of BYETTA ,2010-12-22 16:19:00-05:00,LLY,neutral
768213.0,INCY's INC424 Meets Goal - Analyst Blog,2010-12-22 11:33:00-05:00,LLY,neutral
768214.0,INCY's INC424 Meets Goal - Analyst Blog,2010-12-22 11:15:00-05:00,LLY,neutral
768215.0,Unconfirmed Rumors Circulate that Neurocrine Biosciences Inc. (NBIX) will be taken out by Eli Lilly & Co. (LLY) at $17.00 a share ,2010-12-22 09:49:00-05:00,LLY,positive
768216.0,Eli Lilly Acquires Avid  - Analyst Blog,2010-12-22 09:03:00-05:00,LLY,positive
768217.0,Eli Lilly Acquires Avid  - Analyst Blog,2010-12-22 08:30:00-05:00,LLY,positive
768218.0,Rolling BLA for AMLN's Metreleptin - Analyst Blog,2010-12-21 09:36:00-05:00,LLY,neutral
768219.0,Rolling BLA for AMLN's Metreleptin - Analyst Blog,2010-12-21 09:15:00-05:00,LLY,neutral
768220.0,Safeguard Scientifics to Realize at Least $36M in Initial Sale Proceeds from Eli Lilly's Acquisition of Avid Radiopharmaceuticals  ,2010-12-20 16:43:00-05:00,LLY,positive
768221.0,"Friday's Put/Call Ratio Leaders (PSUN, LO, COCO, LLY, MCHP)",2010-12-17 12:07:00-05:00,LLY,neutral
768222.0,Lilly Study Stopped on Safety Concerns - Analyst Blog,2010-12-14 17:21:00-05:00,LLY,positive
768223.0,Lilly Study Stopped on Safety Concerns - Analyst Blog,2010-12-14 16:29:00-05:00,LLY,positive
768224.0,Loss at BIOD Narrower than Expected - Analyst Blog,2010-12-13 13:33:00-05:00,LLY,negative
768225.0,Loss at BIOD Narrower than Expected - Analyst Blog,2010-12-13 12:58:00-05:00,LLY,negative
768226.0,"Mad Money Lightning Round: Cramer Advises Investors To Buy BlackRock (LLY, DECK, CMI, OXPS, AXP, V, MRK, ABT, BLK)",2010-12-10 03:21:00-05:00,LLY,negative
768227.0,'Mad Money Lightning Round': Go for BlackRock,2010-12-09 19:29:00-05:00,LLY,negative
768228.0,Best Stocks For Creating A Passive Income Stream,2010-12-09 11:00:00-05:00,LLY,positive
768229.0,Neutral on Incyte - Analyst Blog,2010-12-03 17:00:00-05:00,LLY,neutral
768230.0,Neutral on Incyte - Analyst Blog,2010-12-03 16:17:00-05:00,LLY,neutral
768231.0,CBST's Fast-Injection Cubicin OK'd - Analyst Blog,2010-12-03 16:01:00-05:00,LLY,neutral
768232.0,CBST's Fast-Injection Cubicin OK'd - Analyst Blog,2010-12-03 15:32:00-05:00,LLY,neutral
768233.0,Merck Strikes Deal with SmartCells  - Analyst Blog,2010-12-03 11:16:00-05:00,LLY,negative
768234.0,Merck Strikes Deal with SmartCells  - Analyst Blog,2010-12-03 10:11:00-05:00,LLY,negative
768235.0,Acrux and Eli Lilly Receive FDA Approval for Testosterone Drug ,2010-11-29 12:32:00-05:00,LLY,positive
768236.0,Amylin Stays Neutral - Analyst Blog,2010-11-24 12:12:00-05:00,LLY,neutral
768237.0,"Company News for November 24, 2010 - Corporate Summary",2010-11-24 09:30:00-05:00,LLY,neutral
768238.0,FDA Approves Axiron  - Analyst Blog,2010-11-24 09:00:00-05:00,LLY,positive
768239.0,Amylin Stays Neutral - Analyst Blog,2010-11-24 06:20:00-05:00,LLY,neutral
768240.0,"Company News for November 24, 2010 - Corporate Summary",2010-11-24 04:15:00-05:00,LLY,neutral
768241.0,FDA Approves Axiron  - Analyst Blog,2010-11-24 03:39:00-05:00,LLY,positive
768242.0,Impax Laboratories Receives Tentative FDA Approval for Generic Cymbalta,2010-11-22 09:04:00-05:00,LLY,positive
768243.0,"Zings Of The Day (GOOG, LLY)",2010-11-19 15:59:00-05:00,LLY,neutral
768244.0,Citi Gives Valuation Update On Eli Lilly,2010-11-16 08:53:00-05:00,LLY,neutral
768245.0,Hospira Launches Gemcitabine HCL ,2010-11-15 14:48:00-05:00,LLY,neutral
768246.0,"Zacks Analyst Blog Highlights: Lions Gate Entertainment, Amylin Pharmaceuticals, Amylin Pharmaceuticals, Eli Lilly, Alkermes and Novo Nordisk       - Press Releases",2010-11-12 10:33:00-05:00,LLY,positive
768247.0,Eli Lilly's Dividend Security Threatened,2010-11-12 08:35:00-05:00,LLY,negative
768248.0,J.P. Morgan Reiterates Incyte Corporation Rating,2010-11-11 08:33:00-05:00,LLY,neutral
768249.0,Pharma & Biotech Industry Outlook - Nov. 2010 - Zacks Analyst Interviews,2010-11-09 17:03:00-05:00,LLY,neutral
768250.0,Pharma & Biotech Industry Outlook - Nov. 2010 - Industry Outlook,2010-11-09 17:03:00-05:00,LLY,neutral
768251.0,Pharma and Biotech Industry Outlook - Nov. 2010 - Industry Outlook,2010-11-09 17:03:00-05:00,LLY,neutral
768252.0,LLY's Avid Interest in Alzheimer's - Analyst Blog,2010-11-09 12:33:00-05:00,LLY,positive
768253.0,"Eli Lilly Buying Alzheimer's Drug Maker, Is It A Buy? (LLY)",2010-11-08 08:59:00-05:00,LLY,neutral
768254.0,Lilly to Acquire Avid Radiopharmaceuticals for up to $550M,2010-11-08 08:16:00-05:00,LLY,positive
768255.0,Hapoalim Securities Reiterates Sell Rating on Eli Lilly (LLY),2010-10-21 14:53:00-04:00,LLY,positive
768256.0,Lilly Beats by a Penny; Ups View - Analyst Blog,2010-10-21 12:00:00-04:00,LLY,neutral
768257.0,"Stock Market News for October 21, 2010 - Market News",2010-10-21 10:03:00-04:00,LLY,neutral
768258.0,"Company News for October 21, 2010 - Corporate Summary",2010-10-21 10:03:00-04:00,LLY,neutral
768259.0,"Trading Plan for October 21, 2010",2010-10-21 06:45:00-04:00,LLY,neutral
768260.0,"Earnings Scheduled For October 21 (MCD, CAT, T, LLY, CS, UAL, BAX, NVS, UNP, UPS, BBT, PM, RAI, CTXS, SNDK, JBLU, AXP, TRV, LUV, AMZN, STI, HSY, XRX, CB)",2010-10-21 04:27:00-04:00,LLY,neutral
768261.0,Viagra Treatment for Muscular Dystrophy,2010-10-20 12:11:00-04:00,LLY,neutral
768262.0,"""Change Of Heart"" By FDA For LLY",2010-10-20 10:19:00-04:00,LLY,neutral
768263.0,"Benzinga's Top Downgrades (KOF, LLY, ITW, AMLN)",2010-10-20 07:55:00-04:00,LLY,positive
768264.0,Amylin Pharmaceuticals Crushed In Pre-Market (AMLN),2010-10-20 07:35:00-04:00,LLY,negative
768265.0,Citigroup Downgrades LLY To Hold,2010-10-20 07:22:00-04:00,LLY,neutral
768266.0,"In Core Product Trends Report, Citigroup Rates Eli Lilly High Risk",2010-10-19 08:39:00-04:00,LLY,negative
768267.0,Lilly Declares Fourth-Quarter 2010 Dividend of $.49,2010-10-18 15:30:00-04:00,LLY,neutral
768268.0,Eli Lilly Product Trends: Increases Across The Board,2010-10-12 07:39:00-04:00,LLY,neutral
768269.0,"Top 4 NYSE Stocks In The Healthcare Sector With The Highest Dividend Yield (LLY, BMY, GSK, PFE)",2010-10-12 04:16:00-04:00,LLY,positive
768270.0,Eli Lilly Drug Fails Phase 3 Trial (LLY),2010-10-11 08:50:00-04:00,LLY,negative
768271.0,5 Most Undervalued Stocks in the S&P 500 ,2010-10-07 13:26:00-04:00,LLY,neutral
768272.0,"Unconfirmed rumor that Amylin Pharmaceuticals, Inc. (AMLN) is in talks with Eli Lilly & Co. (LLY) to be acquired in the mid $30s",2010-10-06 10:39:00-04:00,LLY,negative
768273.0,Eli Lilly's Core Product Trends For The Week Ending 9/24,2010-10-06 07:51:00-04:00,LLY,neutral
768274.0,J&J-Galapagos in Anti-Cancer Deal - Analyst Blog,2010-10-04 23:21:00-04:00,LLY,neutral
768275.0,Bristol Myers at Neutral - Analyst Blog,2010-10-04 23:21:00-04:00,LLY,neutral
768276.0,Male Menopause: Another Treatment for Pharmaceutical Companies,2010-10-04 19:26:00-04:00,LLY,neutral
768277.0,"Benzinga's Top Pre-Market NASDAQ Gainers (SNTS, LLNW, APWR, MNKD)",2010-09-30 08:37:00-04:00,LLY,positive
768278.0,Unconfirmed Rumor that Eli Lilly & Co. (LLY) is readying bid for MannKind Corp. (MNKD) at $12.50 a share,2010-09-29 09:50:00-04:00,LLY,positive
768279.0,"Mad Money Lightning Round: Cramer Considers Apple As One Of The Best Stocks Ever, Advises Investors To Buy AT&T And Verizon, Sell A-Power Energy (AAPL, LLY, T, VZ, GOOG, APWR, LDK, ARUN)",2010-09-28 06:17:00-04:00,LLY,positive
768280.0,Lilly CEO Says Regional Innovation Important to the Nation's Economy (LLY),2010-09-23 12:02:00-04:00,LLY,positive
768281.0,Yield Versus Yield,2010-09-23 08:23:00-04:00,LLY,neutral
768282.0,"Unconfirmed rumor that Amylin Pharmaceuticals, Inc. (AMLN) will be taken out by Eli Lilly & Co. (LLY) at $32.00",2010-09-22 09:56:00-04:00,LLY,negative
768283.0,Jeffrey A. Winton Named VP At Eli Lilly And Company (LLY),2010-09-21 08:16:00-04:00,LLY,neutral
768284.0,J.P. Morgan Has Underweight Rating On Eli Lilly (LLY),2010-09-21 06:56:00-04:00,LLY,neutral
768285.0,Pipeline Setback for TTHI - Analyst Blog,2010-09-20 16:00:00-04:00,LLY,neutral
768286.0,Thumbs Up for ALKS Drug - Analyst Blog,2010-09-17 15:39:00-04:00,LLY,neutral
768287.0,Pharmaceutical Stocks Worth Owning For The Dividend Alone,2010-09-15 20:06:00-04:00,LLY,neutral
768288.0,Pharmaceutical Stocks Worth Owning For The Dividend Alone,2010-09-15 20:06:00-04:00,LLY,neutral
768289.0,More Unconfirmed Chatter On Vivus Takeover (VVUS),2010-09-10 11:01:00-04:00,LLY,negative
768290.0,PDLI Gives Third-Quarter Outlook - Analyst Blog,2010-09-03 08:36:00-04:00,LLY,neutral
768291.0,U.S. Court of Appeals Upholds Validity of Lilly's Evista Patents (LLY),2010-09-01 12:19:00-04:00,LLY,neutral
768292.0,Incyte Evenly Poised - Analyst Blog,2010-08-30 13:03:00-04:00,LLY,positive
768293.0,Goldman Sachs Introduces And Adjusts Estimates For Major Pharmaceuticals,2010-08-30 11:20:00-04:00,LLY,neutral
768294.0,Repros Schedules Meeting with FDA - Analyst Blog,2010-08-26 15:39:00-04:00,LLY,neutral
768295.0,VVUS) Unconfirmed rumor that (LLY) will buy the company for  $9.00 Cash,2010-08-26 09:45:00-04:00,LLY,negative
768296.0,Jefferies Reiterates Hold Rating on Eli Lilly (LLY),2010-08-20 10:22:00-04:00,LLY,neutral
768297.0,FDA Panel to Review Eli Lilly's Cymbalta - Analyst Blog,2010-08-18 15:10:00-04:00,LLY,neutral
768298.0,Eli Lilly Halts Development Of Alzheimer Drug (LLY),2010-08-17 11:38:00-04:00,LLY,neutral
768299.0,"Top 4 Large-Cap Stocks In The Healthcare Sector With The Highest Dividend Yield (LLY, BMY, GSK, PFE)",2010-08-17 04:57:00-04:00,LLY,positive
768300.0,All Is Not Well In The Pharmaceutical Industry,2010-08-13 14:14:00-04:00,LLY,negative
768301.0,Eli Lilly Cuts Revenue Guidance  - Analyst Blog,2010-08-13 13:07:00-04:00,LLY,negative
768302.0,Eli Lilly Loses Strattera Patent Case; Hapoalim Securities Reiterates Sell Rating (LLY),2010-08-13 12:30:00-04:00,LLY,neutral
768303.0,"U.S. Probing Pharmaceutical Corruption (GSK, PFE, BMY, LLY)",2010-08-13 10:57:00-04:00,LLY,neutral
768304.0,Amgen's Vectibix Disappoints  - Analyst Blog,2010-08-12 14:40:00-04:00,LLY,negative
768305.0,"Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield (LLY, GSK, BMY, PFE)",2010-08-11 05:58:00-04:00,LLY,positive
768306.0,Revenues Dip at Alkermes - Analyst Blog,2010-08-09 17:52:00-04:00,LLY,neutral
768307.0,Finally There Is A Cure For Tobacco Addiction (CIGX),2010-08-09 10:17:00-04:00,LLY,neutral
768308.0,Stocks Going Ex Dividend the Second Week of August 2010,2010-08-03 01:46:00-04:00,LLY,neutral
768309.0,"Top 4 NYSE Stocks In The Healthcare Sector With The Highest Free Cash Flow (PFE, JNJ, MRK, LLY) ",2010-08-02 07:20:00-04:00,LLY,positive
768310.0,July Impressive -- S&Ps Up 6.9%  07-30-2010,2010-07-30 19:07:00-04:00,LLY,positive
768311.0,Corporate Catalysts For The Week Starting July 26 ,2010-07-26 06:51:00-04:00,LLY,neutral
768312.0,Markets Surge on Strong Corporate Earnings (SPY),2010-07-22 11:12:00-04:00,LLY,positive
768313.0,"Eli Lilly Beats Estimates, Raises Forecast (LLY)",2010-07-22 08:50:00-04:00,LLY,neutral
768314.0,"Eli Lilly Reports Strong Sales, Beats on Profit (LLY)",2010-07-22 07:54:00-04:00,LLY,positive
768315.0,"Eli Lilly Posts Better-Than-Expected Q2 Results, Raises 2010 EPS Guidance",2010-07-22 06:42:00-04:00,LLY,neutral
768316.0,Lechleiter Says LLY Has The Most Exciting Pipeline,2010-07-06 17:09:00-04:00,LLY,positive
768317.0,"News Summary (LLY, TM)",2010-07-06 11:11:00-04:00,LLY,neutral
768318.0,Calls Purchased on Eli Lilly & Co. (LLY),2010-07-02 14:10:00-04:00,LLY,neutral
768319.0,"Top 4 Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield (AZN, LLY, GSK, BMY)",2010-06-30 05:58:00-04:00,LLY,positive
768320.0,Hapoalim Securities Expects Eli Lilly To Acquire Amylin Pharmaceuticals Post Approval Of AMLN’s Bydureon ,2010-06-28 06:56:00-04:00,LLY,positive
768321.0,MannKind Corp. Glosses Over FDA Meeting; Hapoalim Balks (MNKD),2010-06-10 13:54:00-04:00,LLY,neutral
768322.0,News Summary ,2010-06-10 12:19:00-04:00,LLY,neutral
768323.0,"Top 5 Large-Cap NYSE Stocks In The Healthcare Sector With The Highest Return On Equity (GSK, LLY, AZN, ACL, NVO)",2010-06-07 06:26:00-04:00,LLY,positive
768324.0,"With Interest Rates this low, Should Investors Look to Equity Dividend Yields?",2010-05-27 12:31:00-04:00,LLY,positive
768325.0,Companies Dodge $60 Billion in Taxes,2010-05-13 17:18:00-04:00,LLY,neutral
768326.0,Stocks Going Ex Dividend the Second Week of May,2010-05-03 13:05:00-04:00,LLY,neutral
768327.0,"Whistleblower Gets Rewarded In AstraZeneca Case (AZN, LLY)",2010-04-28 07:28:00-04:00,LLY,positive
768328.0,"Afternoon-Market Update Abbott Labs (NYSE: ABT), Boeing (NYSE: BA), Tempur-Pedic (NYSE: TPX)",2010-04-21 15:50:00-04:00,LLY,neutral
768329.0,"Company News for April 19, 2010 - Corporate Summary",2010-04-19 17:47:00-04:00,LLY,neutral
768330.0,Eli Lilly Slashes Earnings Guidance (LLY),2010-04-19 16:34:00-04:00,LLY,negative
768331.0,Bulls Bet on Eli Lilly,2010-04-19 11:50:00-04:00,LLY,neutral
768332.0,US Stock Futures Point To A Weak Opening; Investors Eyeing Citigroup Results,2010-04-19 08:55:00-04:00,LLY,negative
768333.0,Eli Lilly & Co. (LLY) Reports A 5% Drop In First-Quarter Profit,2010-04-19 07:50:00-04:00,LLY,positive
768334.0,"Stocks To Watch On April 19 (C, HAL, LLY, IBM, ZION)",2010-04-19 07:49:00-04:00,LLY,neutral
768335.0,"Eli Lilly and Co. (LLY) Profit Falls 5%, As Revenues Climb",2010-04-19 07:13:00-04:00,LLY,positive
768336.0,Citigroup Rates Teva Pharmaceutical Industries (TEVA) A Buy After Court Ruling,2010-04-01 16:24:00-04:00,LLY,neutral
768337.0,"There Are Still Some Bargains In The Market; Barron’s (LLY, PFE, GS, MS, CVX)",2010-03-29 18:41:00-04:00,LLY,neutral
768338.0,Investors Need To Pay More Attention To Dividend ETFs In 2010,2010-03-24 13:44:00-04:00,LLY,negative
768339.0,Before Jumping Into A Single Health Care Stock Consider This ETF,2010-03-23 23:22:00-04:00,LLY,positive
768340.0,Investors Flock To Healthcare ETFs On Historic Reform,2010-03-22 16:13:00-04:00,LLY,neutral
768341.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,LLY,positive
768342.0,This Healthcare ETF (XLV) Is Seeing Above Average Call Buying,2010-03-17 13:42:00-04:00,LLY,neutral
768343.0,"Benzinga’s News Roundup (PEP, ALKS, MRK)",2010-03-15 09:37:00-04:00,LLY,neutral
768344.0,"Benzinga’s Top Pre-Market Gainers (PVH, AMLN, CHRD, ISIS, NVAX)",2010-03-15 09:26:00-04:00,LLY,positive
768345.0,AMLN Is Waiting For A Decision On Byetta,2010-03-08 20:08:00-05:00,LLY,neutral
768346.0,Transition (TTHI) Secures Licensing Deal With Eli Lilly (LLY),2010-03-03 08:36:00-05:00,LLY,positive
768347.0,Eli Lilly Banks On Its Restructured Development Process To Offset Sales Loss (LLY),2010-02-25 13:06:00-05:00,LLY,negative
768348.0,"Market Roundup (BAC, JPM, DELL, WAG, LLY)",2010-02-23 14:57:00-05:00,LLY,negative
768349.0,"Carl Icahn On CNBC (AMLN, GELG, LGM)",2010-02-18 13:03:00-05:00,LLY,neutral
768350.0,"Market Round-up (UBS, GOOG¸ AAPL, MOT¸ PG, PFE, MRK, LLY, CVS, WAG)",2010-02-05 14:08:00-05:00,LLY,neutral
768351.0,Pharma Stocks Dive On Missed Expectations,2010-02-03 11:55:00-05:00,LLY,negative
768352.0,"Five Stocks To Buy Since Analysts Hate Them (LLY, CAN, EEP, LXK, PCX)",2010-02-01 11:39:00-05:00,LLY,negative
768353.0,Eli Lilly (LLY) Has A Healthy Pipeline : CEO Tells CNBC,2010-01-29 08:09:00-05:00,LLY,positive
768354.0,"Eli Lilly & Co. (LLY) Profits Are Up, But Concerns Remain",2010-01-28 13:33:00-05:00,LLY,positive
768355.0,"Bristol (BMY), Lilly (LLY) Up Sales And Settle Dispute",2010-01-28 11:50:00-05:00,LLY,negative
768356.0,"Benzinga’s Earnings Roundup (TYC, BDX, TWC, BLL, LLY)",2010-01-28 07:55:00-05:00,LLY,neutral
768357.0,"FDA Approval For Diabetes Drug Lifts Novo Shares (NVO, AMLN, LLY) ",2010-01-26 08:55:00-05:00,LLY,positive
768358.0,Eli Lilly (LLY) To Outsource Drug Testing,2010-01-05 10:09:00-05:00,LLY,neutral
768359.0,Eli Lilly (LLY) Lacks Near Term Upside Drivers,2009-12-22 13:07:00-05:00,LLY,neutral
768360.0,Play Biotech M&A With This ETF (XBI),2009-12-22 00:26:00-05:00,LLY,positive
768361.0,"Top Gainers in NASDAQ (CHTT, BUCY, INCY, SBLK, MAIL)",2009-12-21 12:54:00-05:00,LLY,positive
768362.0,Eli Lilly’s EPS Guidance Exceeds Estimates (LLY),2009-12-11 13:30:00-05:00,LLY,neutral
768363.0,LLY Has Strong Product Pipeline,2009-12-11 12:43:00-05:00,LLY,positive
768364.0,LLY Issues Disappointing Long Term Guidance,2009-12-11 12:05:00-05:00,LLY,negative
768365.0,Eli Lilly (LLY) Is Facing Big Challenges,2009-12-10 21:18:00-05:00,LLY,positive
768366.0,LLY Issues Disappointing Long-term Guidance,2009-12-10 14:09:00-05:00,LLY,negative
768367.0,SEC On Trail Of Insider Trading Transactions,2009-12-10 09:41:00-05:00,LLY,neutral
768368.0,"Benzinga’s Top Pre- Market Losers (CIEN, LLY, OSIP, PROV, CYTK, AOL, SIGA)",2009-12-10 09:00:00-05:00,LLY,negative
768369.0,"Benzinga’s Earnings Roundup (GIL, LLY, COST, UNFI, ROK)",2009-12-10 08:05:00-05:00,LLY,neutral
768370.0,"Lilly (LLY) Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines ",2009-12-10 08:03:00-05:00,LLY,positive
768371.0,"10 Stocks To Shine In 2010 (C, NYT, LVLT, KBH, LLY)",2009-12-08 08:40:00-05:00,LLY,neutral
768372.0,"Company News for December 01, 2009 - Corporate Summary",2009-12-01 08:56:00-05:00,LLY,neutral
768373.0,Eli Lilly Calls Active (NYSE: LLY),2009-11-13 11:43:00-05:00,LLY,positive
768374.0,"Stocks Running Early (HGSI, VRTX, DNDN, JWN)",2009-11-02 09:29:00-05:00,LLY,neutral
768375.0,Eli Lilly Posts Higher Returns than Expected Behind  Increased Sales Volumes (NYSE: LLY),2009-10-21 10:48:00-04:00,LLY,positive
768376.0,"Today’s Earnings Preview (BA, MS, WFC, EBAY, LLY, MO)",2009-10-21 04:31:00-04:00,LLY,neutral
768377.0,The Week’s Must-Haves and Have-nots According to Jim Cramer,2009-10-19 08:23:00-04:00,LLY,neutral
768378.0,Eli Lilly (LLY) trading in a congestion zone,2009-09-29 12:59:00-04:00,LLY,neutral
768379.0,Eli Lilly and Company (LLY)  Wins  Evista Patent  Till 2014,2009-09-24 05:47:00-04:00,LLY,positive
768380.0,Zignals Stock Charts: 7 Divided Elites from TheStockAdvisors,2009-09-09 10:41:00-04:00,LLY,neutral
768381.0,"Negative Implications for Eli Lilly's (LLY) Efficient, Says Leerink",2009-08-31 09:05:00-04:00,LLY,negative
768382.0,"Trends in the U.K. and Irish Pharmaceutical and Biotechnology Industry, an Industrial Info News Alert",2009-08-17 05:01:00-04:00,LLY,positive
